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Introduction 
Cartilage biology 
Cartilage embryology, anatomy, and physiology  
Cartilage exists in several different forms in the human body: hyaline, elastic, and 
fibrous cartilage. The main focus of this thesis is hyaline cartilage and how to 
repair it. Hyaline cartilage is often referred to as articular cartilage, as this 
connective tissue is found covering the articulating surfaces in synovial joints and 
serves to absorb shock and allow for smooth movements. Briefly, what 
distinguishes the three main types of cartilage from each other are the constituents 
of the extracellular matrix (ECM). The hyaline ECM consists of collagens and 
proteoglycans but has no elastic component. Elastic cartilage is found mainly in 
the epiglottis, the external ear and the auditory tube, with the ECM consisting of 
elastic fibres in addition to the same components as in hyaline ECM. Fibrous 
cartilage can be considered a transitional tissue between dense connective tissue 
and hyaline cartilage and is mainly found in relation to joints in menisci and 
intervertebral discs. The ECM of fibrous cartilage differs from that of hyaline 
cartilage mainly in the type of collagens deposited (Ross, 2003).  
 
Articular cartilage averages 2.4 mm in total height in the human knee. It consists 
of cells, ECM and water and has a distinct histoanatomical organisation (Figure 1) 
(Hunziker, 2002b). Traditionally, cartilage is divided into four different zones 
from the surface down to the subchondral bone. These four zones have clear 
structural differences. The superficial zone lines the joint cavity and is bathed in 
synovial fluid. In this zone the chondrocytes are flattened, with a discoid structure 
that aligns parallel to the surface in a matrix of thin collagen fibrils, which at least 
in early life consists of type I collagen (Treilleux, 1992; Bland, 1996; Tallheden, 
2006). There is a relatively low proteoglycan content, but the chondrocytes 
- 10 - 
produce lubricin (or superficial zone protein) (Flannery, 1999), which is important 
in providing the almost frictionless articulation in diarthrodial joints (Poole, 2001). 
A few publications have found evidence that chondrocyte progenitor cells can be 
found within the superficial zone and that these cells persist throughout life 
(Alsalameh, 2004; Dowthwaite, 2004). Below the superficial zone is the 
transitional (or middle) zone, with more oval-shaped chondrocytes, lower cell 
density and higher proteoglycan content in a randomly distributed type II collagen 
network. The next zone is the deep (or radial) zone, with the lowest cell density 
but the highest proteoglycan content and with the collagen type II fibres oriented 
perpendicular to the surface. Here the chondrocytes are situated in a column-like 
pattern also known as palisades. At the transition between bone and cartilage we 
find the calcified zone just above the subchondral bone plate, marking the border 
to the bone marrow. Cells here usually express the hypertrophic phenotype, 
producing type X collagen and calcify their surroundings, not unlike bone 
Figure 1. Schematic representation of the general structure of human articular cartilage from an adult, 
showing the zones, regions, and relationships with subchondral bone. The insets show the relative 
diameters and organisations of collagen macrofibrils in the different zones. From (Poole, 2001) 
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formation but with no subsequent osteoblast and vascular invasion. The border 
between the uncalcified and the calcified zone is often referred to as the tidemark. 
The metabolism of mature articular cartilage is believed to be very low, with 
major collagens having a half-life of more than 100 years (Hills, 1940; Verzijl, 
2000; Goldring, 2012). However, cartilage is not completely quiescent; 
pericellularly, there is active turnover of collagen and proteoglycan (Aurich, 2002), 
and during growth of articular cartilage, this happens appositionally from the 
surface and downwards (Hayes, 2001). 
 
The cells of the cartilage, the chondrocytes, account for only approximately 2% of 
the volume of adult human articular cartilage (Poole, 2001; Hunziker, 2002b). 
Each individual chondrocyte is a fairly small cell, averaging 13 μm in diameter. 
The mean cell volume is approximately 1750 μm3 with considerable variations 
between zones. The cell height and cell density of articular cartilage show large 
variations between species, but the number of cells underlying 1 mm2 of the 
surface is amazingly consistent averaging approximately 25,500 cells (Stockwell, 
1971). Interestingly, articular chondrocytes form functional gap junctions with 
neighbouring cells, but the physiological significance of this is not clear (Mayan, 
2013). The term chondron has been coined for the chondrocyte and the immediate 
pericellular ECM. The chondron has a distinct anatomical organisation with a 
pericellular glycocalyx enclosed by a fibrillar type VI collagen capsule (Poole, 
1997). It is speculated that chondron remodelling plays an important role in the 
early development of osteoarthritis (Poole, 1997). 
 
The chondrocyte is solely responsible for producing all the constituents of the 
ECM, and even in the light of the very low but existing turnover of the ECM, this 
makes the chondrocyte quite metabolically active (Aurich, 2002). This is 
evidenced by ultrastructural analysis of chondrocytes, showing a highly developed 
endoplasmatic reticulum and Golgi complex and large intracellular accumulation 
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of glycogen and lipids (Geneser, 1999). Chondrocytes have phagocytic and 
autophagocytic abilities, although these features are poorly understood (Aguiar, 
1999; Castillo, 2004). The chondrocyte also has a highly developed actin 
cytoskeleton, at least in vitro but probably also in vivo (Benjamin, 1994). The 
cytoskeleton may be an important mediator between cell-cell/cell-matrix 
interactions influencing the physiology and the differentiation of the cell acting 
through integrin-linked kinases and Rho GTPases (Woods, 2007).  
 
Previously it was believed that chondrocytes in mature cartilage did not replicate 
at all. The discovery of progenitor cells in the superficial zone has challenged this 
(Dowthwaite, 2004), in line with some old reports of mitosis seen in normal 
(Crelin, 1957) and osteoarthritic cartilage (Rothwell, 1973). However, no one has 
been able to establish to what extent such turnover occurs in vivo.  
 
The formation processes of mature articular cartilage during embryogenesis are 
beginning to be elucidated (Goldring, 2006b). They start shortly after gastrulation 
(the process establishing the three germ layers of the developing embryo) in the 
third week of gestation. Paraxial mesoderm along the neural tube condenses into 
paired segments known as somites, which ultimately develop into vertebrae. Early 
in the fourth week, the cells in the ventral and medial walls of the somite lose their 
tight organisation and give rise to a loosely woven tissue known as the sclerotome, 
the start of the axial skeleton. The bones of the limbs are initiated by similar cells 
to that of the sclerotome found in the somatic mesoderm derived from the lateral 
plate mesoderm (Olsen, 2000). The dorsolateral part of the somite differentiates 
into the dermomyotome, the source of the muscular system and the dermis and 
subcutaneous tissues of the skin (Sadler, 2006). The condensation process is not 
fully understood. It is initiated by altered mitotic activity with subsequent 
aggregation of cells towards a centre made possible by elimination of the abundant 
hyaluronic acid present in the developing somite (Hall, 1995). The further 
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differentiation of the somite into the sclerotome and dermomyotome is induced by 
signals from the surrounding tissues. Sonic hedgehog (SHH) is secreted by the 
notochord and is responsible for the induction of the transcription factor PAX1, 
which is highly expressed in the sclerotome and which later in the differentiation 
process induces SOX9, a transcription factor necessary for chondrogenesis. SOX9 
is tightly involved in the regulation of type II collagen production. This enables 
the cells of the sclerotome to lay down a cartilage template for the whole skeleton, 
stabilise the embryo and serve as a template for myo- and neurogenesis. Most of 
this initial template is replaced by bone in a process known as endochondral 
ossification, wherein chondrocytes switch from a type I/II collagen production 
phenotype into the hypertrophic type X collagen production phenotype. Most of 
them subsequently undergo apoptosis. Calcification started by the hypertrophic 
chondrocyte is then continued by invading osteoblasts supported by angiogenesis 
in the primary ossification centres (Olsen, 2000).  
 
On the actual cavitation of joints, little is known about the initiating molecular 
mechanisms. First an increase in cell density is seen in the area of the forming 
joint (the interzone), followed by dedifferentiation of the chondrocytes in the area, 
which switch to type I collagen production, possibly induced by the expression 
and secretion by cells in the area of the glycoprotein WNT9A (previously known 
as WNT14) (Bland, 1996; Hartmann, 2001). Cells in the interzone area become 
elongated and endothelial-like, and in the middle of the zone, cells are 
progressively lost through apoptosis, thereby forming the joint cavity. It is 
believed that movement of the joints occurs through extracellular signal-regulated 
kinases (ERKs), a subgroup of the mitogen-activated protein kinase pathway, to 
modulate the production and secretion of ECM components, especially hyaluronic 
acid. Hyaluronic acid subsequently facilitates a condensation process similar to the 
one outlined for the somites, leading to differentiation of these cells into mature 
chondrocytes and to the formation of the articular cartilage.  
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Articular cartilage is non-vascularised and non-innervated. The calcified zone is 
practically impermeable to gases and fluids, so nutrition of the cells in cartilage 
occurs by diffusion of substances from the synovial fluid to the cells. Synovial 
fluid itself is low in oxygen compared to arterial blood, leaving articular cartilage 
severely hypoxic compared to vascularised tissues. The anatomical properties 
likely do not allow any cell migration within the cartilage. These physiological 
and anatomical properties possibly form the basis of the empiric fact that articular 
cartilage, once injured, does not heal (Hunter, 1742), unless the injury penetrates 
the subchondral bone-plate, after which partial repair often happens, though not 
with histologically normal cartilage (Hunziker, 2002a). 
In vivo chondrogenesis and endochondral ossification 
Embryological chondrogenesis has been depicted above, but it is worthwhile to 
delve a little deeper into the factors that have been established as important in each 
step of chondrogenesis from immature stem cell to mature and then to 
hypertrophic chondrocyte. Much of this knowledge is derived from studies of 
chicken and mouse and more recently from human in vitro cultures of 
differentiating embryonic and adult stem cells (Goldring, 2006b; Nakagawa, 2009; 
Yamashita, 2010). Chondrogenesis is a complex process tightly modulated by 
several identified factors. Figure 2 gives an overview of what is known to regulate 
each step in chondrogenesis. The prechondral mesenchymal cell produces an ECM 
rich in hyaluronic acid and type I collagen, which allows mesenchymal cells to 
migrate to the site of future skeletogenesis dependent on hyaluronidase activity. 
This initiates the condensation process, with the appearance of cell adhesion 
molecules 
- 15 - 
Figure 2. Top panel: The different stages of chondrogenesis represented schematically, showing the 
temporal patterns of growth and differentiation factors (above the arrows) and the transcription factors 
involved (below the arrows). The ECM proteins that distinguish the different stages are indicated below. 
Bottom panel: Schematic representation of the expression of transcriptional regulators at different stages 
of chondrogenesis and endochondral ossification. Additional transcription factors that are inhibitors or 
activators at different stages are indicated below the scheme of cellular transitions (from (Goldring, 
2006b)).
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such as neural cadherin and neural cell adhesion molecule (NCAM). NCAM 
expression is regulated by fibronectin production, which in turn is closely related 
to the cell’s exposure to transforming growth factor beta (TGFβ) (discussed later). 
The condensation process marks the start of chondrocyte differentiation, which is 
characterised mainly by the differences in the type of collagen deposition. From 
Figure 2 it can be seen that several transcription factors are up- and downregulated 
in the differentiation process (Goldring, 2006b). One of the earliest and arguably 
the most important transcription factor is SOX9, which is required for the 
expression of type II collagen (Bi, 1999). SOX9 is the master regulator of 
chondrogenesis (Foster, 1994). The importance of SOX9 for chondrogenesis is 
most clearly illustrated by the autosomal-dominant disease campomelic dysplasia 
(OMIM #114290) caused by a heterozygous SOX9 mutation, which often leads to 
perinatal death due to poorly developed cartilage in the airways (severe 
laryngotracheomalacia). Other distinct features of individuals with campomelic 
dysplasia include craniofacial defects, deformed pelvis, long bones, and 
ambiguous genitalia (Yap, 2011). Correspondingly, Sox9-haploinsufficient 
(Sox9+/-) mice die perinatally, and complete knockout (Sox9-/-) mice die in early 
embryonic life (Bi, 1999; Akiyama, 2002). Conditional knockout experiments 
where one or both alleles can be turned off either globally or in chondrogenic 
tissue (i.e., Col2a1-expressing tissue) at specific timepoints during development 
have shown that Sox9 is needed for mesenchymal condensation and that loss of 
Sox9 leads to enlargement of the hypertrophic zone and premature mineralisation 
(Kist, 2002; Yap, 2011; Dy, 2012). 
 
SOX9 works in chondrogenesis as a homodimer (Bernard, 2003) that can be 
further stabilised by two other SOX proteins from the SoxD family: L-SOX5 and 
SOX6 (Yamashita, 2012). These factors are co-expressed with SOX9 during 
differentiation and are linked to production of type II and IX collagen as well as 
the major proteoglycan aggrecan (Lefebvre, 2001). Their importance is illustrated 
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by other knockout experiments showing that while Sox5- or Sox6-single-null mice 
are born with relatively mild abnormalities but do die in early life, double-null 
mice die in utero with severe chondrodysplasia (Smits, 2001; Akiyama, 2008). 
Recently, a fourth SOX protein, SOX8, has been identified as a possible regulator 
of chondrogenesis (Herlofsen, 2011; Herlofsen, 2014). Another transcription 
factor of major importance is the runt-domain transcription factor RUNX2, also 
known as core binding factor alpha 1 (CBFA1). This factor is upregulated later in 
chondrogenesis and leads to hypertrophy, wherein the cells increase in size and 
shift to type X collagen production. These cells are seen in the deep calcified zone 
of articular cartilage and, importantly when considering tissue engineering, in the 
part of the early cartilaginous skeleton destined to be invaded by osteoblasts. Not 
surprisingly, RUNX2 is also important for osteoblast and osteoclast maturation by 
regulating the proangiogenic VEGF, the matrix degrading/remodellating MMP13 
and MMP9 and the mineralisation protein ALPL (Stickens, 2004; Colnot, 2005; 
Yoshida, 2005). Also SOX8 has been shown to inhibit MMP13 and ALPL perhaps 
playing a crucial role in preventing hypertrophy (Herlofsen, 2014). It is speculated 
that the relationship between SOX9 and RUNX2 ultimately determines which 
parts of cartilage stay cartilage and which parts become bone. One example of this 
is that parathyroid hormone-related peptide (PTHRP), present in the growth plate 
of long bones, prevents chondrocytes from going into the hypertrophic state, likely 
because PTHRP phosphorylates SOX9, increasing its affinity to DNA (de 
Crombrugghe, 2001; Huang, 2001). There is also evidence that SOX9 itself is 
necessary for COL10A1 expression, though it also prevents osteoblastic 
differentiation of prehypertrophic chondrocytes (Dy, 2012). 
 
Several other factors are important in chondrogenesis, among them the secreted 
peptide Indian hedgehog (IHH) from prehypertrophic chondrocytes exposed to 
low levels of PTHRP. IHH in turn induces PTHRP expression, resulting in cells 
being kept prehypertrophic (St-Jacques, 1999). Two splice variants of the ETS-
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related gene (ERG) play a role in determining the functional role of developing 
cartilage (Iwamoto, 2000; Iwamoto, 2007). 
In vitro de- and redifferentiation of chondrocytes 
The term dedifferentiation of chondrocytes is used for the shift in ECM production 
and morphology seen when articular chondrocytes are expanded in a monolayer 
(Holtzer, 1960). When chondrocytes after enzymatic digestion of the ECM are put 
into culture flasks, they rapidly adhere to the plastic and change into a fibroblast-
like shape, with long and eventually entangled cell extensions. At the same time, a 
change from mainly type II collagen to type I collagen production and from 
primarily aggrecan to versican production occurs. The consensus has been that this 
represents chondrocyte dedifferentiation into a more primitive state characteristic 
of the early stages of embryogenic chondrogenesis. This has to some extent been 
substantiated by findings that a change in cell surface markers occurs that makes 
cultured chondrocytes fairly similar to the immunophenotype of cultured 
mesenchymal stem cells (MSCs) (Diaz-Romero, 2005). And some studies have 
shown that cultured chondrocytes do have a limited but existing ability to 
differentiate into other mesenchymal lineages, such as osteocytes and adipocytes 
(Tallheden, 2006). Some evidence has emerged showing that the phenotype of 
chondrocytes is actually modulated over time in culture and is not the result of a 
selective expansion of progenitor/stem cells (Diaz-Romero, 2007). It has also been 
shown that culturing chondrocytes after only a short enzyme treatment that leaves 
some of the ECM intact, delays the dedifferentiation process (Shahdadfar, 2008). 
Nevertheless, it is poorly understood what drives the change of phenotype and 
ECM production and exactly which signals are responsible for the change. So far, 
there are no completely successful systems for redifferentiation of chondrocytes 
into hyaline cartilage. Chondrogenic protocols devised for stem cell differentiation 
can be used with success on chondrocytes (Fernandes, 2013), though with some of 
the same problems as for stem cells (discussed later). 
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Extracellular matrix 
Basically, the ECM can be viewed as the structural framework outside the cells, 
with all its associated molecules. The structural framework makes up 
approximately 90% of the dry weight of articular cartilage and can be subdivided 
into collagens, proteoglycans and non-collagenous proteins and glycoproteins 
(Seibel, 2006). 
Collagens 
Two-thirds of the dry weight of articular cartilage is collagen of various types. At 
least 27 types of collagen are expressed in higher vertebrates, the products of more 
than 40 genes (Eyre, 2004). The key feature of all collagen types is the triple-helix 
structure. It is a coiled-coil structure composed of three polypeptide chains (α-
chains) with glycine in every third position (Seibel, 2006). All fibril-forming 
collagens are synthesised as procollagen chains that assemble in the endoplasmatic 
reticulum to a 300-nm-long triple helix. The procollagen is then secreted and the 
propeptides removed by specific enzymes, which initiates actual fibril formation 
from cross-linking of several collagen molecules. Fibrils can then aggregate into 
actual collagen fibres. High amounts of the amino acids proline and 
hydroxyproline allow for extensive cross-linking within and between each 
collagen molecule (Alberts, 2002). The amount of cross-linking is the basis for the 
tensile strength of collagen and varies highly between tissues and is especially 
high in the Achilles tendon. Type II collagen is the main type of collagen found in 
articular cartilage, accounting for about 90% of the total collagen. Each collagen 
molecule consists of three identical α1[II]-chains that assemble into fibrils. Type 
II collagen is most abundant in the radial zone. It exists in four splice variants 
(McAlinden, 2008). Type IIB is found in mature cartilage, where exon 2, coding 
for 69 amino acids, is spliced out, and type IIA is found together with type IID in 
embryonic cartilage, where exon 2 is retained. Type II collagen forms a copolymer 
with the smaller type XI collagen and with type IX collagen, the latter a so-called 
fibril-associated collagen with interrupted triple helices (FACIT) which facilitates 
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fibril formation (Eyre, 2004). Another important type of collagen normally only 
found in very small amounts in the superficial region of mature cartilage, is type I 
collagen. It is probably the most studied collagen and consists of two α1(I) and 
one α2(I)-chains. It is the most important collagen in skin, bone, tendon and 
fibrous cartilage (e.g., menisci and intervertebral discs). It is also present in high 
concentrations during embryogenesis and plays a role as an adhesive substrate for 
several cells in tissue and organ development; in cell migration, proliferation and 
differentiation; and in wound healing (Seibel, 2006). More important in terms of 
articular cartilage, it is the major collagen found in the tissue seen after 
spontaneous repair of osteochondral injuries. Type X collagen is a so-called 
network-forming collagen. It is a short-chain collagen that forms a pericellular 
network associated with macrofibrils of type II collagen. The function of type X 
collagen is not fully understood, but it plays a role in endochondral ossification. It 
may be involved in avoiding actual bone formation in calcified cartilage yet at the 
same time involved in matrix-vesicle-initiated calcification of hypertrophic 
cartilage (Kwan, 1997; Poole, 2001). Phenotypic changes in two type X collagen 
knockout strains of mice were surprisingly small compared to the severe joint 
defects seen in the human disease Schmid-type metaphyseal chondrodysplasia 
(OMIM #156500), which is caused by a mutation in the type X collagen gene 
(Seibel, 2006). The actual function of another collagen, type VI, is also unknown, 
but it forms the fibrillar pericellular network in the chondrons (Poole, 1997). In 
knockout mice, type VI collagen loss is linked to altered trabecular bone structure 
and delayed cartilage degeneration (Christensen, 2012). 
 
In summary, the fibril-forming collagens, regardless of the tissue, are responsible 
for the tensile strength of the tissue. They also provide a framework that contains 
the pressure from swelling due to embedded proteoglycans. All collagens may 
exert biological effects on the cells through integrins, although this is far from 
understood. 
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Proteoglycans 
The other major component of the structural framework of articular cartilage is the 
proteoglycans. They form a special class of glycoproteins with long, unbranched, 
and highly charged glycosaminoglycan (GAG) chains attached. Due to their 
charge, the GAG chains are highly hydrophilic, and as they are trapped within the 
collagen network and too large to redistribute, water is drawn into the cartilage by 
osmosis. This swells the ECM until equilibrium between the tensile strength of the 
Figure 3. Overview of the proteoglycans present in cartilage. Associated with the cell surface are the 
transmembrane-spanning syndecan proteoglycans, the GPI-linked heparan sulphate proteoglycan, 
glypican, and two forms of hyaluronan, namely hyaluronan bound to the hyaluronan synthase and 
hyaluronan tethered to CD44. Aggrecan binds to cell surface-associated hyaluronan as well as 
hyaluronan within the further removed ECM. Several small proteoglycans, namely decorin, 
fibromodulin and type IX collagen, form strong associations with cartilage collagen fibrils (types II, IX 
and XI collagens). Other proteoglycans, such as biglycan and perlecan, are also present within 
cartilage, but their localisation and binding partners have not been firmly identified. From (Knudson, 
2001). 
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collagen network and the water is reached. Any external force applied to the 
cartilage will then additionally increase the pressure within the cartilage, but since 
fluids are incompressible this gives the cartilage an excellent compressive stiffness. 
The strong charges of the GAG chains also highly diminish fluid flow within the 
cartilage, making the whole cartilage fairly resistant to impact loading, although 
constant sustained loads will eventually force a redistribution of fluid (Seibel, 
2006). 
 
Aggrecan is the main proteoglycan of cartilage and has a core protein of high 
molecular weight (~250 kDa), with three globular and two extended domains. The 
extended domains are highly glycosylated by two types of GAG chains, 
chondroitin sulphate (~100 per aggrecan molecule) and keratan sulphate (~60 per 
molecule). Hyaluronan (also termed hyaluronate or hyaluronic acid) is a long, 
unbranched glycosaminoglycan based on a disaccharide repeat of glucosamine and 
glucuronate found in especially high concentration in embryonic cartilage. It has 
no protein directly associated and is therefore not a proteoglycan per se, but in 
mature cartilage it forms aggregates with aggrecan molecules, as these contain 
highly specific binding sites with high affinity for hyaluronan. This binding is 
stabilised by link protein, a member of a small gene family of proteins tightly 
linked to aggrecan expression, yet the function of the members of this family is 
largely unknown. Hyaluronan has an undefined interaction with the collagen 
fibrils and a defined attachment to the cell surface receptor CD44 present on 
chondrocytes. The function of this binding is not well understood. It is known that 
there is a normal turnover and internalisation of CD44 bound to hyaluronan with 
subsequent degradation of hyaluronan. The internalisation of CD44 is upregulated 
if cells are stripped of attached hyaluronan (Aguiar, 1999; Knudson, 2001). It is 
also known that if blocking of the CD44 receptor occurs by small hyaluronan 
fragments, a chondrolytic state is induced (Knudson, 2002). This does not happen 
if the hyaluronan is larger (higher molecular weight, i.e., longer chain of 
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polysaccharides), as in the commonly occurring hyaluronan in articular cartilage. 
Unlike the long lived collagen fibrils, aggrecan is synthesised and secreted 
continuously (Knudson, 2001). 
Other smaller proteoglycans important to articular cartilage are the leucine-rich 
proteoglycans decorin, fibromodulin, lumican, biglycan and perlecan. These are 
all non-aggregating proteoglycans. Decorin, fibromodulin and lumican play roles 
in the formation and stability of collagen macrofibrils and may have some 
regulatory functions on the chondrocytes, although this is not fully elucidated. 
Both decorin and biglycan bind TGFβ, which may be part of their regulatory 
functions (Poole, 2001). Perlecan is a somewhat larger, multidomain proteoglycan 
that may self-aggregate and localises to the cell surface, possibly through 
interaction with integrin. Addition of perlecan to chondrocyte cell cultures leads to 
re-expression of the type II collagen-producing phenotype, maybe working in 
concert with the transcription factor SOX9 (Knudson, 2001; Seibel, 2006). 
Other components 
Several other molecules not in the above groups are present in cartilage. Some 
have already been mentioned, such as lubricin and link protein. Others include the 
five-armed cartilage oligomeric matrix protein (COMP) of the thrombospondin 
family, matrilins, fibronectin, fibrilins, and chondroadherins. Little is known about 
the functions of these non-collagenous non-proteoglycans. COMP binds type II 
collagen and may be involved in macrofibril assembly. It has been used as a 
marker in synovial fluid of cartilage degradation in the progression of 
osteoarthritis, although its specificity may not be good, as COMP is also present in 
the synovium. Fibronectin is an important protein in early chondrogenesis and 
embryogenesis and is present in mature cartilage at low levels. Interestingly 
fibronectin is upregulated in early and late osteoarthritis (Lorenzo, 2004). 
Chondroadherins may serve to anchor chondrocytes to collagen fibrils (Seibel, 
2006). 
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Cartilage injuries and treatment 
Cartilage is vulnerable to degenerative or traumatic damage. Diseased cartilage 
represents a major cause of chronic disability in developed countries (Centers for 
Disease Control And Prevention, 
2010). Once injured, cartilage 
has a limited healing capacity 
due to its non-innervated and 
non-vascularised nature. 
Traditionally, we divide 
cartilage pathology into 
traumatic (or focal) injury and 
degenerative changes (the latter 
either primary or secondary). 
Cartilage repair is generally 
focused on repairing focal 
injuries to relieve symptoms, 
and hopefully also preventing 
the development of secondary 
osteoarthritis, though the latter 
has not been shown 
convincingly in clinical studies.  
 
Grading and scoring systems for cartilage injury 
By definition, a cartilage (or chondral) lesion does not penetrate the subchondral 
boneplate. If it does penetrate the subchondral boneplate, it is an osteochondral 
lesion. Several grading systems have been developed, but the most common way 
Figure 4. The International Cartilage Repair Society Injury 
Classification Scheme. See text for explanation. From (ICRS, 
2000). 
ICRS Grade 0 - Normal 
 
 
ICRS Grade 1 – Nearly Normal 
Superficial lesions. Soft indentation (A) and/or superficial fissures and cracks (B) 
 
    
A                     B 
 
ICRS Grade 2 – Abnormal 
Lesions extending down to <50% of cartilage depth 
 
 
 
ICRS Grade 3 – Severely Abnormal 
Cartilage defects extending down >50% of cartilage depth (A) as well as down to calcified layer (B) and down to 
but not through the subchondral bone (C). Blisters are included in this Grade (D) 
 
            
A                     B                     C                        D 
 
ICRS Grade 4 – Severely Abnormal 
 
     
A                      B 
Copyright © ICRS 
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to grade chondral and osteochondral injury today is the International Cartilage 
Repair Society (ICRS) evaluation package first proposed in 1998, developed in 
several workshops in 2000 and freely available from the society, with both a 
patient and a surgeon part (Brittberg, 1998; ICRS, 2000; Brittberg, 2003). In this 
system, the macroscopic grading of the injury is based on the simple and 
straightforward classification scale developed by Outerbridge in 1961 
(Outerbridge, 1961). The gradations and their corresponding types of injury are 
depicted in Figure 4. Naturally, in addition to the grade, the size of the lesion is 
also part of the classification. The common consensus (although without solid 
scientific evidence) is that a lesion larger than 2 cm2 is considered a large lesion 
(Behery, 2013). The ICRS evaluation system also includes a grading system for 
osteochondritis dissecans lesions as well as a grading system for macroscopic 
evaluation after cartilage repair.  
 
Cartilage injuries are generally not easily seen on standard weight-bearing 
radiographs unless they are large or are part of a more generalised osteoarthritis 
where diminished joint space can be seen. MRI with special sequences and/or with 
gadolinium contrast (delayed gadolinium-enhanced MRI of cartilage, dGEMRIC) 
specifically quantifies GAG content of diseased portions of the cartilage 
(Nieminen, 2012; Palmer, 2013). This provides a promising tool for non-invasive 
evaluation of cartilage injury. 
Epidemiology 
Injuries to articular cartilage in the knee are fairly common. In a retrospective 
review of 31,516 knee arthroscopies, cartilage lesions were documented in 
approximately 20,000 patients (63%) (Curl, 1997). In two-thirds of these there was 
an associated ligamentous and/or meniscal pathology. Approximately 60% of the 
lesions were grade 3 or worse, and the most common place to have a grade 4 
lesion was the medial femoral condyle. A more recent retrospective review of 
25,124 arthroscopies largely corroborated these findings (Widuchowski, 2007). 
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Two other prospective studies of approximately 1,000 consecutive arthroscopies 
of the knee found lesions of the articular cartilage in 61% and 66% of patients, 
respectively, in line with a retrospective survey (Hjelle, 2002; Aroen, 2004). 
Localised or focal chondral and osteochondral lesions were found in both studies 
in approximately 20% of the knees. Full-thickness lesions (ICRS grades 3 and 4) 
were found in 11% of the knees, and of these, 55% were more than 2 cm2. In both 
studies, cartilage lesions were more frequently seen in conjunction with injuries to 
the cruciate ligaments and/or menisci. In the national Scandinavian registries of 
anterior cruciate ligament (ACL) reconstructions, cartilage injury was noted in 17-
27% of all cases (Granan, 2009). This is concordant with another study that found 
chondral lesions in 19% of ACL ruptures and an increased incidence of associated 
chondral injury with longer duration between rupture and repair (Tandogan, 2004). 
This last finding indicates that not all chondral injuries are apparent at the time of 
ligament injury, but that either the altered biomechanical properties of the knee 
predispose the patient to subsequent chondral injury or that a lesion may develop 
over time, possibly due to damage to the underlying bone sustained at the time of 
injury. Also, severe cartilage injury is more prevalent in athletes (Flanigan, 2010). 
Puzzlingly, this severe injury does not always lead to symptoms (Shellock, 2003; 
Walczak, 2008). These asymptomatic lesions make diagnosis and management of 
cartilage injury a challenging task.  
Pathogenesis 
Several conditions in the knee lead to chondral or osteochondral lesions and 
therefore there is no uniform pathogenetic pattern. In focal lesions, trauma in some 
form is believed to be involved. Animal and ex vivo studies of human cartilage 
have shown that after blunt trauma that does not initially make any macroscopic 
changes to the cartilage, increased apoptotic cell death is seen, along with some 
changes in metabolism, leading to increasing degeneration of collagen and loss of 
proteoglycans (D'Lima, 2001a, b). It is speculated that the bone bruise often seen 
on MRI after a ligament injury could indicate this type of early cartilage 
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degeneration (Nakamae, 2006). It is, however, also speculated that the damage to 
the bone actually over time affects the overlying cartilage due to the changed 
biomechanical properties of the bone after injury and intrinsic repair. In more 
severe trauma to the knee, actual chondral fracture is seen immediately after the 
injury, and in even more severe trauma osteochondral fractures are seen from 
direct impact to the cartilage, but probably more often the traumatic episode 
inflicted a fracture to the bone that extends into the articular surface. There are 
also a few supposedly non-traumatic origins of cartilage injuries. One is the entity 
known as osteochondritis dissecans, where an osteochondral fragment loosens in 
juveniles. The patient presents with a painful knee, often with full dislocation of 
the fragment and a locked knee. The aetiology of this is not known, but animal 
studies suggest that disturbances of vascularisation of the bone in the embryonic 
development may predispose to this condition (Ytrehus, 2004a; Ytrehus, 2004b; 
Ytrehus, 2004c). Another spontaneous condition is osteonecrosis of the 
subchondral boneplate. This is rather uncommon but occurs in older age groups 
and leads to loss of the supportive function of the subchondral bone from necrosis 
and subsequently severely affects the overlying cartilage. It has been suggested 
that the underlying aetiology of this is stress fractures in the subchondral bone 
(Patel, 1998; Mont, 2000). 
 
More recently, advances in molecular biology have led to discoveries of 
relationships between genes, cytokines and growth factors that may help to explain 
the pathogenesis of osteoarthritis which could also possibly play a role in the 
likelihood of a minor traumatic focal injury developing into more severe cartilage 
disease (Lee, 2013). 
Natural history 
The non-innervated, non-vascular nature of articular cartilage may cause chondral 
injuries to be initially asymptomatic. The same properties are responsible for the 
limited self-repair seen in chondral injuries, as no reparative inflammatory 
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response can be initiated. The intrinsic properties of cartilage, in addition, allow 
for limited migration and proliferation of the chondrocytes (Hunziker, 2002a). 
Only in osteochondral injuries is self-repair with fibrous cartilage seen, which is 
attributed to the forming of a blood clot due to bleeding from the bone marrow and, 
supposedly, differentiation of MSCs from the bone marrow into type I collagen 
producing chondrocytes (Hunziker, 2002a).  
 
Information on the natural history of cartilage injury is sparse. It is not known 
whether all cartilage injuries, chondral or osteochondral, will eventually lead to 
secondary osteoarthritis or if there is a critical size or depth that will predict 
progression. One intermediate-term follow-up on a large group of patients with 
arthroscopically verified non-treated chondral injury has been published 
(Shelbourne, 2003). This study analysed patients that had undergone ACL surgery 
with an incidental finding of a chondral injury (grades 3 and 4, n=125), which was 
left untreated, and compared this with a control group also undergoing ACL 
surgery but with no chondral injury present. A slightly but significantly better 
subjective score was found in the control group, but no significant difference was 
present in radiographic scores. Mean follow-up was 6.3 years, and mean defect 
size was 1.7 cm2 (range 0.5–6.5). Strictly speaking, this study is not a true natural 
history study, as the repair of the ACL is an intervention that possibly prevents 
further chondral damage (as evidenced by the higher incidence of chondral 
injuries in old ACL ruptures) and possibly introduces cells from the bone marrow 
into the joint through the tunnels drilled for the ligament graft to be fixated. It is, 
however, clear that in a span of more than 6 years, there was no subjective or 
radiographic evidence of rapidly developing secondary osteoarthritis. One should 
also note that the activity level of the patients included in the study was fairly low. 
Another study followed 28 athletes for more than 14 years (Messner, 1996). In this 
study the athletes had isolated traumatic chondral lesions or osteochondritis 
dissecans. Only limited intervention in the form of removing loose bodies and, in 
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three cases, Pridie drilling was performed. 22 patients had excellent or good knee 
function and were involved in individual sports on a fitness level, yet 12 patients 
had radiographic findings of osteoarthritis in the compartment of the initial injury. 
This is to some extent supported by the Norwegian ACL registry, which indicated 
no difference in preoperative function scores in patients with or without injury 
(Hjermundrud, 2010). 
 
Another study with a mean follow-up of 15.3 years of severe isolated and 
untreated cartilage injuries reported that these injuries had hardly any influence on 
clinical outcomes nor on the development of osteoarthritis, as evidenced by 
radiographic comparisons to the uninjured contralateral knee (Widuchowski, 
2011). 
Treatment modalities 
The ultimate goal of a cartilage repair procedure is to reconstitute the defect with a 
repair tissue with similar properties to that of the original cartilage, including 
perfect integration into the surrounding tissue. Additionally, there should be no 
changes to the subchondral bone or to the surrounding tissue as a consequence of 
the treatment (Hunziker, 2002a). To date, a treatment that fulfils these 
requirements does not exist (Mastbergen, 2013). Below, I shall briefly go through 
several of the techniques used. The list is not exhaustive but includes the most 
commonly used techniques as well as some experimental treatments emerging as 
candidates for future therapy. 
Non-surgical treatment 
Every surgical procedure carries a risk. Therefore, non-surgical treatment of all 
injuries should always be considered and surgical procedures only performed if 
they positively benefit the patient in terms of prognosis with an acceptable risk of 
both minor and major side effects. Non-surgical treatment of symptoms due to 
cartilage injury includes standard analgesic treatments such as non-steroidal anti-
 - 30 - 
inflammatory drugs (NSAIDs) and less evidence-based oral supplements of 
glucosamine sulphate or chondroitin sulphate (Vista, 2011). It is not known if the 
commonly used intra-articular injections of hyaluronic acid in the treatment of 
osteoarthritis is beneficial in the treatment of focal defects (Axe, 2013), though 
there is some evidence from animal studies that it could help heal both 
osteochondral and chondral defects (Miyakoshi, 2005; Jansen, 2008). Arguably 
the most important conservative strategy is physical therapy, aimed at improving 
muscle strength and neuromuscular control (Wilk, 2006). The effect of a well-
planned intensive physical rehabilitation program was perhaps most convincingly 
demonstrated in the Oslo Cartilage Active Rehabilitation and Education Study. 
Patients (all with Lysholm scores below 75) referred for cartilage repair surgery 
achieved very good improvement of functional scores. In fact, a significant 
number of patients opted to not proceed with surgery after three months of 
rehabilitation (Wondrasch, 2013). The long-term sustainability of this 
rehabilitation remains to be established. 
Surgical treatment 
As evident from the previous section, surgical treatment of cartilage defects should 
be limited to patients with symptoms consistent with a full-thickness cartilage 
defect where a conservative treatment has failed to achieve a result that the patient 
considers satisfactory. 
Removal of loose bodies/debridement 
The simplest surgical treatment of cartilage injury is removal of the loose part of 
the cartilage and careful debridement of the lesion without extending the defect 
deeper or penetrating the subchondral bone plate. There is little evidence on the 
long-term results of this treatment, although it is probably performed relatively 
often, especially in patients presenting with a locked joint. In patients where the 
loose body is due to an osteochondritis dissecans lesion, the common consensus is 
that attempts should be made to fixate the fragment if possible or proceed with 
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cartilage repair procedures (Schenck, 1996). It is worth noting that a randomised 
controlled study, though later heavily debated on grounds of its inclusion criteria 
and statistics, found that the placebo effect of a sham arthroscopy operation 
equalled the effect of actual lavage or lavage and debridement in patients with 
osteoarthritis (Moseley, 2002). 
Bone marrow-stimulating procedures 
Microfracture treatment is the most frequently used bone marrow stimulating 
technique. Other techniques in this group are abrasion arthroplasty and 
subchondral drilling. The microfracture technique was introduced by Steadman 
and coworkers and was designed to be less invasive and presumably cause less 
heat necrosis to the subchondral bone plate than subchondral drilling. However, 
recently the latter has been challenged in laboratory studies, and new instruments 
for subchondral drilling has been introduced (Arthrex Powerpick®) (Steadman, 
1998; Chen, 2009; Chen, 2011a). Traditionally, microfracture is performed using a 
specially designed awl to manually penetrate the subchondral bone in several 
places 3-4 mm apart, leading to bleeding and formation of a fibrin clot in the 
defect. Clinical results have shown good improvement and good repair on second-
look arthroscopy, but biopsies show fibrocartilage (Blevins, 1998). Animal studies 
have also shown good filling of defects but also a possibly permanent thickening 
of the subchondral bone plate, the importance of which is not fully known (Aroen, 
2006). Randomised clinical trials on microfractures have shown microfracture to 
be neither superior nor inferior to autologous chondrocyte implantation (ACI) 
when considering clinical outcomes (Knutsen, 2004; Knutsen, 2007; Saris, 2008; 
Vanlauwe, 2011).  
Osteochondral auto-/allograft 
Osteochondral allografts (either fresh or cryopreserved) have been used for 
decades to treat large defects in the knee, at first primarily after tumour surgery 
(Mankin et al., 1976). A 20-year follow-up showed graft survival in 66%, and 
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found that rejection reactions were not a significant problem (Shasha et al., 2002). 
This procedure relies on the availability of suitable donors in terms of size and 
absence of comorbidity. Also, there have been some cases of transfer of 
potentially fatal pathogenic bacteria (Centers for Disease Control and Prevention, 
2002). In Scandinavia, osteochondral allografts are rarely used. Instead, autograft 
procedures, termed mosaicplasty or osteochondral autograft transfer system 
(OATS), have been used in both open and arthroscopic surgeries. The technique 
utilises a hollow burr to remove circular plugs of cartilage, including the 
subchondral bone, from uninjured parts of the knee and press fitting them into the 
prepared cartilage defect (Matsusue, 1993; Hangody, 1997; McCoy, 2012). In 
randomised controlled trials, this technique performed worse than autologous 
chondrocyte implantation in one study (Bentley, 2003) and better than 
microfracture in another study (Gudas, 2005). A third, underpowered randomised 
trial also showed excellent results in the mosaicplasty group (Dozin, 2005). In 
large case series with other authors, this technique has shown excellent results 
(Hangody, 2003; Hangody, 2010). The technique is generally not suitable for very 
large lesions and is advocated in algorithms as most suitable for lesions of 
approximately 1 cm2 (Vanlauwe, 2007). The concern with this technique is, 
naturally, that to repair one defect, one or several new defects are created in the 
joint, presumably in less weight-bearing areas, leading to some donor site 
morbidity (Matricali, 2010). It also carries challenges in achieving a normal 
contour of the repair. 
Autologous chondrocyte implantation  
In 1994 a new concept of cartilage repair emerged (Brittberg, 1994). It had been 
known for decades that enzymatically treated cartilage biopsies made it possible to 
culture and numerically expand chondrocytes in vitro (Green, 1971). Animal 
studies of periosteal transplantation were published, followed by human studies 
(O'Driscoll, 1984; Lorentzon, 1998; Alfredson, 1999). A Swedish group combined 
these two techniques in a procedure termed autologous chondrocyte implantation 
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(ACI). In this procedure, a small cartilage biopsy is arthroscopically harvested 
from the knee, enzymatically treated and cultured for approximately three weeks, 
after which at least one million cells per square centimetre are implanted in a 
small-volume suspension under a periosteal flap in a second open-surgery 
procedure. Later, the periosteal flap has been replaced by a membrane made from 
bovine collagen, making the procedure simpler and alleviating the problems 
initially seen with hypertrophy of the repair tissue, often leading to a re-
arthroscopy rate of 20-25% (Knutsen, 2004; Steinwachs, 2007). The initial study 
reported excellent healing in 14 out 16 patients at two years’ follow-up. Since then, 
the ACI procedure has evolved. Second-generation procedures use a membrane as 
the cell carrier when the cells are implanted (such as MACI® (Verigen, Germany) 
(Enea, 2012). Third-generation procedures culture the cells in three-dimensional 
matrices before implantation. One commercially available example of this made 
from hyaluronic acid is Hyalograft C® (Fidia, Italy) (Marcacci, 2005). Some of 
these advances have also made it possible to perform the second procedure 
arthroscopically.  
 
A fairly recent Cochrane review concluded that there is no evidence that ACI of 
any generation performs any better than other cartilage repair techniques, based on 
six heterogeneous randomised controlled trials (Vasiliadis, 2010). Earlier 
systematic reviews also found severe limitations in the research methods used in 
both randomised controlled trials and case series (Jakobsen, 2005; Jakobsen, 2007). 
Of the trials in the Cochrane review, one trial out of three that examined ACI 
versus mosaicplasty statistically favoured ACI, while another found significant 
improvement for the mosaicplasty group using one functional scoring system but 
not with other scoring systems. Two trials compared ACI or a more sophisticated 
version, termed characterised chondrocyte implantation (CCI), with microfracture 
and found no significant difference on functional outcomes. But in the latter trial 
the results at 18 months showed a significant improvement in the structural repair 
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in the CCI group and at 36 months a significant functional improvement. However, 
the five-year results of this trial, published after the Cochrane review, found no 
significant functional difference between the treatments. A subgroup analysis did 
show a significant improvement in patients treated with symptom onset less than 3 
years (Saris, 2008; Saris, 2009; Vanlauwe, 2011). The other trial comparing ACI 
and microfracture did not find significant differences at two or five years post-
treatment (Knutsen, 2004; Knutsen, 2007). One recently published abstract of the 
SUMMIT randomised controlled trial comparing MACI with microfracture states 
that MACI achieves significantly better functional results at two years, especially 
when lesions were larger than 4 cm2, though details are sparse (Saris, 2013). 
Also with ACI, there are concerns about donor site morbidity in the site of the 
initial cartilage biopsy (typically the intercondylar notch). Perhaps the most 
striking example that this may be a problem is in a study of ACI for lesions of the 
talus, where a biopsy was taken from an otherwise asymptomatic knee. Seven out 
of 10 patients suffered from sustained, moderate knee pain 12 months after the 
biopsy (Whittaker, 2005; Matricali, 2010). 
Stem cell implantation 
As will be discussed further below, using MSCs is a promising way to eliminate 
the need for a cartilage biopsy. This has to some extent already been tried in 
several animal trials with or without scaffolds (Wakitani, 1994; Solchaga, 1999; 
Solchaga, 2002; Koga, 2007; Loken, 2008) (for review, see (Ringe, 2012; Tang, 
2012)). The results are promising, but superiority to other treatments in animal 
studies is not consistent. In human trials, MSCs have only been used in few and 
limited case series, embedded in a type I collagen gel (Wakitani, 2002; Wakitani, 
2004; Kuroda, 2007; Matsumoto, 2010). In the largest of these studies (n=12 in 
each group), the bone marrow-derived MSCs were used to treat osteoarthritic 
knees after high tibial osteotomy. Cells were implanted under periosteal flaps and 
compared to cell free implants. No clinical difference was observed, but the repair 
tissue in the cell group scored higher arthroscopically and histologically (partially 
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hyaline cartilage-like). Although these studies do provide proof of principle, they 
can only serve as foundations for a more stringently designed study that is 
adequately powered to show clinically significant differences or non-inferiority. 
As will be discussed below, the safety of using stem cells is an issue. These 
studies in combination with animal studies provide substantial evidence of the 
safety of these procedures, as no tumour growth has been seen. 
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Stem cell biology 
Stem cells are defined as cells that throughout the lifetime of an organism are able 
to give rise to new stem cells (a property termed self-renewal) and to the variety of 
differentiated cells within that organism (a property termed potency) (Weissman, 
2000; Morrison and Kimble, 2006). 
Stem cell nomenclature and definitions 
Stem cells are classified by their potency and origin (Figure 5). At the top of the 
hierarchy is the totipotent stem cell, which is able to give rise to all cells in a 
developing embryo, including the extraembryonic tissues. The only known 
totipotent stem cell is derived directly from the fertilised zygote and can be 
obtained until approximately day five after fertilisation (i.e., the first cell divisions 
and the morula stage), when the blastocyst forms (Sadler, 2006). From there on, 
totipotency is lost and cells derived from the inner cell mass of the blastocyst are 
Figure 5 Schematic representation of stem cell properties. Adapted from (Diez 
Villanueva, 2012). 
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termed pluripotent and are able to differentiate into all embryonic tissues. These 
cells are the quintessential stem cells referred to as embryonic stem cells (ESCs). 
Human ESCs were first isolated and established in 1998 (Thomson, 1998).  
 
Yamanaka and coworkers discovered another source of pluripotent stem cells 
(Takahashi, 2006). They found that overexpression of only four gene products 
(OCT4, SOX2, KLF4 and cMYC) in fully differentiated skin fibroblasts prompted 
a tiny proportion of these cells to become fully pluripotent (induced pluripotent 
stem cells - iPS cells). This work was quickly expanded on by the same and other 
groups and has become an extremely valuable tool in molecular biology (Okita, 
2007; Yu, 2007). It is used to study rare genetic diseases, to screen for new drugs 
and to understand stem cell differentiation (for review, see (Robinton, 2012)). In 
2012 Yamanaka shared the Nobel Prize in Physiology or Medicine with the 
renowned developmental biologist John Gurdon. Although iPS cells become very 
similar to ESC there are significant differences in the epigenetic signature (Huang, 
2013). Interestingly, it has also been shown that just the introduction of the 
microRNA cluster miR302/367 could induce pluripotency in human and mouse 
somatic cells without the so-called Yamanaka-factors (Anokye-Danso, 2011). 
 
Somatic stem cells, also referred to as adult stem cells, reside in differentiated 
tissues and are thought to be responsible for the general homeostasis of cells in 
that particular tissue as well as participating in the repair after injury or disease 
(Joseph, 2005). They are restricted in potency, being able to differentiate into 
lineages specific to that tissue, and have been found in almost all tissues, including 
tissues previously thought not to regenerate, such as the central nervous system. 
Some somatic stem cells are multipotent, one example being the haematopoietic 
stem cells, which constantly repopulate the blood system with all cell lineages 
specific to haematopoiesis, while others are believed to be only unipotent, being 
able to differentiate into only one lineage (myosatellite cells of muscles, for 
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example (Holterman, 2005)). In general (at least in vivo), somatic stem cells lack 
the ability to differentiate into cells of other tissues (Joseph, 2005).  
 
MSCs are a subgroup of somatic stem cells. These multipotent cells were first 
identified in bone marrow from guinea pigs (Friedenstein, 1970) and subsequently 
isolated from a wide range of human tissues, including bone marrow (Pittenger, 
1999; Jiang, 2002), adipose tissue (Zuk, 2001; Boquest, 2005; Boquest, 2006), 
skeletal muscle (Cao, 2004), trabecular bone (Chen, 2005), epidermis (Watt, 2006), 
peripheral blood (Zhao, 2003), synovium (De Bari, 2001), periosteum (De Bari, 
2006), teeth (Yamazaki, 2007), amniotic fluid (Kaviani, 2001), placenta (Miao, 
2006) and umbilical cord blood (Kogler, 2004) (for reviews, see (Chamberlain, 
2007; Phinney, 2013)). The abundance of tissues from which MSCs have been 
isolated suggests that they may be present in almost all tissues, although both this 
and the actual origin of MSC in various tissues are debated. Also controversial is 
whether they are indeed multipotent or if they possess pluripotentiality, being able 
to differentiate into cells not only of mesenchymal origin but also into ecto- and 
endodermal tissue. 
 
The actual differentiation of a stem cell happens through progenitor or precursor 
cells committed to differentiate into one or a few mature cell types. For this to 
happen, fulfilling the requirement for self-renewal, stem cells need to undergo 
asymmetric division, giving rise to one new stem cell and one committed 
progenitor cell. Stem cells also have the ability to symmetrically divide, giving 
rise to two new stem cells. The mechanisms for determining if division should be 
symmetric or asymmetric are not fully understood (Li, 2013). 
Somatic versus embryonic stem cells 
With a cell source able to differentiate into mature tissues, there is an obvious 
opportunity to try to develop clinical treatments for a variety of conditions, 
including bone healing, cartilage resurfacing, spinal cord injury, multiple sclerosis 
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and diabetes. Whether to use somatic or embryonic/induced pluripotent cells is an 
ongoing debate with both ethical and practical arguments. ESCs are considered to 
have the greatest degree of differentiation potential, but as ESCs are obtained from 
fertilised eggs that are destroyed in the procedure, ethical considerations have been 
raised concerning their use. On more practical grounds, no viable way to 
overcome the need for immunosuppression to avoid rejection of transplanted ESCs 
has emerged. Also, a practical argument against the use of ESCs is the fact that 
they often spontaneously differentiate in vitro and frequently form teratomas in 
vivo (the latter, in fact, is considered an important marker of bona fide ESCs) 
(Findikli, 2006). Techniques have been proposed that overcome the practical 
obstacles of using ESCs in the clinical setting (Jaenisch, 2004; Solter, 2005; 
Hochedlinger, 2006; Jaenisch, 2006). However, the first human trial of ESCs to 
treat spinal cord injury was halted due to concerns about cyst formation and later 
abandoned by the company for financial reasons (Frantz, 2012). Another study 
using ESCs to treat age-related macular degeneration is ongoing (Schwartz, 2012). 
Using iPS cells tailor-made from the patient would bypass both the ethical and 
immunogenic concern, though the concern of tumour formation remains valid. The 
first human trial of iPS cells to treat age-related macular degeneration was initiated 
the summer of 2013 (Melville, 2013). 
 
Somatic stem cells are not burdened with the same ethical considerations as ESCs. 
Several types of somatic stem cells are readily obtainable with little or no 
morbidity for the donor, and in a manner making them suitable for autologous 
transplantation. Indeed, haematopoietic stem cells have been used for decades in 
haematologic cancers, and several other clinical studies of MSCs have been 
performed (Horwitz, 2002; Wakitani, 2002; Baron, 2003; Le Blanc, 2004). To date, 
no tumour formation has been observed after human somatic stem cell 
transplantation in vivo, and the consensus in the field seems to be that within the 
normal ex vivo expansion period of 6-8 weeks, no tumorigenic properties are seen.  
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Mesenchymal stem/stromal cells  
Definition, characterisation and niche 
As stated above, MSCs have been isolated from numerous tissues. Naturally, this 
has been achieved by the effort of several research groups, which in turn has led to 
ambiguities and inconsistencies both in isolation and expansion procedures, as 
well as in their defining characteristics. As a consequence, the Mesenchymal and 
Tissue Stem Cell Committee of The International Society for Cellular Therapy 
(ISCT) issued a position statement defining three minimal criteria for designation 
of multipotent mesenchymal stromal cells, thereby also proposing the term 
"stromal" to be used instead of "stem" (Horwitz, 2005; Dominici, 2006). First, the 
cells must adhere to plastic under standard culture conditions. Second, the cells 
should have a distinct and fairly homogenous phenotype, with ≥95% of the 
population expressing the cell surface markers CD105 (endoglin), CD73 (ecto-
5’nucleotidase) and CD90 (Thy-19). Additionally, ≤2% of the cells should express 
CD45 (a pan-leukocyte marker), CD34 (the endothelial and haematopoietic 
marker), CD14 or CD11 (both monocyte/macrophage markers), CD79 or CD19 
(both B-cell markers) or HLA-DR (a marker of professional antigen-presenting 
cells, only expressed on MSCs if stimulated by IFN-γ). Third, the cells must be 
able to differentiate into the osteogenic, the chondrogenic and the adipogenic 
lineages in vitro as assessed with standard staining methods. Karyotype stability of 
the cells throughout expansion should be considered but is not included in the 
criteria. Despite the high number of tissues from which MSCs can be isolated, 
little is actually known about their in vivo life. They are supposedly mostly 
quiescent, renewing themselves at a very slow rate. The term "stem cell niche" has 
been coined for the location within the tissue where the somatic stem cell resides, 
although for many tissues it is not known exactly where that may be (Moore, 
2006). Interestingly, MSCs themselves seem to be critical for the niche supporting 
the haematopoietic stem cells (Frenette, 2013). The stem cell niche is defined as 
including all extracellular elements and other cells surrounding the stem cells in 
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their native state, and it supposedly works to keep the stem cell in a quiescent and 
undifferentiated state (Lin, 2002). If the niche is broken or if signals from 
cytokines or other signalling molecules reach the stem cell, it is pushed into 
differentiation (Li, 2005). As somatic stem cells are few and far between 
compared to the numbers of differentiated cells in tissues, large difficulties arise 
when trying to investigate this niche directly in vivo. Maybe the most compelling 
indirect evidence of what characterises this niche for the MSCs comes from a 
study in mice, where cells isolated from brain, spleen, liver, kidney, thymus, lung, 
bone marrow, muscle, pancreas and the great vessels all showed MSC properties 
with a strikingly similar morphology, immunophenotype and to some extent 
differentiation potential (da Silva Meirelles, 2006), not unlike human MSCs. The 
authors hypothesised, in line with a few other papers that have investigated the 
niche (Doherty, 1998; Bianco, 2001; Shi, 2003), that the stem cells are intimately 
related to pericytes existing in a perivascular niche, close to the basement 
membrane of blood vessels. This was shown to be true in another study, but it was 
also shown that the pericyte contribution to the MSC population varied from tissue 
to tissue (Feng, 2011). The perivascular localisation would give MSCs easy access 
to most tissues for repair if needed (Francois, 2006). Although MSCs are present 
in peripheral blood, the difficulty of isolating them from this source does 
somewhat contradict this hypothesis.  
Differentiation potential and plasticity 
Plasticity of stem cells is a somewhat vague term with no clear consensus 
definition; it blends in with the property pluripotency described above. The 
following set of criteria for true plasticity have been suggested: A single stem cell 
should be able to self-renew, give rise to the functional cell types of the tissue 
from which it derives, give rise to cell types of unrelated tissues, and repopulate 
both tissues robustly in vivo (Serafini, 2006). The last criterion is the most 
difficult one to prove for any given cell, and often plasticity is proposed only on 
the basis of the first three (in essence showing in vitro pluripotency), and even 
 - 42 - 
then not always meeting the single-cell criterion (opening up the possibility of 
different cell types in the investigated population giving rise to the different cell 
types) (Wagers, 2004; Lakshmipathy, 2005). MSCs by definition should be able to 
differentiate into the adipogenic, osteogenic and chondrogenic lineages, but this is 
multipotency, not plasticity, as all three of these lineages are derived from the 
definitive mesoderm. Especially for both MSCs from bone marrow (BM-MSCs) 
and from adipose tissue (AT-MSCs), the differentiation criterion has been met in 
numerous studies. Evidence is sparser when it comes to plasticity. AT-MSCs have 
been shown to differentiate into neuron-like cells in clonal assays (Boquest, 2005; 
Guilak, 2006), into endothelial cells in non-clonal assays (Cao, 2005), into 
hepatocytes in non-clonal assays (Seo, 2005) and into epithelial cells in non-clonal 
assays (Brzoska, 2005), indicating pluripotentiality, but functionality in vivo has 
not been shown. Regarding BM-MSCs, the picture is even more clouded, yet also 
more promising (Serafini, 2006). Several populations of cells that show multi- and 
pluripotentiality have been isolated from the bone marrow by slightly different 
methods. All populations are adherent cells that exhibit many of the characteristics 
of MSCs, but also characteristics normally associated with ESCs. 
 
The first population described was the multipotent adult progenitor cell (MAPC) 
(Reyes, 2001), from adherent bone marrow cultures supplemented with epidermal 
growth factor and platelet-derived growth factor and with a low serum 
concentration. They showed differentiation into multiple mesodermal lineages in 
clonal assays. Subsequently, in the mouse model, similar cells showed 
differentiation into tissues of all three germ layers at the single-cell level (Jiang, 
2003). MAPCs additionally expressed the ESC-specific transcription factor Oct3/4 
and were able to contribute to chimeras when injected into a blastocyst. Finally, 
when injected into non-damaged recipients, they showed robust engraftment in 
several tissues (Jiang, 2002). However, some concerns, particularly about the 
chimera experiments, have been raised by other researchers, as these results have 
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proved hard to reproduce (NatureNews, 2007). Another cell population termed 
marrow-isolated adult multilineage inducible (MIAMI) cells are isolated and 
cultured using procedures almost identical to MAPCs and show similar 
differentiation potential into cell lineages of all three germ layers, although not at 
the single-cell level (D'Ippolito, 2004). One publication also showed the ability of 
these cells to differentiate into cells with electrophysiological properties similar to 
neurons (Tatard, 2007). A third population, termed human bone marrow-derived 
multipotent stem cells (Yoon, 2005), are similar but slightly different in phenotype 
from MAPC and MIAMI cells. The small differences seen in phenotypic 
appearance between all these populations may in fact be attributed to slightly 
different isolation and culture conditions. The debate around a cell type termed 
very small embryonic-like stem cells, a putative pluripotent tiny cell type present 
in bone marrow and other tissues, highlights some controversy regarding these 
subpopulations of stem cells (Kucia, 2006). Several groups have published that 
this cell type does indeed exist in humans, while other highly renowned groups 
refute their existence (Abbott, 2013; Miyanishi, 2013). 
 
To date, no one has shown true plasticity of somatic stem cells in vivo before ex 
vivo expansion. On the other hand, the studies described above do show that ex 
vivo-expanded stem cells can give rise to functional cells after transplantation into 
recipients in vivo, and this alone gives them a possible therapeutic potential. What 
is not known is whether these cells exist as pluripotent cells in vivo or whether the 
ex vivo manipulation pushes the cells into a dedifferentiated state, thereby 
achieving pluripotentiality (Wagers, 2004). The knowledge from the iPS cell field 
supports to some extent the latter scenario, as a seemingly small change in the 
expression of a few factors can thoroughly change a cell state.  
 
Objections to the pluripotentiality of somatic stem cells in vivo after ex vivo 
manipulation are many, one of which has been mentioned: the possibility that 
 - 44 - 
within the population isolated, more than one type of stem cell exists. No matter 
how purified the population of stem cells, no one has achieved 100% homogenous 
populations. Therefore, only in studies showing pluripotency of single-cell clones 
can plasticity really be proven. The phenomenon known as fusion is another 
objection raised by several authors against studies that have apparently shown 
functional cell engraftment in tissues after stem cell transplantation. Fusion was 
first seen in in vitro cocultures where ESCs adopted the phenotype of neural 
progenitors or bone marrow cells by fusion with these cells at a low rate (Terada, 
2002; Ying, 2002). This has also been shown at very low rates in some in vivo 
systems (Medvinsky, 2003; Alvarez-Dolado, 2007), but in other studies it has been 
ruled out (Harris, 2004). Fusion may still be desirable if it aids in repairing injured 
tissue into functional tissue. 
Other applications of MSCs 
Beside the potential use of MSCs in tissue engineering, which is the focus of this 
thesis, another intriguing use of MSCs is in preventing or treating severe graft-
versus-host disease. Allogeneic MSCs are regarded as immunoprivileged because 
they avoid immune recognition and exert an immunosuppressive effect by 
secreting soluble factors (indoleamine 2,3-dioxygenase, nitric oxide and 
prostaglandin E2) and through direct cell-to-cell contact (English, 2013). 
Promising results have been shown in clinical trials, and multiple trials are 
ongoing (Le Blanc, 2004; Ryan, 2005; Ball, 2013). These findings have even led 
Arthur I. Caplan, who originally suggested the term MSC (Caplan, 1991), to 
suggest they be renamed medicinal stromal cells (Caplan, 2010).  
 
In vitro chondrogenesis of stem cells 
One of the key features of MSCs is the ability to differentiate into mesodermal 
lineages, such as the chondrogenic lineage. Different strategies have been used to 
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induce this process, including the use of cytokines, hormonal stimuli and three-
dimensional culture methods. 
Pellet cultures with growth factors 
The basis for the pellet culture system came from the finding that pellet culture 
could prevent the dedifferentiation that occurred when chondrocytes were grown 
in monolayer cultures (Holtzer, 1960; Manning, 1967). This system was later 
refined for the chondrogenic induction of bone marrow (Johnstone, 1998). After 
centrifugation of 2 x 105 cells into a pellet, the pellet was cultured in a defined 
induction medium that contained transforming growth factor β1 (TGFβ1) and 
dexamethasone. This treatment induced chondrogenesis in all pellet cultures, as 
evidenced by upregulated type II collagen production. Later, this induction 
medium was refined by adding different types of bone morphogenetic proteins 
(BMPs), which further enhanced chondrogenesis (Sekiya, 2001; Sekiya, 2005). In 
these first studies, it is rather unclear why the authors chose the added growth 
factors, but TGFβ1 and BMP-6, -2 and -4 belong to the TGFβ superfamily. This 
superfamily, which also contains activins and inhibins, Müllerian-inhibiting 
substance, cartilage-derived morphogenetic proteins, decapentaplegic gene 
product, Vgr gene products and glial cell line-derived neurotrophic factor, has 
very diverse effects in a wide range of tissues. These effects vary depending on the 
cell type and include effects on cell growth, proliferation, apoptosis, gene 
expression, differentiation and motility (for review, see (Kanaan, 2006; Derynck, 
2007)). The complete function of TGFβ is not fully understood, but various 
members of the superfamily regulate key events in embryogenesis, including the 
forming of the primitive streak and the differentiation of mesoderm and ectoderm 
(Yang, 2003; Sadler, 2006). 
 
The TGFβ subfamily in humans consists of three slightly different proteins (β1, -2, 
-3), the most studied of which is TGFβ1. All of these proteins are encoded as large 
protein precursors of approximately 400 amino acids, the 112-114 amino acid C- 
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terminal region of which becomes the mature molecule that subsequently 
dimerizes into a 25-kDa active molecule (Seibel, 2006). This dimer elicits its 
biological function mainly through two specific transmembrane receptors, TGBR1 
and TGFBR2. The receptor-ligand complexes in turn work through an intracellular 
signalling cascade of specific proteins known as the SMAD family of mediators of 
TGFβ signalling (Derynck, 1996). The end effector of this cascade is an activated 
complex of SMAD4 and SMAD2/3 proteins that, after translocation into the 
nucleus, forms a final complex with a large variety of cofactors. Finally, the 
complex acts as a gene transcription factor generating approximately 300 early 
gene responses (Massague, 2006). The SMAD pathway, from ligand binding to 
phosphorylation of intracellular SMAD proteins, is rather simple compared to 
other pathways, although the responses observed in different cell types are very 
heterogeneous. The discovery that a large variety of cofactors form complexes 
with the activated SMAD complexes is believed to be the explanation for the 
different responses of TGFβ in different cell types (Feng, 2005). Functionally, 
BMPs work in a similar way through specific receptors that activate the SMAD 
cascade using primarily SMAD-1, -5, and -8. They ultimately elicit their function 
as transcription factors that are of activating, enhancing, or inhibiting nature, often 
in conjunction with transcription factors already present in the nucleus (Seibel, 
2006; Keller, 2011). BMPs, like TGFβ proteins, are synthesised as precursors and, 
after proteolytic cleavage, form a biologically active dimer. More than 20 different 
BMPs have been described to have large and varied effects on most cells in 
general and especially on stem cells (Wagner, 2007; Retting, 2009). Briefly, BMP-
2, -4, and -6 have been shown to directly induce SOX9 expression, which is 
important for type II collagen production (Shum, 2002; Sekiya, 2005). BMP-2, -4, 
-5, and -7 can all induce new bone formation in vivo but are also frequently used 
in in vitro chondrogenesis (Handorf, 2014). Finally, several BMPs have been 
shown to have profound effects on differentiation into mesenchymal lineages of 
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stem cells, although a consensus on what is the most efficient dose and mix of 
BMPs for a specific differentiation of a specific cell type is far from being reached.  
 
In summary, BMPs and TGFs have profound effects on cells during 
embryogenesis, especially on the skeleton and associated structures, and, not 
surprisingly, have profound effects on stem cells in vitro. The effects depend on 
the type of BMP/TGF protein and their mix and dosing and on cell type.  
 
Several other molecules have been used in attempts to improve chondrogenesis. 
These include fibroblast growth factors, parathyroid hormone-related peptide and 
various inhibitors of signalling cascades (Liu, 2007; Kim, 2008; Kim, 2010b; 
Weiss, 2010; Handorf, 2011; Im, 2011). Some have been shown to lead to 
improvement, but there does not seem to be any consensus among research groups 
that these molecules should be included in the standard cocktails used to induce 
chondrogenesis. This debate might change in the coming years.  
Matrix-assisted cultures 
As discussed above, a three-dimensional culture of chondrocytes or stem cells is a 
requirement for chondrogenesis. Pellet cultures are, however, not a feasible 
strategy for tissue engineering, as they cannot be made a sufficient size without 
suffering from central necrosis due to limited oxygen and nutrient passage. 
Therefore, extensive research has been focused on finding a scaffold that can be 
used for in vitro studies of chondrocytes and MSCs (Hunziker, 2002a; Ge, 2012). 
The ideal scaffold would support cell viability, distribution, and proliferation; be 
biocompatible and biodegradable; provide structural support; and have a proper 
pore size to allow for diffusion of nutrients and waste products. For clinical use, 
they should also be suitable for handling and should be able to allow for 
integration to the adjacent tissue. Scaffolds used in the literature have been 
protein-based, made from fibrin, collagen and gelatin, or carbohydrate-based 
polymers, such as alginate, polylactic acid, polyglycolic acid and hyaluronic acid 
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scaffolds. In addition, artificial polymers such as Dacron, Teflon, hydroxyapatite, 
titanium and carbon fibres have been used. Some of these scaffolds, in addition to 
capturing the cells in a three-dimensional system, provide biological cues to the 
cells via cell-matrix interactions. These are typically scaffolds made from 
constituents normally present in the ECM, such as collagen and hyaluronic acids. 
Other scaffolds, such as alginate derived from brown algae and polylactic and 
polyglycolic acid, are rather inert and do not bind to cell receptors.  
 
Currently, no scaffold has emerged as unequivocally superior (Ge, 2012). It seems 
that MSCs and chondrocytes can undergo chondrogenesis in a large variety of 
scaffolds. However, a major problem for most, if not all, systems is that the 
differentiated cells do not stop in the prehypertrophic state. They continue to 
express the unwanted type I collagen, and induce type X collagen expression, as 
well as unwanted enzymes MMP13 and alkaline phosphatase and osteogenic 
transcription factor RUNX2 (Pelttari, 2006; Dickhut, 2009; Tang, 2012). The work 
in this thesis is based on scaffolds made from alginate or hyaluronic acid. These 
types of systems have been used successfully by several other research groups (Ma, 
2003; Cristino, 2005; Tognana, 2007; Gharravi, 2012; Ma, 2012).  
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MicroRNAs 
MicroRNAs are a fairly recently discovered class of non-coding RNAs that 
regulate gene and protein expression (for reviews, see (Ambros, 2004; Bartel, 
2004, 2009)). MicroRNAs are double-stranded and 21-25 nucleotides long when 
fully processed. They target complementary nucleotide sequences in mRNA, 
primarily in the 3´-untranslated 
region (3´UTR) in animals 
(Figure 6). They are 
transcribed as longer 
transcripts, termed primary 
microRNA. Primary 
microRNAs are recognised by 
the Drosha microprocessor 
complex in the nucleus and are 
cleaved, leaving a 3’ two-
nucleotide overhang hairpin 
precursor microRNA. The 
precursor is transported via 
exportin 5 to the cytoplasm, 
where it is processed by Dicer, which cleaves the hairpin loop, leaving the mature 
double-stranded microRNA. One or both of the strands may have a biological 
effect (in general based on the stability of each strand) and are given suffixes 
based on which arm they come from (the 5p or 3p arm). Mature microRNAs are 
then incorporated into the RNA-induced silencing complex (RISC) and may then 
exert their effect by binding with full or incomplete complementarity to mRNA 
(He, 2004). Regarding complementarity, one normally considers only the so-called 
seed sequence, which is the sequence from nucleotide two to nucleotide seven 
counted from the 5´ end, though it is sometimes expanded to nucleotides eight and 
Figure 6. Canonical maturation of mammalian microRNAs. 
See text for explanation. From (Winter, 2009) 
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one (Bartel, 2009). Full complementarity of this sequence generally leads to 
cleavage of the mRNA, which is then degraded. Incomplete complementarity 
generally leads to translational repression so that gene products are not produced; 
however, the mRNA is unaffected. New discoveries have also expanded our view 
of how microRNAs work by showing that they may, in some instances, enhance 
gene expression through activation instead of translation or by binding directly to 
promoters inducing or repressing transcription (Lin, 2011; Vasudevan, 2012; 
Meijer, 2013). Binding may also occur in the 5´UTR (Orom, 2008).  
 
The latest release of the full catalogue of all known microRNAs maintained by the 
University of Manchester (www.mirbase.org) lists more than 2,000 human 
microRNAs. As one microRNA may target more than 100 different mRNAs, the 
total effect of microRNAs in human cells is mind-boggling (Brennecke, 2005). It 
is estimated that 60% of all genes are regulated by microRNAs to some extent 
(Friedman, 2009). 
Role of microRNAs in cartilage biology and pathology 
The essential role of microRNAs in the normal development of cartilage was 
convincingly demonstrated in mice deficient for Dicer in chondrogenic regions. 
These mice showed severe skeletal malformations and died in early postnatal life 
(Kobayashi, 2008). One specific microRNA, miR-140, has been identified as 
especially important in cartilage and is almost exclusively expressed in cartilage 
(Tuddenham, 2006; Miyaki, 2009; Araldi, 2010; Miyaki, 2010). miR-140 is 
located in an intron in the WWP2 gene and has its own promoter; its expression is 
induced by SOX9 (Yang, 2011b; Nakamura, 2012). In vivo studies have 
substantiated the importance of miR-140 in chondrogenesis. miR-140-deficient 
mice show relatively small skeletal differences compared to wild-type mice. The 
skeleton of miR-140-deficient mice is slightly shorter, and the cartilage growth 
plate is thinner with fewer proliferating chondrocytes compared to wild-type mice. 
More strikingly, the deficient mice were much more prone to develop both age-
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related and surgically induced osteoarthritis. The explanation for the susceptibility 
to osteoarthritis might be that miR-140 targets the aggrecanase ADAMTS5 
(Miyaki, 2010). This corresponds with the finding that miR-140 expression is 
reduced in human osteoarthritic cartilage in which a loss of proteoglycans is often 
a hallmark (Iliopoulos, 2008; Miyaki, 2009). It has also been shown that miR-140 
deficiency leads to accelerated hypertrophic differentiation of chondrocytes, 
thereby impairing endochondral bone formation, possibly by modulating BMP 
signalling through the target DNPEP gene (Nakamura, 2011).  
 
Multiple publications support the significance of miR-140 in chondrogenesis. This 
microRNA has been validated to target SMAD3 (only at the protein level), SP1, 
BMP2, CXCL12 and HDAC4, which are all known to influence cartilage 
development or homeostasis (Tuddenham, 2006; Nicolas, 2008; Pais, 2010; 
Nicolas, 2011b; Yang, 2011b).  
 
It is likely that other microRNAs play important roles in cartilage development. 
For example, miR-145 has been shown to target SOX9 (Yang, 2011a; Martinez-
Sanchez, 2012). miR-675, if overexpressed, positively regulates type II collagen 
expression in chondrocytes (Dudek, 2010). The bicistronic miR-family of miR-
221 and miR-222 has been shown to negatively regulate chondrogenesis in chick 
limb stem cells, possibly through an influence on mechanotransduction (Dunn, 
2009; Kim, 2010a). 
 
In osteoarthritic cartilage, a variety of microRNAs has been shown to be 
dysregulated. For example, the expression of miR-25, -26a, -27a, -27, -29a, -140, -
210, and -337 is lower in osteoarthritic cartilage compared to normal cartilage. 
The significance of these changes remains to be determined for most of the 
microRNAs, with miR-140 as a notable exception (Goldring, 2006a; Iliopoulos, 
2008; Miyaki, 2012).  
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Future applications of microRNA in treatment, diagnosis, and prognosis 
As illustrated by miR-140 and osteoarthritis, microRNAs may be dysregulated in 
human disease. Many other examples of microRNA dysregulation have been 
found in recent years, especially within cancer and autoimmune diseases (Thai, 
2010). However, in many instances, it is not known whether the dysregulation is 
causal. Nevertheless, some of these dysregulations are quite specific and may 
therefore be potential biomarkers for diagnosis and prognosis. For example, miR-
21 has been proposed as a marker for colorectal cancer, miR-221/222 as a marker 
to aid in prognosis in advanced breast cancers, and miR-30d has been investigated 
as a prognostic marker in prostate cancer (Kobayashi, 2012; Falkenberg, 2013; 
Toiyama, 2013). These types of studies have mainly been conducted on tissue 
samples, but recent studies have also tried to use circulating microRNAs isolated 
from serum or plasma as a non-invasive opportunity to access disease-specific 
information (Ouyang, 2013). The exact origin or function of circulating 
microRNAs are not entirely clear, although it appears that cells secrete 
microRNAs continuously, normally as exosomes, and in some instances as free 
microRNAs that circulate bound to 
RNA-binding proteins. 
Additionally, it not entirely clear if 
this secretion is a representative 
sample of the cytoplasmic 
microRNAs or if the mechanism 
has some level of selectivity (De 
Guire, 2013). It is likely that the 
research field on circulating 
microRNAs as disease markers will 
expand considerably in the coming 
years. 
Figure 7 A subset of microRNAs currently being 
pursued in preclinical and clinical trials (MPD: 
myeloproliferate diseases; HCV: hepatitis C virus). From 
(van Rooij, 2012). 
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MicroRNAs are also being investigated for therapeutic purposes. A novel example 
of this is the use of a miR-122 inhibitor as a treatment for hepatitis C virus 
infection. This virus type is dependent on miR-122 expression for replication 
(Lanford, 2010). In a phase 2a clinical trial, a specific inhibitor of miR-122 
(Miravirsen®) was shown to induce a dose-dependent reduction in hepatitis C 
virus RNA without evidence of viral resistance (Janssen, 2013). Other anti-miRs 
being pursued for therapy are illustrated in Figure 7.  
 
So far, there have not been clinical trials of microRNA mimics for therapeutic 
purposes, although there are some preclinical studies with promising results. Let-
7b mimics were shown to reduce tumour formation in a mouse model of lung 
cancer (Esquela-Kerscher, 2008). Recently, a phase 1 clinical trial was announced 
to test a mimic of miR-34, believed to act as a tumour suppressor in patients with 
unresectable primary liver cancer 
(http://clinicaltrials.gov/ct2/show/NCT01829971). More related to the subject of 
this thesis, intra-articular injection of miR-210 was shown to be effective in 
promoting healing of torn ACLs in a rat model (Shoji, 2012).  
 
Several companies have been established to research a multitude of microRNAs 
and anti-microRNAs the last few years, and it is likely that new therapies will 
evolve in the coming decade.  
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Aims of the study 
The overall aim of this study was to explore the biology of in vitro chondrogenesis 
in a translational setting. We aimed to deepen the existing knowledge on several 
aspects of tissue engineering of human articular cartilage as described below.  
 
Specific aims related to the included papers: 
 
Paper I. To examine the in vitro chondrogenic potential of adipose tissue-derived 
and bone marrow-derived MSCs in a clinically available scaffold made from 
esterified hyaluronic acid, as evaluated by gene and protein expression of key 
cartilage markers. Dedifferentiated chondrocytes cultured in the same scaffold 
were used for comparison. 
 
Paper II. To evaluate if MSCs could be harvested, cultured and implanted in the 
same scaffold as used above in paper I for the repair of a critically sized 
osteochondral defect in a rabbit model. 
 
Paper III. To investigate the global microRNA expression profile of human MSCs 
undergoing chondrogenic differentiation and compare the profile to that of freshly 
isolated human articular chondrocytes undergoing dedifferentiation to identify 
those with a reciprocal relationship. Subsequently, to investigate the role of these 
microRNAs in in vitro chondrogenesis and identify possible targets. 
 
Paper IV. To validate the use of factorial design and high-throughput mRNA 
profiling to dissect in vitro chondrogenesis in general; specifically, to analyse the 
effects of five commonly used chondrogenic factors in directed differentiation of 
human bone marrow-derived MSCs. 
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Summary of results 
Paper I 
In this study, we compared MSCs from adipose tissue and bone marrow with 
articular chondrocytes. We used a clinically available scaffold made from non-
woven hyaluronic acid, HYAFF-11®, which at the time of our experiments was 
being tested in clinical trials with cultured chondrocytes for the repair of chondral 
defects. Cells were expanded in monolayer cultures and seeded onto the scaffold. 
Three-dimensional MSC cultures were supplemented with a chondrogenic 
medium containing TGFβ1, BMP2 and dexamethasone. Three-dimensional 
chondrocyte cultures were not given chondrogenic medium to keep the culture 
conditions similar to what was used in the clinical trials. We assessed 
chondrogenesis using quantitative RT-PCR and immunohistochemistry on fixed 
sections and by ELISA on supernatants. 
 
We found that the MSC cultures responded to the medium and scaffold by 
upregulating chondrogenic markers measured at the mRNA level. Notably, this 
included both the upregulation of the wanted hyaline cartilage marker COL2A1 
and potentially unwanted markers, such as COL10A1. The most pronounced effect 
was observed when the MSCs were continuously exposed to chondrogenic factors. 
Bone marrow-derived MSCs induced much higher levels of type II collagen 
mRNA expression than did adipose tissue-derived MSCs and chondrocytes. Type 
II collagen protein was seen by immunohistochemistry within the cells in the 
scaffold; however, only small amounts of extracellular type II collagen were 
observed extracellularly. Instead, considerable amounts of type II collagen were 
found in the culture supernatants.  
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Paper II 
Although ACI is widely used, there are concerns related to its use, especially 
donor site morbidity, the need for a two-stage intra-articular procedure and the risk 
of graft hypertrophy. In addition, the dedifferentiation of chondrocytes in culture 
questions whether the chondrocytes will be able to re-establish good quality 
hyaline cartilage. The use of MSCs as an alternative would effectively eliminate 
these concerns. Therefore, the purpose of this study was to evaluate the efficiency 
of MSCs in a hyaluronic acid scaffold to repair an osteochondral defect in rabbit 
knee. We harvested bone marrow from 11 New Zealand White rabbits, isolated 
MSCs and cultured them in autologous serum for 28 days. Forty-eight hours prior 
to implantation, cells were seeded onto the scaffold at density of 107 cells/cm2. 
Circular defects that were 4 mm wide and 1.5 mm deep were created on the medial 
femoral condyle of both knees, and the cell-loaded scaffold was implanted in one 
knee and an empty scaffold in the other knee. The rabbits were killed after 24 
weeks. Condyles were fixed and subjected to semiquantitative and quantitative 
evaluation by blinded observers. We found a high degree of filling in both cell-
loaded and control defects, with no statistically significant difference in filling. 
However, there was a tendency for better quality repair tissue in the cell-treated 
defects. We did not observe any hypertrophy in either group.  
Paper III 
In paper III, we focused on the biology of in vitro chondrogenesis of MSCs 
compared to the dedifferentiation process of articular chondrocytes in culture. 
Based on a previous study from our group (Karlsen, 2011), we particularly wanted 
to study the microRNA expression profile during in vitro chondrogenesis in a 
novel self-gelling alginate scaffold. We first identified cartilage-related miR-140-
5p and -3p to be among the most highly expressed microRNAs in differentiated 
MSCs. We also identified miR-210 and miR-221 to be reciprocally expressed. 
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miR-210 increased during differentiation of MSCs and decreased during 
dedifferentiation of chondrocytes, whereas the opposite was true for miR-221. 
There was a 57% overlap for the 100 most highly expressed microRNAs in 
differentiated MSCs and uncultured chondrocytes; for other microRNAs, the 
expression pattern was quite different. 
 
Next, we transiently and stably overexpressed or inhibited miR-140-5p and -3p. 
Global mRNA analysis showed that inhibition of miR-140-5p led to the 
upregulation of genes involved in cytoskeleton remodelling and cell division and 
the downregulation of genes related to extracellular regions and ECM. Further, we 
found chondrogenesis to be functionally impaired in MSCs stably overexpressing 
anti-miR-140-5p as assessed by protein expression of key cartilage markers and 
secretion of GAGs. Surprisingly, SOX9 and aggrecan proteins were found to be 
downregulated in anti-miR-140-transduced differentiating MSCs despite 
unchanged mRNA levels. This suggests that miR-140 may directly or indirectly 
stimulate in vitro chondrogenesis by the upregulation of these molecules at the 
protein level. We identified several possible new targets of miR-140-5p and -3p, 
including CD248, LIPA, RALA, THBS2, and TMEM119. We validated RALA to be 
a target by luciferase reporter assay. Knockdown experiments showed that RALA 
regulated SOX9 at the protein level. RALA is a small GTPase believed to be 
involved in TGFβ/activin signalling but not previously known to play a role in 
chondrogenesis.  
Paper IV 
The in vitro process of chondrogenic differentiation of MSCs for tissue 
engineering requires three-dimensional culture along with the addition of 
differentiation factors to the culture medium. In this study, we focused on the role 
of differentiation factors in the same alginate scaffold as used in paper III.  
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Our aim was to explore factorial quality-by-design and high-throughput digital 
mRNA profiling as tools to characterise directed differentiation of MSCs and to 
validate the most commonly used chondrogenic growth factors. Factors used for 
chondrogenesis vary but regularly include members of the TGFβ superfamily and 
dexamethasone, sometimes in conjunction with fibroblast growth factor 2 and 
insulin-like growth factor 1. We combined a factorial quality-by-design 
experiment with high-throughput mRNA profiling of a customised 
chondrogenesis-related gene set of 364 genes to study in vitro chondrogenesis of 
bone marrow-derived MSCs in alginate. Forty-eight different conditions of 
different combinations of TGFβ1,- 2 and -3; BMP2, -4 and -6; dexamethasone; 
insulin-like growth factor 1; fibroblast growth factor 2 and cell seeding density 
were included in the experiment and assayed after one and seven days of induction 
in several donors.  
 
First, we showed that high-throughput mRNA profiling could be efficiently 
performed on lysates of MSCs during in vitro chondrogenesis in alginate. We also 
found that changes in gene expression observed just one day after induction 
predicted later changes. The analysis revealed that the best of the tested 
differentiation cocktails included TGFβ1 and dexamethasone. Dexamethasone 
acted in synergy with TGFβ1 by increasing many chondrogenic markers while 
directly downregulating the expression of the pro-osteogenic gene osteocalcin. 
However, all factors beneficial to the expression of desirable hyaline cartilage 
markers also induced undesirable molecules, indicating that perfect chondrogenic 
differentiation could not be achieved with the current differentiation protocols. 
 
The method validated in this study could quite easily be adapted to screen large 
numbers of molecules that might enhance chondrogenesis. Together, the 
implications of these findings could decrease both the cost and workload 
considerably in future experiments.  
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Methodological considerations 
In this section, a brief introduction is given to the methods used in the included 
papers highlighting some of the advantages and limitations. The section is not 
exhaustive. Methods that are very standardised and only used in a limited number 
or supplementary experiments are not discussed in detail. When relevant, 
problems that occurred during experiments and how they were solved or avoided 
will be mentioned. Detailed descriptions of the protocols used are in the methods 
and materials sections of the original papers.  
Cell culture and supplements 
Isolation of MSCs from bone marrow and adipose tissue was performed using 
established protocols previously described by our group and others and included a 
centrifugation step to separate out the mononucleated cells, which were then 
cultured in standard plastic culture flasks. Adipose tissue was obtained as a "by-
product" from elective liposuction procedures, and bone marrow was obtained by 
aspiration from the iliac crest of human volunteers. Articular chondrocytes were 
isolated from healthy or diseased cartilage biopsies using short-time enzymatic 
digestion before standard cell culture, following established protocols (Shahdadfar, 
2008). All procedures on humans were approved by the Regional Committee for 
Medical Research Ethics and on rabbits by the Norwegian Animal Research 
Authority. 
 
During monolayer culture, we used standard culture medium supplemented with 
antibiotics. Most cell types also need the medium to be supplemented with foetal 
bovine serum (FBS) for survival and proliferation. In the cultures in the later 
experiments included here, we substituted FBS with human platelet lysate plasma 
(hPLP) produced following published protocols (Schallmoser, 2009). This reflects 
a change in our lab over the last few years that happened for two main reasons: 
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Firstly, we have made an effort to fully humanise our culture system to avoid any 
issues related to xenoreactivity, and secondly, FBS variability is a recognised fact 
that especially for MSC culture represents a problem in that different batches of 
FBS vary immensely in the ability to support MSC proliferation (Caplan, 2005). 
Three-dimensional culture and choice of scaffold 
In vitro chondrogenesis of stem cells requires a three-dimensional culture system. 
As presented in the introduction, a multitude of different systems and scaffolds 
have been used. In the work presented here, we used two different scaffolds, one 
made from hyaluronic acid (Hyaff-11®) and one made from alginate, which 
represent two different approaches. Hyaluronic acid is a constituent of the ECM of 
articular cartilage with a defined binding to and effect on chondrocytes via CD44. 
The Hyaff-11® scaffold is a polymer derived from the total esterification of 
sodium hyaluronate (80-200 kDa). The configuration we used was a non-woven 
mesh composed of a random array of polymer fibres with a diameter of 
approximately 40 nm. In aqueous solution, the material hydrates and undergoes 
degradation by spontaneous hydrolysis of the ester bonds. Further degradation in 
vivo may then be faciliated by the enzyme family of hyaluronidases. This process 
is quite rapid when no cells are seeded into the scaffold in vitro, and studies in rats 
aimed to evaluate the in vivo biodegradation of Hyaff-11® have shown that the 
material had mostly disappeared after approximately 4 months following 
implantation (Grigolo, 2002). The material is easily sterilised by γ-irradiation. The 
clear advantages of this scaffold are the proven track record with chondrocytes in 
clinical studies, including the ability to implant the scaffold arthroscopically, and 
its excellent biocompatibility. However, as illustrated in the results from paper I, 
there are problems in retaining the extracellular matrix in the scaffold. We were 
kindly provided the scaffold by the manufacturer Fidia Advanced Biopolymers for 
the studies in papers I and II. However, we were not able to secure an agreement 
on using the scaffold in future clinical studies. In parallel with these experiments, 
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our group had started working with scaffolds made from alginate for MSC culture 
(Duggal, 2009). It has been shown that encapsulating chondrocytes in alginate 
supports the articular chondrocyte phenotype in long-term cultures and promotes 
the re-expression of cartilage specific genes in dedifferentiated chondrocytes 
(Bonaventure, 1994; Hauselmann, 1994). There have been several other studies 
using various types of alginate scaffold for in vitro chondrogenesis of MSC (Ma, 
2003; Gharravi, 2012; Ma, 2012). Our group has validated a novel self-gelling 
alginate system for in vitro chondrogenesis (Herlofsen, 2011). Therefore, for the 
experiments in papers III and IV, we used this scaffold. Alginate is a 
polysaccharide naturally found in brown seaweed. It consists of β-D-mannuronic 
acid (M) and α-L-guluronic acid (G) monomers that are randomly distributed 
(Smidsrod, 1990). Divalent cations interact with the G-blocks, causing the 
polysaccharides to form a gel. Alginate has several advantages in tissue 
engineering. It is biocompatible and is already used as a delivery vehicle for drugs 
and as dressing for thermal burn wounds (Tonnesen, 2002; Opasanon, 2010). 
Ultrapure clinical-grade alginates are also readily available, which prevent issues 
of toxicity and immunogenicity. In its pure form, especially with a G-block 
content above 50%, alginate has been shown to not induce significant immune 
responses (Andersen, 2012), although some publications have shown that a higher 
M-block content does induce an innate immune reaction (Yang, 2009). Alginate is 
not degraded actively after implantation in living tissue but is believed to decay 
slowly. However, this potential issue in tissue engineering could be overcome by 
dissolving the alginate by chelating agents, such as EDTA or citrate, which bind 
divalent cations (usually Ca2+ or Sr2+). Ideally, this chelation could be conducted 
as soon as sufficient ECM has been produced to support the three-dimensional 
structure. Other molecules, growth factors or supplements may also easily be 
mixed into the alginate before gelling.  
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In summary, both scaffolds used in this study could support chondrogenesis; 
however, due to availability for independent research and excellent properties for 
future adaptations, the alginate scaffold is currently our scaffold of choice. 
Transfections and transductions 
To study the effect of microRNAs and to inhibit specific mRNAs, we used two 
different methods to introduce the microRNAs, small inhibiting RNAs (siRNA) or 
complementary sequences to specific micro-RNAs (anti-miRs) into our target cells. 
One method was transient, the other permanent. The transient method is generally 
referred to as transfection and intentionally introduces nucleic acids into the cell 
cytoplasm without any incorporation into the genome of the cell. Transfection 
methods fall in two main groups: physical, such as electroporation or 
microinjection, and chemical, such the use of lipid carriers or salts (Kim, 2010c). 
In both transfection methods, the introduced nucleic acids are fairly rapidly diluted 
out due to cell division or degradation, and in general, the effect is lost in 3-5 days. 
Cell type, confluency at the time of transfection, cell cycle phase and stability of 
the delivered RNA are some of the factors influencing how well transfection 
works, in addition to the transfection method.  
 
We used liposomal transfections and electroporation in our experiments, but the 
results obtained in the lab at the time of the experiments for paper III led us to use 
electroporation almost exclusively in the published paper. It was found that 
liposomal delivery, in which nucleic acids are contained in spontaneously formed 
small vesicles (liposomes), led to a significant upregulation of immune-related 
genes (Karlsen, 2013). This upregulation could potentially affect the results even 
when controlled for by appropriate negative controls. The same effect is not 
observed when using electroporation, in which nucleic acids are introduced into 
the cells following a short electric impulse, which transiently makes small pores in 
the cell membrane. It requires specialised equipment; however, it is easily 
 - 63 - 
performed and works well on a wide variety of cells. The manufacturer often 
provides specialised protocols for various cell types, but adaption for each specific 
cell type and workflow is still needed. We optimised our protocols with regards to 
cell number and ratio of serum to cell medium to optimise cell survival and found 
an optimum of 106 cells and 20% FBS per electroporation. 
 
Both an advantage and disadvantage of transfection is its transience. On the one 
hand, the cells are left quite unharmed by the transfection with no interference 
with the cell genome; on the other hand, if one is interested in long-term effects, 
serial transfections are needed. In the case of three-dimensional culture, this is not 
possible because electroporation requires cells to be in suspension, and liposomes 
will not penetrate the alginate due to charge and size. 
 
To overcome this problem, we used a standard viral method termed transduction. 
By combining viral genes and an expression vector for the RNA sequence we 
want the cells to express, it is possible to stably affect the cells. We used a system 
based on lentivirus genes (for a review of methods, see (Durand, 2011)). Briefly, 
several plasmids containing the genes encoding all necessary proteins needed to 
make infection-competent viral particles are transfected into a so-called packaging 
cell line together with a plasmid encoding the RNA sequence to be expressed in 
the target cells. The packaging cell line then packages this expression vector into 
viral particles and secretes them into the cell medium, which is harvested. This 
medium may then be added to the target cell line, whereby particles infect the cells, 
and the expression vector is reversely transcribed into DNA, which is then 
integrated by the viral integrase randomly into the genome of the target cell. The 
integrated DNA incorporates a constitutive promoter, in our case the CMV 
promoter, that drives the expression of the transgene. The insertion also 
constitutively expresses an antibiotic resistance gene, in our case, to puromycin, to 
select the transduced cells. This is a very effective way of overexpressing or 
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knocking down genes or microRNAs; however, it involves several steps that need 
optimisation and also includes some potential hazards. The latter is generally dealt 
with by using later-generation systems with all viral genes on separate plasmids; 
the former by pilot experiments to determine optimal transfections of the 
packaging cell line, viral titre, multiplicity of infection, concentrations of 
antibiotics for selections and optimism. Disadvantages to be aware of are the 
random nature of integration that may disrupt tumour suppressor genes and that 
the CMV promoter has been shown to be gradually inactivated in stem cells (Xia, 
2007).  
Gene and microRNA expression analysis 
Quantitative RT-PCR 
Quantitative RT-PCR (RT-qPCR) has been the mainstay of gene expression 
analysis of a single or a moderate number of genes over the last decade. It is 
highly specific, sensitive and reproducible and allows for an easy assessment of 
the input RNA of a specific gene if a few requirements are met. It can be done 
either as an absolute quantification or relative to a reference sample, the latter 
being the most frequently applied. First, RNA should be of a sufficient quality and 
purity, usually judged by spectrophotometry. Second, the amount of cDNA 
formed during the reverse transcription reaction should accurately reflect the input 
RNA. This is secured by allowing for an excess of reagents and assessing for 
inhibitors of transcription by preparing dilution series. Third, a stable internal 
reference gene (endogenous control gene) is needed for normalisation, and this is 
normally tested for in each set of experiments, choosing from a common set of 
possible control genes. In the experiments included here, we have found the 
commonly used GAPDH gene to perform well. Fourth, the target gene and internal 
reference gene should have similar amplification efficiencies, preferably above 
90%. We generally use TaqMan probes (Applied Biosystems), which are tested by 
the supplier to perform to this standard or above, and we have tested several to 
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confirm this. There are disadvantages of RT-qPCR, especially that it is feasible to 
test only a limited number of genes for practical and economic reasons. In addition, 
the constant debate on which reference genes or combination of reference genes to 
use, especially if reporting on only minor fold differences, needs consideration. 
Finally, the problem with all gene expression assays is that they do not necessarily 
reflect functional differences in the cell, i.e., changes in protein expression. 
Nanostring 
A new way of testing gene expression has emerged the last few years. This is 
marketed as Nanostring 
nCounter Gene Expression, 
or in some publications, it 
is termed digital 
mRNA/microRNA 
profiling. We used this for 
gene and microRNA 
expression analysis in 
papers III and IV. The 
biggest difference from RT-
qPCR is that there are no 
enzymatic conversions or 
amplifications. The input 
RNA (purified or as cell 
lysates or even whole 
blood) is directly hybridised 
to fluorescently labelled 
probes (several 
fluorochromes are attached 
in a specific order to 
Figure 8 (a) Total RNA is mixed directly with nCounter reporter 
and capture probes. (b–d) After hybridisation (b), excess reporters 
and capture probes are removed (c), and the purified ternary 
complexes are bound to the imaging surface, elongated and 
immobilised (d). (e) Reporter probes, representing individual 
copies of mRNA, are tabulated for each gene. From (Fortina, 
2008). 
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distinguish each probe from each other). These probes are subsequently 
immobilised in a cartridge, with a small current aligning all captured RNA in the 
same direction. Thereafter, the number of different probes is a direct measure of 
RNA templates captured (Geiss, 2008; Malkov, 2009).  
 
The system has been shown to perform with sensitivity, specificity and 
reproducibility comparable to RT-qPCR but in a highly multiplexed system that 
can test up to 800 genes/microRNA in one sample. It has frequently been used to 
validate microarray analyses. The analyses of results are performed using 
measurements from spiked-in RNA to normalise for variability in hybridisation 
efficiency, and later using the same statistical analysis as applied for microarray 
data. Perhaps the biggest advantage of this method is that it can be performed 
directly on lysates of cells and tissues, allowing for a very efficient workflow in 
larger experiments and avoiding variability introduced by RNA isolation, although 
this does require a set of endogenous controls to be used to control for input. 
Functional assays (protein and proteoglycan quantification) 
Western blots 
Western blotting, or, more accurately, protein blotting, is widely used to detect 
proteins in cell or tissue lysates, serum or cell culture supernatants. The technique 
involves both a size-separation phase by electrophoresis in a polymer membrane 
and a subsequent labelling of the blot with a specific antibody to the target protein. 
This so-called primary antibody is then bound by a secondary antibody that can be 
visualised by radioactivity, chemiluminescence, fluorescence, or gold particles, 
depending on the system used. In our system, we used a chemiluminescence 
approach. Generally, protein blotting is not used in a precise quantitative manner 
but rather in a semiquantitative manner judged "by eye" as showing more, less, or 
similar amounts of protein in the samples being compared. In any case, a 
judgement on the protein amount present depends on equal loading onto the 
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membrane as determined by the loading control. The protein beta-actin is probably 
the most commonly used loading control. There are numerous steps involved in 
protein blotting, and each may be optimised for the specific cell type and antibody 
used. For our experiments, the step demanding the most optimisation was how to 
prepare good lysates from the alginate discs. We tried several ways, including 
dissolving the alginate by chelators or isolating protein by an adapted Trizol 
method, but these methods were unsuccessful. Instead, we ended up pulverising 
the alginate discs in liquid nitrogen and dissolving them directly in the lysis buffer 
before loading them onto the membranes. This worked well, but we did see 
broader bands in samples from alginate than from cell pellets, especially for 
aggrecan. 
ELISA 
Another way to quantify proteins using antibodies is the enzyme-linked 
immunosorbent assay used in paper I. This method uses a specific antibody to bind 
an antigen, in our case type II collagen. These assays are usually performed in 
special 96-well plates with commercially available kits, in which the secondary 
antibody is linked to an enzyme that, after adding of a specific substrate, produces 
a visible signal that can be read on a spectrophotometer.  
Immunohistochemistry 
A third way to visualise proteins is immunohistochemistry performed on sections 
of cells, tissues or, in our case, "tissue-engineered" cartilage. Whereas protein 
blotting gives a readout that is semiquantitative, immunohistochemistry on 
sections also gives a spatial readout. In our experiments, immunohistochemstry 
was used to validate the protein expression of cartilage markers. There are 
numerous optimisation steps needed for successful immunohistochemistry, which, 
in our case, was performed when the self-gelling alginate system was validated for 
chondrogenic differentiation (Herlofsen, 2011). 
 - 68 - 
Quantification of sulphated proteoglycans and glycosaminoglycans 
The last method we employed to functionally support gene expression data, was to 
quantify the production of sulphated proteoglycans present in the culture medium. 
Much like for ELISA, we used a commercially available kit used by our group and 
others previously (Jia, 2012; Fernandes, 2013). This kit uses a specific dye that 
binds to sulphated GAGs and can be read on a standard spectrophotometer. 
Quantification is then performed with the help of a standard curve from supplied 
standard concentrations of GAGs. 
MicroRNA luciferase reporter assay 
To validate the binding of a microRNA to a specific mRNA, we utilised a 
luciferase reporter system (Nicolas, 2011a). This simple system uses the 3´UTR of 
the suspected target cloned into a vector constitutively expressing luciferase. If 
this vector is cotransfected with a microRNA that binds to this sequence, then the 
luciferase expression will be turned off due to cleavage or translational repression. 
Luciferase leads to light emission, which can be quantified on a plate reader. Any 
decrease in the level of emitted light suggests a binding of the microRNA. 
Combined with the appropriate controls of irrelevant miRs and 3´UTR-sequences, 
it is possible to validate that the microRNA directly affects the mRNA with a high 
degree of certainty. The vectors can be easily cloned in the lab, but to save time, 
we purchased a vector from a commercial vendor.  
Quality-by-design experiments 
Optimising a process one factor at a time is common in biological experiments. 
However, it is time consuming and laborious. In the chemical and other industries, 
factorial analysis, quality-by-design experiments, sometimes termed "Design of 
Experiment" approaches, have been utilised to determine the effect of several 
factors on a chosen response simultaneously in a cost-effective manner (Chen, 
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2011b; Enochson, 2012; Crapnell, 2013). This demands a specific experimental 
set-up in which the investigated factors are included in different runs in a 
randomised manner. These set-ups can be easily designed with the use of 
statistical software packages, such as MiniTAB®. There are some requirements 
that need to be met for the analysis (which is essentially an analysis of variance 
(ANOVA)) to be valid, including that the data need to be tested for normality and, 
if needed, log-transformed to pass the normality test before testing for significant 
effects on the response. The data can then be fitted with a regression model, which 
will explain as much as possible of the variance in the dataset and subsequently 
test which factors affect the response significantly. More important, and a great 
advantage of this type of experimental setup, is that it is possible to test how 
factors influence each other in synergistic or antagonistic ways with regard to the 
chosen response. This technique potentially allows for a more efficient 
optimisation of processes than the standard one-factor-at-the-time-step-by-step-
approach. 
Animal experiments 
The rabbit animal model 
Several animal models have been used in studies of cartilage repair, including 
sheep, goats, dogs, minipigs and horses (Hunziker, 2002). The rabbit model is by 
far the most commonly used, most likely due to size, availability, and price. 
Rabbits have been used by our group for previous studies; therefore, this animal 
was chosen for the current study (Aroen et al., 2005; Aroen et al., 2006). 
Advantages of using animal models are numerous; perhaps most importantly, the 
whole joint can be evaluated histologically as opposed to a small biopsy in human 
trials. All parameters other than the actual treatment can be held constant, which 
means that any observed changes are more likely be a cause of the treatment. 
Using an animal model also provides a way to observe the safety of a given 
treatment before initiating human trials. There are, however, several 
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considerations to be aware of when using animal models. One is interspecies 
variations. In the rabbit, the height of the cartilage is approximately 0.4 – 1.0 mm 
as opposed to 2 – 3.3 mm in humans, and the subchondral bone of the rabbit is 
substantially thicker than in humans. This makes it very hard to make only grade 3 
lesions experimentally, and most research has been performed on osteochondral 
lesions (Hunziker, 2002). In our experiments, we had a specialised burr made that 
allowed us to control the depth to 1.5 mm and 4 mm in diameter. It should also be 
considered that young animals have a very good natural healing response (Wei et 
al., 1997), stressing the fact that post-pubertal animals should be used, which for 
rabbits is when they are approximately 6 months and approximately 4 kg 
(O'Driscoll et al., 2001). Another consideration is that a seemingly large variation 
exists between so-called good healers and bad healers, which introduces a bias 
into the study unless large groups of animals are used or unless every animal is 
used as its own control (Solchaga et al., 1999). The latter is the preferred solution 
for most researchers. Bilateral lesions are made, and only one is given the 
experimental treatment. Finally, the issue of rehabilitation is hard to address in 
most animal models, especially smaller animals. We allowed rabbits to move 
freely immediately after surgery, which is commonly the norm but is significantly 
different from rehabilitation protocols in humans after cartilage surgery, in which 
early movement but no or low weight bearing activity seems to be the consensus 
(Mithoefer, 2012). 
Histology 
One of the advantages to studying cartilage repair in animal models is that the 
complete joint is available for evaluation when the research animals are killed. 
However, the three-dimensional lesion and repaired tissue are still only evaluated 
by a limited number of fixed and stained two-dimensional sections. In the rabbit 
study, we used two approaches to evaluate healing. First, a qualitative scoring, and 
second, a novel quantitative evaluation of filling based on point counting.  
 - 71 - 
The qualitative assay was modified from the original scoring system developed by 
O`Driscoll that evaluates five aspects of the repair tissue: 1. amount of hyaline 
cartilage, 2. surface regularity, 3. necrosis, 4. integration of borders, and 5. 
chondrocyte clustering. This or similar scoring systems have been used in 
numerous publications, but it does present some problems, for example, the 
importance of each parameter and its relation to the others is not clear. We 
therefore chose to report individual scores instead of a summarised score, as 
proposed in the ICRS scoring system (Mainil-Varlet, 2003). However, we also 
wanted to quantify filling by a more robust method, as the reproducibility and 
validity of the semiquantitative qualitative scoring systems have been questioned 
(Hyllested, 2002). We therefore used a computer program to overlay the sections 
randomly with a grid. A round of pilot experiments led to a grid with 200-μm 
squares, resulting in approximately 160 points overlying the micrograph as shown 
in the paper. Every point was then scored as being above or below the tidemark 
and as bone, cartilage, or no tissue, allowing the proportions to be calculated. This 
method had excellent inter- and intra-rater reliability and was chosen as our main 
outcome.  
 
There are several approaches to studying the histology of cartilage repair, and in 
recent years, more automated methods have been put forward. However, the recent 
white paper by the ICRS still advocates the semiquantitative qualitative scores and 
scores for the filling of the defects, but stresses the fact that evaluation should be 
blinded and performed by at least two independent investigators (Hoemann, 2011). 
Statistical considerations 
Paper I 
The statistics in paper I are primarily related to the gene expression data. We used 
one-way analysis of variance (ANOVA) to compare the means of the gene 
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expression levels within each donor type. Normally, if only one mean is compared 
to another, a Student’s t test would be the standard parametric method, but as soon 
as more than two groups/time points are compared, the problem of multiple 
comparison and how to correct for it arises. In our case, ANOVA was coupled 
with Tukey’s post-hoc test, which compares every mean to every other mean, and 
we report a p-value adjusted for the multiple testing. There are some assumptions 
for an ANOVA test to be valid: 1. The populations should have approximately the 
same variance, though this assumption is not very important when groups have the 
same number of subjects. The variance can be tested using the Bartlett´s test, 
which is performed automatically in the GraphPad Prism program we used, and 
we did not find variance to be significantly different between the groups. 2. 
Populations should be normally distributed or, more correctly, they should be 
sampled from a population that is normally distributed. Normality tests on the 
actual data have little value in terms of proving that the underlying population is 
normally distributed. However, it is often advocated to log-transform the data 
from gene expression data to better meet this assumption. We did not do this in 
this experiment, though it would probably have been prudent. However, ANOVA 
is generally fairly resistant to violations of this assumption (Motulsky, 2010). This 
assumption could also be circumvented by using a nonparametric test that does not 
assume normality; however, especially with low numbers of subjects in the groups, 
non-parametric tests have extremely low power. If there are only three subjects in 
each group, it is actually impossible to find a statistically significant difference 
with a nonparametric test.  
 
By an almost incomprehensible oversight by us, the figures in the published paper 
did not contain markings of significance, even though the statistics are explained 
in the paper. Figures with the correct markings are included in this thesis and 
submitted to the journal as an erratum.  
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Paper II 
In this study, every rabbit served as its own control to account for the intrinsic 
variability in healing between animals. Our main outcome parameter was the 
filling, and to make sure we had sufficient statistical power, we performed a power 
analysis in the planning of the study with input from previous rabbit experiments 
in the group (Aroen, 2006). We considered a difference of 25% in filling between 
two treatments to be a "clinically" relevant threshold. We used a paired Student´s t 
test to compare the degree of filling. This parametric test has the same assumption 
about normality as described above. With 11 subjects in each group, we could 
have chosen the non-parametric Wilcoxon match pairs test without losing too 
much power, even though it is not completely irrational to assume that the data 
were sampled from a normally distributed population. This test was used for the 
ordinal categorical variables from the semiquantitative evaluation of the repair. 
 
We calculated the mean difference between measurements of observer one and 
two and between the first and second time a section was scored by the same 
observer to judge the inter- and intra-rater reliability. Only very minuscule 
differences existed, though we should most likely have calculated the intra-class 
coefficients as well to show this in a single value. 
Paper III 
We presented much of the data in this paper as individual donors, and the majority 
of the statistics is related to the global mRNA and microRNA profiling. When we 
performed statistical testing, it was along the lines of testing used in paper I, 
though we also used the Dennett’s post hoc test, which is used when comparing 
the means of the groups to only one mean and not all combinations. We also 
performed log-transformations of the data to better meet the normality assumption. 
For the global profiling, we used a previously established line of analysis to both 
normalise and quality control the data (Karlsen, 2011). The subsequent testing for 
differential expression was performed using the rank product false discovery rate 
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method (Breitling, 2004). This method is based on biological reasoning rather than 
just pure statistical thinking and calculates the rank products from replicate 
experiments. It also employs the false discovery rate as a more powerful and 
intuitive way of correcting for multiple testing than for example the highly 
conservative Bonferroni method. Explained in clear terms, the false discovery rate 
is the percentage of false positives expected among the discoveries (i.e., the 
rejected null-hypotheses). For example, if 100 genes are found to be differentially 
expressed with a FDR of 0.05, it is expected that 5 of these 100 are false positives 
(but it remains unknown which are false). 
Paper IV 
The high-throughput methods used and the relatively high number of conditions 
tested in paper IV demanded a somewhat different statistical approach. First, to 
normalise the data from lysates, we needed more than one internal reference gene. 
We used the commonly used geometric mean method to more robustly achieve a 
good normalisation with five reference genes (Vandesompele, 2002). Visualisation 
of data is often a very powerful way to grasp the content of huge datasets, and 
several common principles to do this exist, such as heat maps and scatterplots. We 
utilised a standard principle known as Studentisation to centralise and normalise 
the data around a mean of 0 to be able to present graphically the variation related 
to the different treatments. To statistically test the graphical findings, we 
performed gene set enrichment tests by fitting a linear model to the data, as used 
previously for similar data (Ostrup, 2010). Here, we also employed FDR to 
account for the issue of multiple comparisons. Our customised chondrogenic gene 
set was composed of 364 genes.  
 
Principal component analysis is a very powerful way of reducing the complexity 
of large datasets to elucidate the underlying variations (Li, 2010). This method 
calculates so-called components so that the first component explains the largest 
amount of variation in the data, the next component explains the largest amount of 
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variation given that it is, statistically speaking, uncorrelated with the first 
component, and so forth. The analysis is usually restricted to two or three 
components judging by how much of the variation is explained by each of the 
components. One feasible way to analyse in connection with PCA is to look at 
which genes then contribute the most to each component. However, we instead 
focused on markers known to be relevant as either wanted for hyaline cartilage or 
related to alternative differentiation lineages or hypertrophic cartilage. 
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General discussion 
Paper I 
Based on our findings presented here and in the literature discussed in the 
introduction, there are certainly indications that the use of human MSCs is one 
way to improve the cartilage repair procedures existing today. We found that type 
II collagen production could be induced in human BM-MSCs that by far exceeded 
the production observed in AT-MSCs and in unstimulated chondrocytes. In 
addition, in a recent paper from our group, BM-MSCs and chondrocytes from 
osteoarthritic cartilage were actually found to respond quite similarly to each other 
when subjected to differentiation factors in the same system as we used in papers 
III and IV (Fernandes, 2013). The difference in inducibility between MSCs from 
adipose tissue and bone marrow was found despite multiple global gene 
expression analyses showing MSC from various sources to be remarkably similar 
(Lee, 2004; Djouad, 2005; Wagner, 2005). However, the result is in line with other 
publications (Winter, 2003; Im, 2005; Afizah, 2007). At the time of the 
experiments, the reasons for this were not fully understood, but findings of 
reduced levels of BMP2, -4 and -6 and TGFβ receptor 1 (TGFBR1) and enhanced 
levels of integral membrane protein 2A (ITM2A) in AT-MSCs are most likely part 
of the explanation (Hennig, 2007; Boeuf, 2009). The reduced inducibility of AT-
MSCs has also been shown to be overcome by using BMP6 in addition to TGFβ1; 
however, in our case we already used BMP6 and still observed less induction. 
However, the true reason behind differences in inducibility from different sources 
of stem cells in general is likely due to epigenetic changes. The epigenetic control 
of cells is a multifaceted issue that includes not only the DNA methylation status, 
but also histone modifications, microRNAs and other regulatory molecules. MSCs 
from various sources have been studied for differences in DNA methylation status, 
but the comparison found only minor differences and not in gene regions likely to 
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explain the differences in inducibility (Aranda, 2009; Sorensen, 2010). More 
likely, the differences are due to variability in histone modifications between the 
various stem cells. A detailed description of histone modification is beyond the 
scope of this thesis; briefly, histones around which the DNA is wrapped has tails 
of amino acids that can be modified, for instance by acetylation and methylation of 
specific amino acid residues. These modifications specify if the DNA region is 
primed, open, or closed to transcription. Histone modifications during 
chondrogenesis of BM-MSCs and of adipogenesis of AT-MSCs have been studied 
in detail (Mikkelsen, 2010; Herlofsen, 2013), but to the best of our knowledge, no 
one has directly compared histone modifications between undifferentiated AT- 
and BM-MSCs. However, this comparison should be readily feasible from the raw 
data from the studies presented here. 
 
There are some puzzling and potentially important findings in our study as well as 
some weaknesses. We found that although type II collagen was highly upregulated 
and produced when BM-MSCs received chondrogenic induction for the full 
duration of the culture period, it was not retained in the scaffold but rather secreted 
into the supernatant. The Hyaff-11-scaffold is a very loose mesh and has no 
inherent barrier to the diffusion of even very large molecules. This is a desired 
feature in regard to diffusion of nutrient and waste products; however, the 
retention of ECM is then completely dependent on the interlocking of molecules 
or connection to cell receptors or integrins. This property is a potential drawback 
to using this scaffold clinically, and results from the initial preclinical studies of 
this scaffold seemed to mirror the same pattern of cells clumped together with 
large open areas in the scaffold, although extracellular staining of collagens was 
observed (Grigolo, 2002; Facchini, 2006). Quite puzzlingly, we found the same 
intracellular distribution pattern of type I collagen, but we did not detect collagen I 
in the supernatant. We do not have any explanation for this, and, in retrospect, it 
should have been investigated more thoroughly. 
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Another finding to highlight is the increase in type X collagen gene expression, 
which is not necessarily specific to this study but instead a general disadvantage of 
MSCs in chondrogenesis. Currently, it seems that in all cases in which MSCs are 
brought in the chondrogenic direction, type X collagen is induced (Boeuf, 2010; 
Herlofsen, 2011). Numerous studies have investigated ways to reduce this 
induction by adding other factors to the differentiation medium. Most 
convincingly, reduction, but not elimination, is observed with PTHRP, which 
opposes the Indian hedgehog pathway (Kim, 2008; Weiss, 2010). Perhaps type X 
collagen is primarily a problem of in vitro chondrogenesis, during which the 
differentiating cells do not get any spatial cues from the surrounding environment. 
For example, it has been shown that MSCs used to treat a cartilage defect in a 
minipig model did not express type X collagen other than in close proximity to the 
subchondral bone and in general showed better ratios between wanted and 
unwanted ECM molecules (Steck, 2009). Type I collagen is less often identified as 
a problem in in vitro chondrogenesis, but we also observed that it was highly 
expressed and upregulated. Most likely even more so than for type X collagen, 
persistent high gene and protein expression of type I collagen seems to be found in 
all differentiation systems. With the clinical findings of fibrocartilage after both 
ACI and spontaneous healing in human defects, this is an area for future research 
regardless of using chondrocytes or MSCs (Roberts, 2009). 
Paper II 
In the experimental study in rabbits, we did not reach a good filling of the defect, 
nor did we see a clear advantage of having MSCs in the scaffold. These results 
correlate well with the literature (Radice, 2000; Solchaga, 2005; Kayakabe, 2006), 
which shows that MSCs did not lead to improved filling of defects; however, the 
rate of degradability of the scaffolds was found to affect the repair. Also in these 
referenced studies, if cells had been cultured with fibroblast growth factor, then a 
positive effect was observed.  
 - 79 - 
We did see an increase in clustering, which could be argued to be a sign of a 
different repair response in the cell-loaded scaffold, indicating that adding cells 
does have an effect. In our model, we cannot conclude if this is a sign of cell 
division of the implanted cells or a trophic effect of the implanted cells on the cells 
invading from the bone marrow directly, or a combination of both. There are 
several publications that show that MSCs have trophic effects in tissue repair and 
that this may even be their most important function (Caplan, 2006). Conversely, 
there are also publications showing that implanted cells contribute directly to the 
repair of tissue (Oshima, 2005; Koga, 2008). The findings in paper I suggest that 
we might have observed a better repair in the rabbit studies had the MSCs been 
cultured for a longer time in the scaffold with growth factors. However, the 
inherent problem in our model and several other small animal models of cartilage 
repair is that the defects need to be osteochondral due to the very limited thickness 
of the articular cartilage in the rabbit. In the defects with cell-free scaffolds, we do 
see repair, presumably due to cells migrating from the bone marrow. Therefore, it 
is difficult to show the real advantages of having cells in the scaffolds.  
 
In 2011, the ICRS published a white paper on preclinical studies in which this is 
discussed (Hurtig, 2011). They strongly advocate for the use of larger species, 
though they also acknowledge that if good histological confirmation of defect 
depth is used and if animals are mature, there is a lot of support for using the 
rabbit model. This was also the finding of a systematic review of animal models 
for cartilage repair (Ahern, 2009). Larger animal models that could be considered 
include minipigs, dogs, pigs, goats, sheep, or horses. Comparisons of the cartilage 
thickness of several species show that horse cartilage is closest to the thickness of 
human cartilage, approximately 2.5 mm (Frisbie, 2006). Few groups work 
primarily in a horse model, but it may yield results that can more easily be applied 
in the human setting (Koch, 2008; Frisbie, 2011; Fortier, 2012; Schnabel, 2013). 
Even keeping the disadvantages of the rabbit model or any small animal model in 
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mind, it is clear that testing new treatments for cartilage repair in larger animals 
carries disadvantages of its own. The cost of both animals and animal care 
increases rapidly, and the dosing of antibiotics and analgesics is per kg, which is 
considerably more in, for example, the horse model, also adding to the cost. In 
addition, rehabilitation issues become more important and difficult, though 
arguably these issues are often completely ignored in small animal models. 
Therefore, although it is not the optimal model, the rabbit model may still be the 
only practically available animal model for a large proportion of research groups. 
Perhaps there may be room for larger collaborative projects between research 
groups when going from smaller to larger animal models. 
Paper III 
The rationale for paper III came from previous studies in our lab of microRNA 
expression in native human chondrocytes undergoing dedifferentiation (Karlsen, 
2011). We already knew that MSCs undergoing differentiation largely mirrored 
the gene expression of articular chondrocytes, although with some notable 
exceptions, such as type I and type X collagen expression. However, we did not 
know to what extent differentiated MSCs mirrored the microRNA profile of native 
chondrocytes. One would predict similar but not identical expression, and this was 
indeed what we found, further highlighting that the directed differentiation of 
MSCs into chondrocytes is not producing bona fide chondrocytes. However, we 
initially focused on the similarities, particularly the effect of miR-140, to 
complement the understanding of the role of this microRNA. As described in the 
introduction, miR-140 had recently been established to have an important role in 
cartilage homeostasis by targeting an aggrecanase ADAMTS5. However, 
strangely, it was not shown to target gene expression or translation of any of the 
major transcription factors or ECM-molecules. It was therefore an unexpected 
finding that the inhibition of miR-140-5p led to a clear downregulation of the 
aggrecan and SOX9 proteins, yet it did not have a clear effect on the 
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corresponding mRNAs. The change in aggrecan might be at least partly explained 
by the known effect of miR-140 on ADAMTS5 (Miyaki, 2009), where less miR-
140 would lead to more ADAMTS5, which subsequently would lead to 
degradation of aggrecan protein. However, there was no obvious explanation of 
how miR-140 would directly lead to an upregulation of SOX9 protein levels. 
 
Although microRNAs are commonly believed to exert most of their effect through 
canonical binding in the 3´UTR with ultimate downregulation of target gene 
protein expression, recent studies have discovered non-canonical pathways 
whereby microRNAs activate gene expression, sometimes through binding in the 
5´UTR (Orom, 2008; Lin, 2011; Vasudevan, 2012; Meijer, 2013). We found 
potential binding sites for miR-140-5p in the 5´UTR of both SOX9 and aggrecan 
with similar predicted thermodynamic stabilities as the already validated binding 
sites. However, the literature is not abundant with examples of the activating 
effects of miRs, and we did not perform any experiments to validate whether miR-
140-5p bound the predicted sequences; therefore, it remains an open question if 
this mechanism contributes to the explanation in our experiments. Another way to 
explain the effect on SOX9 follows the same logic as for aggrecan and 
ADAMTS5: If miR-140 targets a gene that in turn inhibits protein expression of 
SOX9, this would potentially explain why SOX9 expression is decreased when 
miR-140 expression is repressed. This effect would also potentially add an 
additional feedback loop, as SOX9 is already known to control expression of miR-
140 expression in zebra fish (Nakamura, 2012). We identified several potential 
targets of miR-140-5p and -3p and validated RALA as target. Surprisingly but very 
interestingly, we found that knocking down RALA led to an increase in SOX9 
protein levels without affecting SOX9 mRNA or actin protein. This suggests that 
the effect of inhibiting miR-140 on SOX9 could be an effect of RALA on the 
translation of SOX9. However, exactly how this occurs and how this affects in 
vitro chondrogenesis is another unanswered question. 
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RALA has not previously been described to be important for chondrogenesis. 
RALA is a small GTPase involved in TGFβ/activin signalling (Kardassis, 2009). It 
contributes to the internalisation of activin receptors, thus reducing the number of 
receptors available for ligand interaction, which in turn could inhibit signalling. 
The activin A receptor was shown to be positively linked to chondrogenesis, with 
type II collagen and sulphated GAGs being reduced when the activin A receptor 
was knocked down (Djouad, 2010). Furthermore, RALA has been shown to inhibit 
exocytosis (Wang, 2004). Aggrecan and its associated GAGs are transported 
through the endoplasmic reticulum–Golgi pathway before being secreted from the 
cell surface (Luo, 2000). miR-181a has interestingly also been shown to target 
RALA (Fei, 2012) and very recently was shown to interfere with aggrecan 
expression through an indirect mechanism (Sumiyoshi, 2013). We also found 
miR-181a to be upregulated during chondrogenesis of MSCs; however, it was only 
barely detected in uncultured chondrocytes. 
 
We gathered large datasets for paper III and were not able to follow up on all 
interesting microRNAs. For example, miR-21 has been shown to be upregulated 
by TGFβ and has been associated with increased type I collagen synthesis in some 
experiments (Kim, 2010a). A change from type II to type I collagen synthesis is a 
hallmark of dedifferentiating chondrocytes (Holtzer, 1960). Consistent with this, 
miR-21 was also one of the upregulated microRNAs during dedifferentiation and 
also when MSCs differentiate, possibly explaining why type I collagen synthesis is 
kept high during the directed differentiation of MSCs. miR-210 is commonly 
labelled as a hypoxic microRNA because it is upregulated under hypoxic 
conditions (Chan, 2012). We found that miR-210 was gradually upregulated 
during chondrogenesis and downregulated during dedifferentiation. The 
upregulation would be consistent with increasingly hypoxic conditions in the 
three-dimensional cultures, where matrix production and increased metabolism 
may lead to decreased oxygen diffusion into discs. We observed that miR-335 is 
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downregulated during chondrogenesis. This is in line with already published 
findings that the downregulation of miR-335 is critical for MSC differentiation 
(Tome, 2011; Zhang, 2011) but in contrast to a recent study in mouse showing that 
miR-335 promotes chondrogenesis (Lin, 2013). Recently, miR-574-3p was shown 
to inhibit MSC chondrogenesis (Guerit, 2013). Interestingly, we found this 
microRNA to be significantly upregulated at day 21 in differentiating MSCs and 
the complementary miR-574-5p to be upregulated at day 7 in dedifferentiating 
chondrocytes.  
 
In general, our findings in paper III illustrate that microRNAs play important roles 
in in vitro chondrogenesis and could be manipulated to improve the current 
protocols of in vitro chondrogenesis. 
Paper IV 
In paper IV, we used factorial analysis and high-throughput gene expression 
profiling to dissect the expression of a chondrogenesis-relevant gene set during in 
vitro chondrogenesis of MSCs subjected to 48 different conditions of growth 
factors and cell densities. We aimed to validate this approach for studying directed 
differentiation and to find out if presently used factors could be combined more 
cleverly to promote a better differentiation cocktail. The main findings were stated 
above, and the discussion in the paper shows that our findings are largely in line 
with the published literature. Perhaps most interestingly, we found that no matter 
which combination of factors was used, upregulating wanted chondrogenic 
markers also upregulated unwanted markers. The only exception was that adding 
dexamethasone to TGFβ or BMP2 generally led to favourable changes, such as a 
downregulation of osteocalcin (BGLAP), though not to an elimination of unwanted 
markers. These results further support the findings from paper I and III that the 
current differentiation cocktails do not lead to a perfect hyaline differentiation.  
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We propose that the method used in paper IV may provide a suitable way to 
improve the current protocols; however, it is important to remember the limitation 
that we only considered gene expression at the level of transcribed mRNA, which 
does not necessarily correlate with protein synthesis (Schwanhausser, 2011). We 
found that profiling could be performed directly on lysates and that changes in 
gene expression observed after just one day of induction predicted later changes. 
We also found that the findings from our analysis were largely supported by the 
literature. Taken together, we believe this way of studying directed differentiation 
is sound and could be expanded to larger experiments. For example, it would be 
interesting to plan further experiments with a more elaborate design in terms of 
concentration of factors. This would allow for statistical analysis with response 
optimisation to be performed instead of the more crude two-level design of either 
absence or presence (Enochson, 2012).  
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Conclusions and future studies 
More often than not, research, and perhaps basic science research in particular, 
raises more questions than it answers. This remains true for the presented studies. 
Here, a brief list is given of the general conclusions of our studies and the future 
studies that could be pursued. 
 
1. Bone marrow MSCs were more easily induced into the chondrogenic 
lineage than adipose tissue MSCs. 
 
Even though the experiments leading to this conclusion were performed several 
years ago, there is still no simple explanation as to why MSCs from various tissues, 
although remarkably similar, have different differentiation capacities. One obvious 
way to study this further would be to compare the different cell sources 
epigenetically, looking at histone modifications, which could be conducted using 
publicly available data (Mikkelsen, 2010; Herlofsen, 2013) and possibly also 
looking at global microRNA profiles. This might help to determine if one cell 
source should be preferred for cartilage tissue engineering.  
 
2. MSCs in a hyaluronic acid scaffold did not lead to better filling in a rabbit 
model, though there was a tendency of better quality repair tissue in the cell-
treated defects.  
 
Tissue-engineered constructs need functional verification in animal models. The 
rabbit model seems to be the most practical first model in which to test new tissue 
engineered constructs; however, larger animals could provide a test situation more 
similar to human. There are also studies showing that xenotransplantation is 
possible with human cells in larger animals, which would also advocate a move to 
larger species for future animal experiments (Li, 2012).  
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3. The microRNA profile of chondrogenically differentiated MSCs resembled 
that of uncultured chondrocytes, though they were not identical. Several 
microRNAs showed a reciprocal relationship during the dedifferentiation of 
chondrocytes and chondrogenic differentiation of MSCs.  
 
Several future experiments could be pursued based on these findings. Currently, 
we are looking at the role of miR-221 in chondrogenesis, which was one of the 
microRNAs identified to be reciprocally regulated. It would also be interesting to 
look further into the differences in the microRNA profile between native 
chondrocytes and differentiated MSCs to see if there could be clues to the 
unwanted production of ECM, such as type I and X collagen. 
 
In addition, in vivo studies of the therapeutic potential of microRNAs in disease 
models related to bone or cartilage pathology could be a path to follow. 
 
Finally, testing if extracellular microRNAs in synovial fluid, plasma or even urine 
could be used as diagnostic or prognostic markers in skeletal diseases would be an 
interesting study to pursue. 
 
4. miR-140 had a profound impact on in vitro chondrogenesis with a positive 
effect on SOX9 and aggrecan post-transcriptionally, possibly, at least partly, 
through RALA, which we identified as being a target of miR-140-5p. 
 
Further studies of RALA and activin signalling in the context of chondrogenesis 
are warranted. How does RALA influence the translation of SOX9 and does this 
influence extend to other genes? Is this signalling pathway a major player in or 
just a fine-tuner of chondrogenesis?  
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Additionally, exploring the hypothesis of 5´UTR binding of miR-140-5p in SOX9 
and ACAN would be natural, possibly with a combination of luciferase reporter 
assays with the 5´UTR sequences and co-immunoprecipitation of miR-140-5p. 
 
5. Better differentiation cocktails are needed to avoid the expression of 
unwanted markers, such as type I and X collagen. This cannot be achieved by 
the commonly used differentiation factors, but screening for new molecules 
might be performed in a multifactorial fashion using quality by design and 
high-throughput profiling with a limited set of chondrogenesis-related genes. 
 
High-throughput screening in tissue engineering has led to important discoveries, 
highlighted for example by the discovery of kartogenin as small chondrogenic 
molecule (Johnson, 2012). The current protocols for differentiation are not perfect. 
Screens for modifiers of in vitro chondrogenesis with particular focus on 
eliminating the expression of unwanted ECM production would be an interesting 
path to explore, as would a more temporal adaptation of in vitro chondrogenesis to 
embryogenesis of cartilage in vitro (Wu, 2013). 
  
 - 88 - 
References 
Abbott, A. (2013). Doubt cast over tiny stem cells. Nature 499, 390. 
Afizah, H., Yang, Z., Hui, J.H., Ouyang, H.W., and Lee, E.H. (2007). A comparison between the 
chondrogenic potential of human bone marrow stem cells (BMSCs) and adipose-derived stem cells 
(ADSCs) taken from the same donors. Tissue Eng. 13, 659-666. 
Aguiar, D.J., Knudson, W., and Knudson, C.B. (1999). Internalization of the hyaluronan receptor CD44 by 
chondrocytes. Exp. Cell Res. 252, 292-302. 
Ahern, B.J., Parvizi, J., Boston, R., and Schaer, T.P. (2009). Preclinical animal models in single site 
cartilage defect testing: a systematic review. Osteoarthritis Cartilage 17, 705-713. 
Akiyama, H. (2008). Control of chondrogenesis by the transcription factor Sox9. Modern rheumatology / 
the Japan Rheumatism Association 18, 213-219. 
Akiyama, H., Chaboissier, M.C., Martin, J.F., Schedl, A., and de Crombrugghe, B. (2002). The 
transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway 
and is required for expression of Sox5 and Sox6. Genes Dev. 16, 2813-2828. 
Alberts, B. (2002). Molecular biology of the cell. Garland Science: New York. 
Alfredson, H., and Lorentzon, R. (1999). Superior results with continuous passive motion compared to 
active motion after periosteal transplantation. A retrospective study of human patella cartilage defect 
treatment. Knee Surg. Sports Traumatol. Arthrosc. 7, 232-238. 
Alsalameh, S., Amin, R., Gemba, T., and Lotz, M. (2004). Identification of mesenchymal progenitor cells 
in normal and osteoarthritic human articular cartilage. Arthritis Rheum. 50, 1522-1532. 
Alvarez-Dolado, M. (2007). Cell fusion: biological perspectives and potential for regenerative medicine. 
Front. Biosci. 12, 1-12. 
Ambros, V. (2004). The functions of animal microRNAs. Nature 431, 350-355. 
Andersen, T., Strand, B.L., Formo, K., Alsberg, B.E., and Christensen, B.E. (2012). Alginates as 
biomaterials in tissue engineering. Carbohydrate Chemistry 37, 227-258. 
Anokye-Danso, F., Trivedi, C.M., Juhr, D., Gupta, M., Cui, Z., Tian, Y., Zhang, Y., Yang, W., Gruber, P.J., 
Epstein, J.A., and Morrisey, E.E. (2011). Highly efficient miRNA-mediated reprogramming of mouse and 
human somatic cells to pluripotency. Cell Stem Cell 8, 376-388. 
Araldi, E., and Schipani, E. (2010). MicroRNA-140 and the silencing of osteoarthritis. Genes Dev. 24, 
1075-1080. 
Aranda, P., Agirre, X., Ballestar, E., Andreu, E.J., Roman-Gomez, J., Prieto, I., Martin-Subero, J.I., 
Cigudosa, J.C., Siebert, R., Esteller, M., and Prosper, F. (2009). Epigenetic signatures associated with 
different levels of differentiation potential in human stem cells. PloS one 4, e7809. 
Aroen, A., Heir, S., Loken, S., Engebretsen, L., and Reinholt, F.P. (2006). Healing of articular cartilage 
defects. An experimental study of vascular and minimal vascular microenvironment. J. Orthop. Res. 24, 
1069-1077. 
 - 89 - 
Aroen, A., Loken, S., Heir, S., Alvik, E., Ekeland, A., Granlund, O.G., and Engebretsen, L. (2004). 
Articular cartilage lesions in 993 consecutive knee arthroscopies. Am. J. Sports Med. 32, 211-215. 
Aurich, M., Poole, A.R., Reiner, A., Mollenhauer, C., Margulis, A., Kuettner, K.E., and Cole, A.A. (2002). 
Matrix homeostasis in aging normal human ankle cartilage. Arthritis Rheum. 46, 2903-2910. 
Axe, J.M., Snyder-Mackler, L., and Axe, M.J. (2013). The role of viscosupplementation. Sports Med 
Arthrosc 21, 18-22. 
Ball, L.M., Bernardo, M.E., Roelofs, H., van Tol, M.J., Contoli, B., Zwaginga, J.J., Avanzini, M.A., 
Conforti, A., Bertaina, A., Giorgiani, G., Jol-van der Zijde, C.M., Zecca, M., Le Blanc, K., Frassoni, F., 
Egeler, R.M., Fibbe, W.E., Lankester, A.C., and Locatelli, F. (2013). Multiple infusions of mesenchymal 
stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-
host disease. Br. J. Haematol. 163, 501-509. 
Baron, F., Storb, R., and Little, M.T. (2003). Hematopoietic cell transplantation: five decades of progress. 
Arch. Med. Res. 34, 528-544. 
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297. 
Bartel, D.P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233. 
Behery, O., Siston, R.A., Harris, J.D., and Flanigan, D.C. (2013). Treatment of Cartilage Defects of the 
Knee: Expanding on the Existing Algorithm. Clin. J. Sport Med. 
Benjamin, M., Archer, C.W., and Ralphs, J.R. (1994). Cytoskeleton of cartilage cells. Microsc. Res. Tech. 
28, 372-377. 
Bentley, G., Biant, L.C., Carrington, R.W., Akmal, M., Goldberg, A., Williams, A.M., Skinner, J.A., and 
Pringle, J. (2003). A prospective, randomised comparison of autologous chondrocyte implantation versus 
mosaicplasty for osteochondral defects in the knee. J. Bone Joint Surg. Br. 85, 223-230. 
Bernard, P. (2003). Dimerization of SOX9 is required for chondrogenesis, but not for sex determination. 
Hum. Mol. Genet. 12, 1755-1765. 
Bi, W., Deng, J.M., Zhang, Z., Behringer, R.R., and de Crombrugghe, B. (1999). Sox9 is required for 
cartilage formation. Nat. Genet. 22, 85-89. 
Bianco, P., Riminucci, M., Gronthos, S., and Robey, P.G. (2001). Bone marrow stromal stem cells: nature, 
biology, and potential applications. Stem Cells 19, 180-192. 
Bland, Y.S., and Ashhurst, D.E. (1996). Development and ageing of the articular cartilage of the rabbit 
knee joint: distribution of the fibrillar collagens. Anat. Embryol. (Berl). 194, 607-619. 
Blevins, F.T., Steadman, J.R., Rodrigo, J.J., and Silliman, J. (1998). Treatment of articular cartilage defects 
in athletes: an analysis of functional outcome and lesion appearance. Orthopedics 21, 761-767; discussion 
767-768. 
Boeuf, S., Borger, M., Hennig, T., Winter, A., Kasten, P., and Richter, W. (2009). Enhanced ITM2A 
expression inhibits chondrogenic differentiation of mesenchymal stem cells. Differentiation 78, 108-115. 
Boeuf, S., and Richter, W. (2010). Chondrogenesis of mesenchymal stem cells: role of tissue source and 
inducing factors. Stem cell research & therapy 1, 31. 
 - 90 - 
Bonaventure, J., Kadhom, N., Cohen-Solal, L., Ng, K.H., Bourguignon, J., Lasselin, C., and Freisinger, P. 
(1994). Reexpression of cartilage-specific genes by dedifferentiated human articular chondrocytes cultured 
in alginate beads. Exp. Cell Res. 212, 97-104. 
Boquest, A.C., Shahdadfar, A., Brinchmann, J.E., and Collas, P. (2006). Isolation of stromal stem cells 
from human adipose tissue. Methods Mol. Biol. 325, 35-46. 
Boquest, A.C., Shahdadfar, A., Fronsdal, K., Sigurjonsson, O., Tunheim, S.H., Collas, P., and Brinchmann, 
J.E. (2005). Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration 
of gene expression after in vitro cell culture. Mol. Biol. Cell 16, 1131-1141. 
Breitling, R., Armengaud, P., Amtmann, A., and Herzyk, P. (2004). Rank products: a simple, yet powerful, 
new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 573, 
83-92. 
Brennecke, J., Stark, A., Russell, R.B., and Cohen, S.M. (2005). Principles of microRNA-target recognition. 
PLoS biology 3, e85. 
Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C., Isaksson, O., and Peterson, L. (1994). Treatment of 
deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331, 889-
895. 
Brittberg, M., and Peterson, L. (1998). Introduction of an articular cartilage classification. ICRS Newsletter 
1, 5-8. 
Brittberg, M., and Winalski, C.S. (2003). Evaluation of cartilage injuries and repair. J. Bone Joint Surg. Am. 
85-A Suppl 2, 5-8. 
Brzoska, M., Geiger, H., Gauer, S., and Baer, P. (2005). Epithelial differentiation of human adipose tissue-
derived adult stem cells. Biochem. Biophys. Res. Commun. 330, 142-150. 
Cao, B., and Huard, J. (2004). Muscle-derived stem cells. Cell cycle (Georgetown, Tex 3, 104-107. 
Cao, Y., Sun, Z., Liao, L., Meng, Y., Han, Q., and Zhao, R.C. (2005). Human adipose tissue-derived stem 
cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem. 
Biophys. Res. Commun. 332, 370-379. 
Caplan, A.I. (1991). Mesenchymal stem cells. J. Orthop. Res. 9, 641-650. 
Caplan, A.I. (2005). Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. 
Tissue Eng. 11, 1198-1211. 
Caplan, A.I. (2010). What's in a Name? Tissue Eng Part A. 
Caplan, A.I., and Dennis, J.E. (2006). Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98, 
1076-1084. 
Castillo, E.C., and Kouri, J.B. (2004). A new role for chondrocytes as non-professional phagocytes. An in 
vitro study. Microsc. Res. Tech. 64, 269-268. 
Centers for Disease Control and Prevention. (2002). Update: allograft-associated bacterial infections--
United States, 2002. MMWR. Morb. Mortal. Wkly. Rep. 51, 207-210. 
(2010). Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation --- United 
States, 2007-2009. Centers for disease control and prevention, 1545-861X (Electronic) 
0149-2195 (Linking). 
 - 91 - 
Chamberlain, G., Fox, J., Ashton, B., and Middleton, J. (2007). Mesenchymal Stem Cells: their Phenotype, 
Differentiation Capacity, Immunological Features and Potential for Homing. Stem Cells. 
Chan, Y.C., Banerjee, J., Choi, S.Y., and Sen, C.K. (2012). miR-210: The Master Hypoxamir. 
Microcirculation 19, 215-223. 
Chen, H., Chevrier, A., Hoemann, C.D., Sun, J., Ouyang, W., and Buschmann, M.D. (2011a). 
Characterization of subchondral bone repair for marrow-stimulated chondral defects and its relationship to 
articular cartilage resurfacing. Am. J. Sports Med. 39, 1731-1740. 
Chen, H., Sun, J., Hoemann, C.D., Lascau-Coman, V., Ouyang, W., McKee, M.D., Shive, M.S., and 
Buschmann, M.D. (2009). Drilling and microfracture lead to different bone structure and necrosis during 
bone-marrow stimulation for cartilage repair. J. Orthop. Res. 27, 1432-1438. 
Chen, J., Wang, C., Lu, S., Wu, J., Guo, X., Duan, C., Dong, L., Song, Y., Zhang, J., Jing, D., Wu, L., Ding, 
J., and Li, D. (2005). In vivo chondrogenesis of adult bone-marrow-derived autologous mesenchymal stem 
cells. Cell Tissue Res. 319, 429-438. 
Chen, Y., Bloemen, V., Impens, S., Moesen, M., Luyten, F.P., and Schrooten, J. (2011b). Characterization 
and optimization of cell seeding in scaffolds by factorial design: quality by design approach for skeletal 
tissue engineering. Tissue engineering. Part C, Methods 17, 1211-1221. 
Christensen, S.E., Coles, J.M., Zelenski, N.A., Furman, B.D., Leddy, H.A., Zauscher, S., Bonaldo, P., and 
Guilak, F. (2012). Altered trabecular bone structure and delayed cartilage degeneration in the knees of 
collagen VI null mice. PloS one 7, e33397. 
Colnot, C. (2005). Cellular and molecular interactions regulating skeletogenesis. J. Cell. Biochem. 95, 688-
697. 
Crapnell, K., Blaesius, R., Hastings, A., Lennon, D.P., Caplan, A.I., and Bruder, S.P. (2013). Growth, 
differentiation capacity, and function of mesenchymal stem cells expanded in serum-free medium 
developed via combinatorial screening. Exp. Cell Res. 319, 1409-1418. 
Crelin, E.S. (1957). Mitosis in adult cartilage. Science 125, 650. 
Cristino, S., Grassi, F., Toneguzzi, S., Piacentini, A., Grigolo, B., Santi, S., Riccio, M., Tognana, E., 
Facchini, A., and Lisignoli, G. (2005). Analysis of mesenchymal stem cells grown on a three-dimensional 
HYAFF 11-based prototype ligament scaffold. Journal of biomedical materials research. Part A 73, 275-
283. 
Curl, W.W., Krome, J., Gordon, E.S., Rushing, J., Smith, B.P., and Poehling, G.G. (1997). Cartilage 
injuries: a review of 31,516 knee arthroscopies. Arthroscopy 13, 456-460. 
D'Ippolito, G., Diabira, S., Howard, G.A., Menei, P., Roos, B.A., and Schiller, P.C. (2004). Marrow-
isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human 
cells with extensive expansion and differentiation potential. J. Cell Sci. 117, 2971-2981. 
D'Lima, D.D., Hashimoto, S., Chen, P.C., Colwell, C.W., Jr., and Lotz, M.K. (2001a). Human chondrocyte 
apoptosis in response to mechanical injury. Osteoarthritis Cartilage 9, 712-719. 
D'Lima, D.D., Hashimoto, S., Chen, P.C., Colwell, C.W., Jr., and Lotz, M.K. (2001b). Impact of 
mechanical trauma on matrix and cells. Clin Orthop Relat Res, S90-99. 
da Silva Meirelles, L., Chagastelles, P.C., and Nardi, N.B. (2006). Mesenchymal stem cells reside in 
virtually all post-natal organs and tissues. J. Cell Sci. 119, 2204-2213. 
 - 92 - 
De Bari, C., Dell'Accio, F., Tylzanowski, P., and Luyten, F.P. (2001). Multipotent mesenchymal stem cells 
from adult human synovial membrane. Arthritis Rheum. 44, 1928-1942. 
De Bari, C., Dell'Accio, F., Vanlauwe, J., Eyckmans, J., Khan, I.M., Archer, C.W., Jones, E.A., McGonagle, 
D., Mitsiadis, T.A., Pitzalis, C., and Luyten, F.P. (2006). Mesenchymal multipotency of adult human 
periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum. 54, 1209-1221. 
de Crombrugghe, B., Lefebvre, V., and Nakashima, K. (2001). Regulatory mechanisms in the pathways of 
cartilage and bone formation. Curr. Opin. Cell Biol. 13, 721-727. 
De Guire, V., Robitaille, R., Tetreault, N., Guerin, R., Menard, C., Bambace, N., and Sapieha, P. (2013). 
Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human 
diseases: promises and challenges. Clin. Biochem. 46, 846-860. 
Derynck, R., and Akhurst, R.J. (2007). Differentiation plasticity regulated by TGF-beta family proteins in 
development and disease. Nature cell biology 9, 1000-1004. 
Derynck, R., Gelbart, W.M., Harland, R.M., Heldin, C.H., Kern, S.E., Massague, J., Melton, D.A., Mlodzik, 
M., Padgett, R.W., Roberts, A.B., Smith, J., Thomsen, G.H., Vogelstein, B., and Wang, X.F. (1996). 
Nomenclature: vertebrate mediators of TGFbeta family signals. Cell 87, 173. 
Diaz-Romero, J., Gaillard, J.P., Grogan, S.P., Nesic, D., Trub, T., and Mainil-Varlet, P. (2005). 
Immunophenotypic analysis of human articular chondrocytes: changes in surface markers associated with 
cell expansion in monolayer culture. J. Cell. Physiol. 202, 731-742. 
Diaz-Romero, J., Nesic, D., Grogan, S.P., Heini, P., and Mainil-Varlet, P. (2007). Immunophenotypic 
changes of human articular chondrocytes during monolayer culture reflect bona fide dedifferentiation rather 
than amplification of progenitor cells. J. Cell. Physiol. 214, 75-83. 
Dickhut, A., Pelttari, K., Janicki, P., Wagner, W., Eckstein, V., Egermann, M., and Richter, W. (2009). 
Calcification or dedifferentiation: requirement to lock mesenchymal stem cells in a desired differentiation 
stage. J. Cell. Physiol. 219, 219-226. 
Diez Villanueva, P., Sanz-Ruiz, R., Nunez Garcia, A., Fernandez Santos, M.E., Sanchez, P.L., and 
Fernandez-Aviles, F. (2012). Functional multipotency of stem cells: what do we need from them in the 
heart? Stem cells international 2012, 817364. 
Djouad, F., Bony, C., Haupl, T., Uze, G., Lahlou, N., Louis-Plence, P., Apparailly, F., Canovas, F., Reme, 
T., Sany, J., Jorgensen, C., and Noel, D. (2005). Transcriptional profiles discriminate bone marrow-derived 
and synovium-derived mesenchymal stem cells. Arthritis Res Ther 7, R1304-1315. 
Djouad, F., Jackson, W.M., Bobick, B.E., Janjanin, S., Song, Y., Huang, G.T., and Tuan, R.S. (2010). 
Activin A expression regulates multipotency of mesenchymal progenitor cells. Stem cell research & 
therapy 1, 11. 
Doherty, M.J., Ashton, B.A., Walsh, S., Beresford, J.N., Grant, M.E., and Canfield, A.E. (1998). Vascular 
pericytes express osteogenic potential in vitro and in vivo. J. Bone Miner. Res. 13, 828-838. 
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, 
A., Prockop, D., and Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal 
cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317. 
Dowthwaite, G.P., Bishop, J.C., Redman, S.N., Khan, I.M., Rooney, P., Evans, D.J., Haughton, L., Bayram, 
Z., Boyer, S., Thomson, B., Wolfe, M.S., and Archer, C.W. (2004). The surface of articular cartilage 
contains a progenitor cell population. J. Cell Sci. 117, 889-897. 
 - 93 - 
Dozin, B., Malpeli, M., Cancedda, R., Bruzzi, P., Calcagno, S., Molfetta, L., Priano, F., Kon, E., and 
Marcacci, M. (2005). Comparative evaluation of autologous chondrocyte implantation and mosaicplasty: a 
multicentered randomized clinical trial. Clin. J. Sport Med. 15, 220-226. 
Dudek, K.A., Lafont, J.E., Martinez-Sanchez, A., and Murphy, C.L. (2010). Type II collagen expression is 
regulated by tissue-specific miR-675 in human articular chondrocytes. J. Biol. Chem. 285, 24381-24387. 
Duggal, S., Fronsdal, K.B., Szoke, K., Shahdadfar, A., Melvik, J.E., and Brinchmann, J.E. (2009). 
Phenotype and gene expression of human mesenchymal stem cells in alginate scaffolds. Tissue Eng Part A 
15, 1763-1773. 
Dunn, W., DuRaine, G., and Reddi, A.H. (2009). Profiling microRNA expression in bovine articular 
cartilage and implications for mechanotransduction. Arthritis Rheum. 60, 2333-2339. 
Durand, S., and Cimarelli, A. (2011). The inside out of lentiviral vectors. Viruses 3, 132-159. 
Dy, P., Wang, W., Bhattaram, P., Wang, Q., Wang, L., Ballock, R.T., and Lefebvre, V. (2012). Sox9 
directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes. 
Developmental cell 22, 597-609. 
Enea, D., Cecconi, S., Busilacchi, A., Manzotti, S., Gesuita, R., and Gigante, A. (2012). Matrix-induced 
autologous chondrocyte implantation (MACI) in the knee. Knee Surg. Sports Traumatol. Arthrosc. 20, 862-
869. 
English, K. (2013). Mechanisms of mesenchymal stromal cell immunomodulation. Immunol. Cell Biol. 91, 
19-26. 
Enochson, L., Brittberg, M., and Lindahl, A. (2012). Optimization of a chondrogenic medium through the 
use of factorial design of experiments. BioResearch open access 1, 306-313. 
Esquela-Kerscher, A., Trang, P., Wiggins, J.F., Patrawala, L., Cheng, A., Ford, L., Weidhaas, J.B., Brown, 
D., Bader, A.G., and Slack, F.J. (2008). The let-7 microRNA reduces tumor growth in mouse models of 
lung cancer. Cell cycle (Georgetown, Tex 7, 759-764. 
Eyre, D.R. (2004). Collagens and cartilage matrix homeostasis. Clin Orthop Relat Res, S118-122. 
Facchini, A., Lisignoli, G., Cristino, S., Roseti, L., De Franceschi, L., Marconi, E., and Grigolo, B. (2006). 
Human chondrocytes and mesenchymal stem cells grown onto engineered scaffold. Biorheology 43, 471-
480. 
Falkenberg, N., Anastasov, N., Rappl, K., Braselmann, H., Auer, G., Walch, A., Huber, M., Hofig, I., 
Schmitt, M., Hofler, H., Atkinson, M.J., and Aubele, M. (2013). MiR-221/-222 differentiate prognostic 
groups in advanced breast cancers and influence cell invasion. Br. J. Cancer 109, 2714-2723. 
Fei, J., Li, Y., Zhu, X., and Luo, X. (2012). miR-181a post-transcriptionally downregulates oncogenic RalA 
and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). PloS one 7, 
e32834. 
Feng, J., Mantesso, A., De Bari, C., Nishiyama, A., and Sharpe, P.T. (2011). Dual origin of mesenchymal 
stem cells contributing to organ growth and repair. Proc. Natl. Acad. Sci. U. S. A. 108, 6503-6508. 
Feng, X.H., and Derynck, R. (2005). Specificity and versatility in tgf-beta signaling through Smads. Annu. 
Rev. Cell Dev. Biol. 21, 659-693. 
 - 94 - 
Fernandes, A.M., Herlofsen, S.R., Karlsen, T.A., Kuchler, A.M., Floisand, Y., and Brinchmann, J.E. (2013). 
Similar properties of chondrocytes from osteoarthritis joints and mesenchymal stem cells from healthy 
donors for tissue engineering of articular cartilage. PloS one 8, e62994. 
Findikli, N., Candan, N.Z., and Kahraman, S. (2006). Human embryonic stem cell culture: current 
limitations and novel strategies. Reproductive biomedicine online 13, 581-590. 
Flanigan, D.C., Harris, J.D., Trinh, T.Q., Siston, R.A., and Brophy, R.H. (2010). Prevalence of chondral 
defects in athletes' knees: a systematic review. Med. Sci. Sports Exerc. 42, 1795-1801. 
Flannery, C.R., Hughes, C.E., Schumacher, B.L., Tudor, D., Aydelotte, M.B., Kuettner, K.E., and Caterson, 
B. (1999). Articular cartilage superficial zone protein (SZP) is homologous to megakaryocyte stimulating 
factor precursor and Is a multifunctional proteoglycan with potential growth-promoting, cytoprotective, and 
lubricating properties in cartilage metabolism. Biochem. Biophys. Res. Commun. 254, 535-541. 
Fortier, L.A. (2012). Making progress in the what, when and where of regenerative medicine for our equine 
patients. Equine Vet. J. 44, 511-512. 
Fortina, P., and Surrey, S. (2008). Digital mRNA profiling. Nat. Biotechnol. 26, 293-294. 
Foster, J.W., Dominguez-Steglich, M.A., Guioli, S., Kwok, C., Weller, P.A., Stevanovic, M., Weissenbach, 
J., Mansour, S., Young, I.D., Goodfellow, P.N., and et al. (1994). Campomelic dysplasia and autosomal sex 
reversal caused by mutations in an SRY-related gene. Nature 372, 525-530. 
Francois, S., Bensidhoum, M., Mouiseddine, M., Mazurier, C., Allenet, B., Semont, A., Frick, J., Sache, A., 
Bouchet, S., Thierry, D., Gourmelon, P., Gorin, N.C., and Chapel, A. (2006). Local irradiation not only 
induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread 
engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem 
Cells 24, 1020-1029. 
Frantz, S. (2012). Embryonic stem cell pioneer Geron exits field, cuts losses. Nat. Biotechnol. 30, 12-13. 
Frenette, P.S., Pinho, S., Lucas, D., and Scheiermann, C. (2013). Mesenchymal stem cell: keystone of the 
hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 31, 
285-316. 
Friedenstein, A.J., Chailakhjan, R.K., and Lalykina, K.S. (1970). The development of fibroblast colonies in 
monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 3, 393-403. 
Friedman, R.C., Farh, K.K., Burge, C.B., and Bartel, D.P. (2009). Most mammalian mRNAs are conserved 
targets of microRNAs. Genome Res. 19, 92-105. 
Frisbie, D.D., Cross, M.W., and McIlwraith, C.W. (2006). A comparative study of articular cartilage 
thickness in the stifle of animal species used in human pre-clinical studies compared to articular cartilage 
thickness in the human knee. Vet Comp Orthop Traumatol 19, 142-146. 
Frisbie, D.D., and Stewart, M.C. (2011). Cell-based therapies for equine joint disease. Vet. Clin. North Am. 
Equine Pract. 27, 335-349. 
Ge, Z., Li, C., Heng, B.C., Cao, G., and Yang, Z. (2012). Functional biomaterials for cartilage regeneration. 
Journal of biomedical materials research. Part A 100, 2526-2536. 
Geiss, G.K., Bumgarner, R.E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D.L., Fell, H.P., Ferree, S., 
George, R.D., Grogan, T., James, J.J., Maysuria, M., Mitton, J.D., Oliveri, P., Osborn, J.L., Peng, T., 
Ratcliffe, A.L., Webster, P.J., Davidson, E.H., Hood, L., and Dimitrov, K. (2008). Direct multiplexed 
measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26, 317-325. 
 - 95 - 
Geneser, F., and Dørup, J. (1999). Histology: Molecular biology based text book. [Histologi: på 
molekylærbiologisk grundlag.]. Munksgaard: København. 
Gharravi, A.M., Orazizadeh, M., Ansari-Asl, K., Banoni, S., Izadi, S., and Hashemitabar, M. (2012). 
Design and fabrication of anatomical bioreactor systems containing alginate scaffolds for cartilage tissue 
engineering. Avicenna J Med Biotechnol 4, 65-74. 
Goldring, M.B. (2006a). Are bone morphogenetic proteins effective inducers of cartilage repair? Ex vivo 
transduction of muscle-derived stem cells. Arthritis Rheum. 54, 387-389. 
Goldring, M.B. (2012). Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in 
health and osteoarthritis. Ther Adv Musculoskelet Dis 4, 269-285. 
Goldring, M.B., Tsuchimochi, K., and Ijiri, K. (2006b). The control of chondrogenesis. J. Cell. Biochem. 
97, 33-44. 
Granan, L.P., Forssblad, M., Lind, M., and Engebretsen, L. (2009). The Scandinavian ACL registries 2004-
2007: baseline epidemiology. Acta orthopaedica 80, 563-567. 
Green, W.T., Jr. (1971). Behavior of articular chondrocytes in cell culture. Clin Orthop Relat Res 75, 248-
260. 
Grigolo, B., Lisignoli, G., Piacentini, A., Fiorini, M., Gobbi, P., Mazzotti, G., Duca, M., Pavesio, A., and 
Facchini, A. (2002). Evidence for redifferentiation of human chondrocytes grown on a hyaluronan-based 
biomaterial (HYAff 11): molecular, immunohistochemical and ultrastructural analysis. Biomaterials 23, 
1187-1195. 
Gudas, R., Kalesinskas, R.J., Kimtys, V., Stankevicius, E., Toliusis, V., Bernotavicius, G., and Smailys, A. 
(2005). A prospective randomized clinical study of mosaic osteochondral autologous transplantation versus 
microfracture for the treatment of osteochondral defects in the knee joint in young athletes. Arthroscopy 21, 
1066-1075. 
Guerit, D., Philipot, D., Chuchana, P., Toupet, K., Brondello, J.M., Mathieu, M., Jorgensen, C., and Noel, 
D. (2013). Sox9-Regulated miRNA-574-3p Inhibits Chondrogenic Differentiation of Mesenchymal Stem 
Cells. PloS one 8, e62582. 
Guilak, F., Lott, K.E., Awad, H.A., Cao, Q., Hicok, K.C., Fermor, B., and Gimble, J.M. (2006). Clonal 
analysis of the differentiation potential of human adipose-derived adult stem cells. J. Cell. Physiol. 206, 
229-237. 
Hall, B.K., and Miyake, T. (1995). Divide, accumulate, differentiate: cell condensation in skeletal 
development revisited. Int. J. Dev. Biol. 39, 881-893. 
Handorf, A.M., and Li, W.J. (2011). Fibroblast growth factor-2 primes human mesenchymal stem cells for 
enhanced chondrogenesis. PloS one 6, e22887. 
Handorf, A.M., and Li, W.J. (2014). Induction of mesenchymal stem cell chondrogenesis through 
sequential administration of growth factors within specific temporal windows. J. Cell. Physiol. 229, 162-
171. 
Hangody, L., Dobos, J., Balo, E., Panics, G., Hangody, L.R., and Berkes, I. (2010). Clinical experiences 
with autologous osteochondral mosaicplasty in an athletic population: a 17-year prospective multicenter 
study. Am. J. Sports Med. 38, 1125-1133. 
 - 96 - 
Hangody, L., and Fules, P. (2003). Autologous osteochondral mosaicplasty for the treatment of full-
thickness defects of weight-bearing joints: ten years of experimental and clinical experience. J. Bone Joint 
Surg. Am. 85-A Suppl 2, 25-32. 
Hangody, L., Kish, G., Karpati, Z., Szerb, I., and Udvarhelyi, I. (1997). Arthroscopic autogenous 
osteochondral mosaicplasty for the treatment of femoral condylar articular defects. A preliminary report. 
Knee Surg. Sports Traumatol. Arthrosc. 5, 262-267. 
Harris, R.G., Herzog, E.L., Bruscia, E.M., Grove, J.E., Van Arnam, J.S., and Krause, D.S. (2004). Lack of 
a fusion requirement for development of bone marrow-derived epithelia. Science 305, 90-93. 
Hartmann, C., and Tabin, C.J. (2001). Wnt-14 plays a pivotal role in inducing synovial joint formation in 
the developing appendicular skeleton. Cell 104, 341-351. 
Hauselmann, H.J., Fernandes, R.J., Mok, S.S., Schmid, T.M., Block, J.A., Aydelotte, M.B., Kuettner, K.E., 
and Thonar, E.J. (1994). Phenotypic stability of bovine articular chondrocytes after long-term culture in 
alginate beads. J. Cell Sci. 107 ( Pt 1), 17-27. 
Hayes, A.J., MacPherson, S., Morrison, H., Dowthwaite, G., and Archer, C.W. (2001). The development of 
articular cartilage: evidence for an appositional growth mechanism. Anat. Embryol. (Berl). 203, 469-479. 
He, L., and Hannon, G.J. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nature 
reviews. Genetics 5, 522-531. 
Hennig, T., Lorenz, H., Thiel, A., Goetzke, K., Dickhut, A., Geiger, F., and Richter, W. (2007). Reduced 
chondrogenic potential of adipose tissue derived stromal cells correlates with an altered TGFbeta receptor 
and BMP profile and is overcome by BMP-6. J. Cell. Physiol. 211, 682-691. 
Herlofsen, S.R., Bryne, J.C., Hoiby, T., Wang, L., Issner, R., Zhang, X., Coyne, M.J., Boyle, P., Gu, H., 
Meza-Zepeda, L.A., Collas, P., Mikkelsen, T.S., and Brinchmann, J.E. (2013). Genome-wide map of 
quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal 
stem cells. BMC genomics 14, 105. 
Herlofsen, S.R., Høiby, T., Cacchiarelli, D., Zhang, X., Mikkelsen, T.S., and Brinchmann, J.E. (2014). 
Importance of SOX8 for in vitro chondrogenic differentiation of human mesenchymal stromal cells. Stem 
Cells In Press. 
Herlofsen, S.R., Kuchler, A.M., Melvik, J.E., and Brinchmann, J.E. (2011). Chondrogenic differentiation of 
human bone marrow-derived mesenchymal stem cells in self-gelling alginate discs reveals novel 
chondrogenic signature gene clusters. Tissue Eng Part A 17, 1003-1013. 
Hills, G.M. (1940). The metabolism of articular cartilage. Biochem. J. 34, 1070-1077. 
Hjelle, K., Solheim, E., Strand, T., Muri, R., and Brittberg, M. (2002). Articular cartilage defects in 1,000 
knee arthroscopies. Arthroscopy 18, 730-734. 
Hjermundrud, V., Bjune, T.K., Risberg, M.A., Engebretsen, L., and Aroen, A. (2010). Full-thickness 
cartilage lesion do not affect knee function in patients with ACL injury. Knee Surg. Sports Traumatol. 
Arthrosc. 18, 298-303. 
Hochedlinger, K., and Jaenisch, R. (2006). Nuclear reprogramming and pluripotency. Nature 441, 1061-
1067. 
Hoemann, C., Kandel, R., Roberts, S., Saris, D.B.F., Creemers, L., Mainil-Varlet, P., Methot, S., Hollander, 
A.P., and Buschmann, M.D. (2011). International Cartilage Repair Society (ICRS) Recommended 
 - 97 - 
Guidelines for Histological Endpoints for Cartilage Repair Studies in Animal Models and Clinical Trials. 
Cartilage 2, 153-172. 
Holterman, C.E., and Rudnicki, M.A. (2005). Molecular regulation of satellite cell function. Semin. Cell 
Dev. Biol. 16, 575-584. 
Holtzer, H., Abbott, J., Lash, J., and Holtzer, S. (1960). The Loss of Phenotypic Traits by Differentiated 
Cells in Vitro, I. Dedifferentiation of Cartilage Cells. Proc. Natl. Acad. Sci. U. S. A. 46, 1533-1542. 
Horwitz, E.M., Gordon, P.L., Koo, W.K., Marx, J.C., Neel, M.D., McNall, R.Y., Muul, L., and Hofmann, T. 
(2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in 
children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc. Natl. Acad. Sci. U. S. A. 
99, 8932-8937. 
Horwitz, E.M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I., Marini, F.C., Deans, R.J., 
Krause, D.S., and Keating, A. (2005). Clarification of the nomenclature for MSC: The International Society 
for Cellular Therapy position statement. Cytotherapy 7, 393-395. 
Huang, K., Shen, Y., Xue, Z., Bibikova, M., April, C., Liu, Z., Cheng, L., Nagy, A., Pellegrini, M., Fan, J.-
B., and Fan, G. (2013). A Panel of CpG Methylation Sites Distinguishes Human Embryonic Stem Cells and 
Induced Pluripotent Stem Cells. Stem cell reports. 
Huang, W., Chung, U.I., Kronenberg, H.M., and de Crombrugghe, B. (2001). The chondrogenic 
transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth 
plate of endochondral bones. Proc. Natl. Acad. Sci. U. S. A. 98, 160-165. 
Hunter, W. (1742). Of the Structure and Diseases of Articulating Cartilages, by William Hunter, Surgeon. 
Philosophical Transactions of the Royal Society of London 42, 514-521. 
Hunziker, E.B. (2002a). Articular cartilage repair: basic science and clinical progress. A review of the 
current status and prospects. Osteoarthritis Cartilage 10, 432-463. 
Hunziker, E.B., Quinn, T.M., and Hauselmann, H.J. (2002b). Quantitative structural organization of normal 
adult human articular cartilage. Osteoarthritis Cartilage 10, 564-572. 
Hurtig, M.B., Buschmann, M.D., Fortier, L.A., Hoemann, C.D., Hunziker, E.B., Jurvelin, J.S., Mainil-
Varlet, P., McIlwraith, C.W., Sah, R.L., and Whiteside, R.A. (2011). Preclinical Studies for Cartilage 
Repair: Recommendations from the International Cartilage Repair Society. Cartilage 2, 137-152. 
Hyllested, J.L., Veje, K., and Ostergaard, K. (2002). Histochemical studies of the extracellular matrix of 
human articular cartilage--a review. Osteoarthritis Cartilage 10, 333-343. 
ICRS. (2000). ICRS Cartilage Injury Evaluation Package, ed. M. Brittberg. 
Iliopoulos, D., Malizos, K.N., Oikonomou, P., and Tsezou, A. (2008). Integrative microRNA and 
proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and 
inflammatory networks. PloS one 3, e3740. 
Im, G.I., Lee, J.M., and Kim, H.J. (2011). Wnt inhibitors enhance chondrogenesis of human mesenchymal 
stem cells in a long-term pellet culture. Biotechnology letters 33, 1061-1068. 
Im, G.I., Shin, Y.W., and Lee, K.B. (2005). Do adipose tissue-derived mesenchymal stem cells have the 
same osteogenic and chondrogenic potential as bone marrow-derived cells? Osteoarthritis Cartilage 13, 
845-853. 
 - 98 - 
Iwamoto, M., Higuchi, Y., Koyama, E., Enomoto-Iwamoto, M., Kurisu, K., Yeh, H., Abrams, W.R., 
Rosenbloom, J., and Pacifici, M. (2000). Transcription factor ERG variants and functional diversification 
of chondrocytes during limb long bone development. J. Cell Biol. 150, 27-40. 
Iwamoto, M., Tamamura, Y., Koyama, E., Komori, T., Takeshita, N., Williams, J.A., Nakamura, T., 
Enomoto-Iwamoto, M., and Pacifici, M. (2007). Transcription factor ERG and joint and articular cartilage 
formation during mouse limb and spine skeletogenesis. Dev. Biol. 305, 40-51. 
Jaenisch, R. (2004). Human cloning - the science and ethics of nuclear transplantation. N. Engl. J. Med. 
351, 2787-2791. 
Jaenisch, R., and Meissner, A. (2006). Politically correct human embryonic stem cells? N. Engl. J. Med. 
354, 1208-1209; author reply 1208-1209. 
Jakobsen, R.B., and Engebretsen, L. (2007). An analysis of the quality of cartilage repair studies — An 
Update. ISAKOS CURRENT CONCEPTS. 
Jakobsen, R.B., Engebretsen, L., and Slauterbeck, J.R. (2005). An analysis of the quality of cartilage repair 
studies. J. Bone Joint Surg. Am. 87, 2232-2239. 
Jansen, E.J., Emans, P.J., Douw, C.M., Guldemond, N.A., Van Rhijn, L.W., Bulstra, S.K., and Kuijer, R. 
(2008). One intra-articular injection of hyaluronan prevents cell death and improves cell metabolism in a 
model of injured articular cartilage in the rabbit. J. Orthop. Res. 26, 624-630. 
Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, 
A.J., Patick, A.K., Chen, A., Zhou, Y., Persson, R., King, B.D., Kauppinen, S., Levin, A.A., and Hodges, 
M.R. (2013). Treatment of HCV Infection by Targeting MicroRNA. N. Engl. J. Med. 
Jia, S., Liu, L., Pan, W., Meng, G., Duan, C., Zhang, L., Xiong, Z., and Liu, J. (2012). Oriented cartilage 
extracellular matrix-derived scaffold for cartilage tissue engineering. J Biosci Bioeng 113, 647-653. 
Jiang, Y., Henderson, D., Blackstad, M., Chen, A., Miller, R.F., and Verfaillie, C.M. (2003). 
Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proc. Natl. Acad. Sci. U. S. 
A. 100 Suppl 1, 11854-11860. 
Jiang, Y., Jahagirdar, B.N., Reinhardt, R.L., Schwartz, R.E., Keene, C.D., Ortiz-Gonzalez, X.R., Reyes, M., 
Lenvik, T., Lund, T., Blackstad, M., Du, J., Aldrich, S., Lisberg, A., Low, W.C., Largaespada, D.A., and 
Verfaillie, C.M. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418, 
41-49. 
Johnson, K., Zhu, S., Tremblay, M.S., Payette, J.N., Wang, J., Bouchez, L.C., Meeusen, S., Althage, A., 
Cho, C.Y., Wu, X., and Schultz, P.G. (2012). A Stem Cell-Based Approach to Cartilage Repair. Science. 
Johnstone, B., Hering, T.M., Caplan, A.I., Goldberg, V.M., and Yoo, J.U. (1998). In vitro chondrogenesis 
of bone marrow-derived mesenchymal progenitor cells. Exp. Cell Res. 238, 265-272. 
Joseph, N.M., and Morrison, S.J. (2005). Toward an understanding of the physiological function of 
Mammalian stem cells. Developmental cell 9, 173-183. 
Kanaan, R.A., and Kanaan, L.A. (2006). Transforming growth factor beta1, bone connection. Med Sci 
Monit 12, RA164-169. 
Kardassis, D., Murphy, C., Fotsis, T., Moustakas, A., and Stournaras, C. (2009). Control of transforming 
growth factor beta signal transduction by small GTPases. The FEBS journal 276, 2947-2965. 
 - 99 - 
Karlsen, T.A., and Brinchmann, J.E. (2013). Liposome delivery of microRNA-145 to mesenchymal stem 
cells leads to immunological off-target effects mediated by RIG-I. Mol Ther 21, 1169-1181. 
Karlsen, T.A., Shahdadfar, A., and Brinchmann, J.E. (2011). Human primary articular chondrocytes, 
chondroblasts-like cells, and dedifferentiated chondrocytes: differences in gene, microRNA, and protein 
expression and phenotype. Tissue engineering. Part C, Methods 17, 219-227. 
Kaviani, A., Perry, T.E., Dzakovic, A., Jennings, R.W., Ziegler, M.M., and Fauza, D.O. (2001). The 
amniotic fluid as a source of cells for fetal tissue engineering. J. Pediatr. Surg. 36, 1662-1665. 
Kayakabe, M., Tsutsumi, S., Watanabe, H., Kato, Y., and Takagishi, K. (2006). Transplantation of 
autologous rabbit BM-derived mesenchymal stromal cells embedded in hyaluronic acid gel sponge into 
osteochondral defects of the knee. Cytotherapy 8, 343-353. 
Keller, B., Yang, T., Chen, Y., Munivez, E., Bertin, T., Zabel, B., and Lee, B. (2011). Interaction of 
TGFbeta and BMP signaling pathways during chondrogenesis. PloS one 6, e16421. 
Kim, D., Song, J., and Jin, E.J. (2010a). MicroRNA-221 regulates chondrogenic differentiation through 
promoting proteosomal degradation of slug by targeting Mdm2. J. Biol. Chem. 285, 26900-26907. 
Kim, H.J., and Im, G.I. (2010b). The effects of ERK1/2 inhibitor on the chondrogenesis of bone marrow- 
and adipose tissue-derived multipotent mesenchymal stromal cells. Tissue Eng Part A 16, 851-860. 
Kim, T.K., and Eberwine, J.H. (2010c). Mammalian cell transfection: the present and the future. Analytical 
and bioanalytical chemistry 397, 3173-3178. 
Kim, Y.J., Kim, H.J., and Im, G.I. (2008). PTHrP promotes chondrogenesis and suppresses hypertrophy 
from both bone marrow-derived and adipose tissue-derived MSCs. Biochem. Biophys. Res. Commun. 373, 
104-108. 
Kist, R., Schrewe, H., Balling, R., and Scherer, G. (2002). Conditional inactivation of Sox9: a mouse model 
for campomelic dysplasia. Genesis 32, 121-123. 
Knudson, C.B., and Knudson, W. (2001). Cartilage proteoglycans. Semin. Cell Dev. Biol. 12, 69-78. 
Knudson, W., and Loeser, R.F. (2002). CD44 and integrin matrix receptors participate in cartilage 
homeostasis. Cell. Mol. Life Sci. 59, 36-44. 
Knutsen, G., Drogset, J.O., Engebretsen, L., Grontvedt, T., Isaksen, V., Ludvigsen, T.C., Roberts, S., 
Solheim, E., Strand, T., and Johansen, O. (2007). A randomized trial comparing autologous chondrocyte 
implantation with microfracture. Findings at five years. J. Bone Joint Surg. Am. 89, 2105-2112. 
Knutsen, G., Engebretsen, L., Ludvigsen, T.C., Drogset, J.O., Grontvedt, T., Solheim, E., Strand, T., 
Roberts, S., Isaksen, V., and Johansen, O. (2004). Autologous chondrocyte implantation compared with 
microfracture in the knee. A randomized trial. Journal of Bone & Joint Surgery - American Volume 86-A, 
455-464. 
Kobayashi, N., Uemura, H., Nagahama, K., Okudela, K., Furuya, M., Ino, Y., Ito, Y., Hirano, H., Inayama, 
Y., Aoki, I., Nagashima, Y., Kubota, Y., and Ishiguro, H. (2012). Identification of miR-30d as a novel 
prognostic maker of prostate cancer. Oncotarget 3, 1455-1471. 
Kobayashi, T., Lu, J., Cobb, B.S., Rodda, S.J., McMahon, A.P., Schipani, E., Merkenschlager, M., and 
Kronenberg, H.M. (2008). Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. 
Proc. Natl. Acad. Sci. U. S. A. 105, 1949-1954. 
 - 100 -
Koch, T.G., Berg, L.C., and Betts, D.H. (2008). Concepts for the clinical use of stem cells in equine 
medicine. Can. Vet. J. 49, 1009-1017. 
Koga, H., Muneta, T., Ju, Y.J., Nagase, T., Nimura, A., Mochizuki, T., Ichinose, S., von der Mark, K., and 
Sekiya, I. (2007). Synovial stem cells are regionally specified according to local microenvironments after 
implantation for cartilage regeneration. Stem Cells 25, 689-696. 
Koga, H., Shimaya, M., Muneta, T., Nimura, A., Morito, T., Hayashi, M., Suzuki, S., Ju, Y.J., Mochizuki, 
T., and Sekiya, I. (2008). Local adherent technique for transplanting mesenchymal stem cells as a potential 
treatment of cartilage defect. Arthritis Res Ther 10, R84. 
Kogler, G., Sensken, S., Airey, J.A., Trapp, T., Muschen, M., Feldhahn, N., Liedtke, S., Sorg, R.V., Fischer, 
J., Rosenbaum, C., Greschat, S., Knipper, A., Bender, J., Degistirici, O., Gao, J., Caplan, A.I., Colletti, E.J., 
Almeida-Porada, G., Muller, H.W., Zanjani, E., and Wernet, P. (2004). A new human somatic stem cell 
from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med. 200, 123-135. 
Kucia, M., Reca, R., Campbell, F.R., Zuba-Surma, E., Majka, M., Ratajczak, J., and Ratajczak, M.Z. 
(2006). A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells 
identified in adult bone marrow. Leukemia 20, 857-869. 
Kuroda, R., Ishida, K., Matsumoto, T., Akisue, T., Fujioka, H., Mizuno, K., Ohgushi, H., Wakitani, S., and 
Kurosaka, M. (2007). Treatment of a full-thickness articular cartilage defect in the femoral condyle of an 
athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage 15, 226-231. 
Kwan, K.M., Pang, M.K., Zhou, S., Cowan, S.K., Kong, R.Y., Pfordte, T., Olsen, B.R., Sillence, D.O., 
Tam, P.P., and Cheah, K.S. (1997). Abnormal compartmentalization of cartilage matrix components in 
mice lacking collagen X: implications for function. J. Cell Biol. 136, 459-471. 
Lakshmipathy, U., and Verfaillie, C. (2005). Stem cell plasticity. Blood Rev. 19, 29-38. 
Lanford, R.E., Hildebrandt-Eriksen, E.S., Petri, A., Persson, R., Lindow, M., Munk, M.E., Kauppinen, S., 
and Orum, H. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus 
infection. Science 327, 198-201. 
Le Blanc, K., Rasmusson, I., Sundberg, B., Gotherstrom, C., Hassan, M., Uzunel, M., and Ringden, O. 
(2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal 
stem cells. Lancet 363, 1439-1441. 
Lee, A.S., Ellman, M.B., Yan, D., Kroin, J.S., Cole, B.J., van Wijnen, A.J., and Im, H.J. (2013). A current 
review of molecular mechanisms regarding osteoarthritis and pain. Gene 527, 440-447. 
Lee, R.H., Kim, B., Choi, I., Kim, H., Choi, H.S., Suh, K., Bae, Y.C., and Jung, J.S. (2004). 
Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose 
tissue. Cell. Physiol. Biochem. 14, 311-324. 
Lefebvre, V., Behringer, R.R., and de Crombrugghe, B. (2001). L-Sox5, Sox6 and Sox9 control essential 
steps of the chondrocyte differentiation pathway. Osteoarthritis Cartilage 9 Suppl A, S69-75. 
Li, J., Ezzelarab, M.B., and Cooper, D.K. (2012). Do mesenchymal stem cells function across species 
barriers? Relevance for xenotransplantation. Xenotransplantation 19, 273-285. 
Li, L. (2010). Dimension reduction for high-dimensional data. Methods Mol. Biol. 620, 417-434. 
Li, L., and Xie, T. (2005). Stem cell niche: structure and function. Annu. Rev. Cell Dev. Biol. 21, 605-631. 
Li, R. (2013). The art of choreographing asymmetric cell division. Developmental cell 25, 439-450. 
 - 101 -
Lin, C.C., Liu, L.Z., Addison, J.B., Wonderlin, W.F., Ivanov, A.V., and Ruppert, J.M. (2011). A KLF4-
miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell 
context. Mol. Cell. Biol. 31, 2513-2527. 
Lin, H. (2002). The stem-cell niche theory: lessons from flies. Nature reviews. Genetics 3, 931-940. 
Lin, X., Wu, L., Zhang, Z., Yang, R., Guan, Q., Hou, X., and Wu, Q. (2013). MiR-335-5p Promotes 
Chondrogenesis in Mouse Mesenchymal Stem Cells and is Regulated Through Two Positive Feedback 
Loops. J. Bone Miner. Res. 
Liu, Z., Lavine, K.J., Hung, I.H., and Ornitz, D.M. (2007). FGF18 is required for early chondrocyte 
proliferation, hypertrophy and vascular invasion of the growth plate. Dev. Biol. 302, 80-91. 
Loken, S., Jakobsen, R.B., Aroen, A., Heir, S., Shahdadfar, A., Brinchmann, J.E., Engebretsen, L., and 
Reinholt, F.P. (2008). Bone marrow mesenchymal stem cells in a hyaluronan scaffold for treatment of an 
osteochondral defect in a rabbit model. Knee Surg. Sports Traumatol. Arthrosc. 16, 896-903. 
Lorentzon, R., Alfredson, H., and Hildingsson, C. (1998). Treatment of deep cartilage defects of the patella 
with periosteal transplantation. Knee Surg. Sports Traumatol. Arthrosc. 6, 202-208. 
Lorenzo, P., Bayliss, M.T., and Heinegard, D. (2004). Altered patterns and synthesis of extracellular matrix 
macromolecules in early osteoarthritis. Matrix Biol. 23, 381-391. 
Luo, W., Guo, C., Zheng, J., Chen, T.L., Wang, P.Y., Vertel, B.M., and Tanzer, M.L. (2000). Aggrecan 
from start to finish. J. Bone Miner. Metab. 18, 51-56. 
Ma, H.L., Hung, S.C., Lin, S.Y., Chen, Y.L., and Lo, W.H. (2003). Chondrogenesis of human 
mesenchymal stem cells encapsulated in alginate beads. Journal of biomedical materials research. Part A 64, 
273-281. 
Ma, K., Titan, A.L., Stafford, M., Zheng, C., and Levenston, M.E. (2012). Variations in chondrogenesis of 
human bone marrow-derived mesenchymal stem cells in fibrin/alginate blended hydrogels. Acta 
biomaterialia 8, 3754-3764. 
Mainil-Varlet, P., Aigner, T., Brittberg, M., Bullough, P., Hollander, A., Hunziker, E., Kandel, R., Nehrer, 
S., Pritzker, K., Roberts, S., Stauffer, E., and International Cartilage Repair, S. (2003). Histological 
assessment of cartilage repair: a report by the Histology Endpoint Committee of the International Cartilage 
Repair Society (ICRS). J. Bone Joint Surg. Am. 85-A Suppl 2, 45-57. 
Malkov, V.A., Serikawa, K.A., Balantac, N., Watters, J., Geiss, G., Mashadi-Hossein, A., and Fare, T. 
(2009). Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter 
Assay System. BMC research notes 2, 80. 
Manning, W.K., and Bonner, W.M., Jr. (1967). Isolation and culture of chondrocytes from human adult 
articular cartilage. Arthritis Rheum. 10, 235-239. 
Marcacci, M., Berruto, M., Brocchetta, D., Delcogliano, A., Ghinelli, D., Gobbi, A., Kon, E., Pederzini, L., 
Rosa, D., Sacchetti, G.L., Stefani, G., and Zanasi, S. (2005). Articular cartilage engineering with 
Hyalograft C: 3-year clinical results. Clin Orthop Relat Res 435, 96-105. 
Martinez-Sanchez, A., Dudek, K.A., and Murphy, C.L. (2012). Regulation of human chondrocyte function 
through direct inhibition of cartilage master regulator SOX9 by microRNA-145 (miRNA-145). J. Biol. 
Chem. 287, 916-924. 
Massague, J., and Gomis, R.R. (2006). The logic of TGFbeta signaling. FEBS Lett. 580, 2811-2820. 
 - 102 -
Mastbergen, S.C., Saris, D.B., and Lafeber, F.P. (2013). Functional articular cartilage repair: here, near, or 
is the best approach not yet clear? Nature reviews. Rheumatology 9, 277-290. 
Matricali, G.A., Dereymaeker, G.P., and Luyten, F.P. (2010). Donor site morbidity after articular cartilage 
repair procedures: a review. Acta Orthop. Belg. 76, 669-674. 
Matsumoto, T., Okabe, T., Ikawa, T., Iida, T., Yasuda, H., Nakamura, H., and Wakitani, S. (2010). 
Articular cartilage repair with autologous bone marrow mesenchymal cells. J. Cell. Physiol. 225, 291-295. 
Matsusue, Y., Yamamuro, T., and Hama, H. (1993). Arthroscopic multiple osteochondral transplantation to 
the chondral defect in the knee associated with anterior cruciate ligament disruption. Arthroscopy 9, 318-
321. 
Mayan, M.D., Carpintero-Fernandez, P., Gago-Fuentes, R., Martinez-de-Ilarduya, O., Wang, H.Z., 
Valiunas, V., Brink, P., and Blanco, F.J. (2013). Human articular chondrocytes express multiple gap 
junction proteins: differential expression of connexins in normal and osteoarthritic cartilage. Am. J. Pathol. 
182, 1337-1346. 
McAlinden, A., Johnstone, B., Kollar, J., Kazmi, N., and Hering, T.M. (2008). Expression of two novel 
alternatively spliced COL2A1 isoforms during chondrocyte differentiation. Matrix Biol. 27, 254-266. 
McCoy, B., and Miniaci, A. (2012). Osteochondral autograft transplantation/mosaicplasty. J Knee Surg 25, 
99-108. 
Medvinsky, A., and Smith, A. (2003). Stem cells: Fusion brings down barriers. Nature 422, 823-825. 
Meijer, H.A., Kong, Y.W., Lu, W.T., Wilczynska, A., Spriggs, R.V., Robinson, S.W., Godfrey, J.D., Willis, 
A.E., and Bushell, M. (2013). Translational repression and eIF4A2 activity are critical for microRNA-
mediated gene regulation. Science 340, 82-85. 
Melville, H., Carpiniello, M., Hollis, K., Staffaroni, A., and Golestaneh, N. (2013). Stem cells: a new 
paradigm for disease modeling and developing therapies for age-related macular degeneration. J Transl 
Med 11, 53. 
Messner, K., and Maletius, W. (1996). The long-term prognosis for severe damage to weight-bearing 
cartilage in the knee: a 14-year clinical and radiographic follow-up in 28 young athletes. Acta Orthop. 
Scand. 67, 165-168. 
Miao, Z., Jin, J., Chen, L., Zhu, J., Huang, W., Zhao, J., Qian, H., and Zhang, X. (2006). Isolation of 
mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem 
cells. Cell Biol. Int. 30, 681-687. 
Mikkelsen, T.S., Xu, Z., Zhang, X., Wang, L., Gimble, J.M., Lander, E.S., and Rosen, E.D. (2010). 
Comparative epigenomic analysis of murine and human adipogenesis. Cell 143, 156-169. 
Mithoefer, K., Hambly, K., Logerstedt, D., Ricci, M., Silvers, H., and Della Villa, S. (2012). Current 
concepts for rehabilitation and return to sport after knee articular cartilage repair in the athlete. J. Orthop. 
Sports Phys. Ther. 42, 254-273. 
Miyaki, S., and Asahara, H. (2012). Macro view of microRNA function in osteoarthritis. Nature reviews. 
Rheumatology 8, 543-552. 
Miyaki, S., Nakasa, T., Otsuki, S., Grogan, S.P., Higashiyama, R., Inoue, A., Kato, Y., Sato, T., Lotz, M.K., 
and Asahara, H. (2009). MicroRNA-140 is expressed in differentiated human articular chondrocytes and 
modulates interleukin-1 responses. Arthritis Rheum. 60, 2723-2730. 
 - 103 -
Miyaki, S., Sato, T., Inoue, A., Otsuki, S., Ito, Y., Yokoyama, S., Kato, Y., Takemoto, F., Nakasa, T., 
Yamashita, S., Takada, S., Lotz, M.K., Ueno-Kudo, H., and Asahara, H. (2010). MicroRNA-140 plays dual 
roles in both cartilage development and homeostasis. Genes Dev. 24, 1173-1185. 
Miyakoshi, N., Kobayashi, M., Nozaka, K., Okada, K., Shimada, Y., and Itoi, E. (2005). Effects of 
intraarticular administration of basic fibroblast growth factor with hyaluronic acid on osteochondral defects 
of the knee in rabbits. Arch. Orthop. Trauma Surg. 125, 683-692. 
Miyanishi, M., Mori, Y., Seita, J., Chen, J.Y., Karten, S., Chan, C.K., Nakauchi, H., and Weissman, I.L. 
(2013). Do pluripotent stem cells exist in adult mice as very small embryonic stem cells? Stem cell reports 
1, 198-208. 
Mont, M.A., Baumgarten, K.M., Rifai, A., Bluemke, D.A., Jones, L.C., and Hungerford, D.S. (2000). 
Atraumatic osteonecrosis of the knee. J. Bone Joint Surg. Am. 82, 1279-1290. 
Moore, K.A., and Lemischka, I.R. (2006). Stem cells and their niches. Science 311, 1880-1885. 
Moseley, J.B., O'Malley, K., Petersen, N.J., Menke, T.J., Brody, B.A., Kuykendall, D.H., Hollingsworth, 
J.C., Ashton, C.M., and Wray, N.P. (2002). A controlled trial of arthroscopic surgery for osteoarthritis of 
the knee. N. Engl. J. Med. 347, 81-88. 
Motulsky, H. (2010). Intuitive Biostatistics - A Nonmathematical Guide to Statistical Thinking. Oxford 
University Press: New York. 
Nakagawa, T., Lee, S.Y., and Reddi, A.H. (2009). Induction of chondrogenesis from human embryonic 
stem cells without embryoid body formation by bone morphogenetic protein 7 and transforming growth 
factor beta1. Arthritis Rheum. 60, 3686-3692. 
Nakamae, A., Engebretsen, L., Bahr, R., Krosshaug, T., and Ochi, M. (2006). Natural history of bone 
bruises after acute knee injury: clinical outcome and histopathological findings. Knee Surg. Sports 
Traumatol. Arthrosc. 14, 1252-1258. 
Nakamura, Y., He, X., Kato, H., Wakitani, S., Kobayashi, T., Watanabe, S., Iida, A., Tahara, H., Warman, 
M.L., Watanapokasin, R., and Postlethwait, J.H. (2012). Sox9 is upstream of microRNA-140 in cartilage. 
Appl. Biochem. Biotechnol. 166, 64-71. 
Nakamura, Y., Inloes, J.B., Katagiri, T., and Kobayashi, T. (2011). Chondrocyte-specific microRNA-140 
regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein 
signaling. Mol. Cell. Biol. 31, 3019-3028. 
NatureNews. (2007). Stem cells: The hard copy. Nature 446, 485-486. 
Nicolas, F.E. (2011a). Experimental validation of microRNA targets using a luciferase reporter system. 
Methods Mol. Biol. 732, 139-152. 
Nicolas, F.E., Pais, H., Schwach, F., Lindow, M., Kauppinen, S., Moulton, V., and Dalmay, T. (2008). 
Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140. RNA 14, 
2513-2520. 
Nicolas, F.E., Pais, H., Schwach, F., Lindow, M., Kauppinen, S., Moulton, V., and Dalmay, T. (2011b). 
mRNA expression profiling reveals conserved and non-conserved miR-140 targets. RNA biology 8, 607-
615. 
Nieminen, M.T., Nissi, M.J., Mattila, L., and Kiviranta, I. (2012). Evaluation of chondral repair using 
quantitative MRI. J. Magn. Reson. Imaging 36, 1287-1299. 
 - 104 -
O'Driscoll, S.W., and Salter, R.B. (1984). The induction of neochondrogenesis in free intra-articular 
periosteal autografts under the influence of continuous passive motion. An experimental investigation in 
the rabbit. J. Bone Joint Surg. Am. 66, 1248-1257. 
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-competent induced pluripotent 
stem cells. Nature 448, 313-317. 
Olsen, B.R., Reginato, A.M., and Wang, W. (2000). Bone development. Annu. Rev. Cell Dev. Biol. 16, 
191-220. 
Opasanon, S., Muangman, P., and Namviriyachote, N. (2010). Clinical effectiveness of alginate silver 
dressing in outpatient management of partial-thickness burns. Int Wound J 7, 467-471. 
Orom, U.A., Nielsen, F.C., and Lund, A.H. (2008). MicroRNA-10a binds the 5'UTR of ribosomal protein 
mRNAs and enhances their translation. Mol. Cell 30, 460-471. 
Oshima, Y., Watanabe, N., Matsuda, K., Takai, S., Kawata, M., and Kubo, T. (2005). Behavior of 
transplanted bone marrow-derived GFP mesenchymal cells in osteochondral defect as a simulation of 
autologous transplantation. J. Histochem. Cytochem. 53, 207-216. 
Ostrup, E., Bauersachs, S., Blum, H., Wolf, E., and Hyttel, P. (2010). Differential endometrial gene 
expression in pregnant and nonpregnant sows. Biol. Reprod. 83, 277-285. 
Outerbridge, R.E. (1961). The etiology of chondromalacia patellae. J. Bone Joint Surg. Br. 43-B, 752-757. 
Ouyang, L., Liu, P., Yang, S., Ye, S., Xu, W., and Liu, X. (2013). A three-plasma miRNA signature serves 
as novel biomarkers for osteosarcoma. Med. Oncol. 30, 340. 
Pais, H., Nicolas, F.E., Soond, S.M., Swingler, T.E., Clark, I.M., Chantry, A., Moulton, V., and Dalmay, T. 
(2010). Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein 
level. RNA 16, 489-494. 
Palmer, A.J., Brown, C.P., McNally, E.G., Price, A.J., Tracey, I., Jezzard, P., Carr, A.J., and Glyn-Jones, S. 
(2013). Non-invasive imaging of cartilage in early osteoarthritis. Bone Joint J 95-B, 738-746. 
Patel, D.V., Breazeale, N.M., Behr, C.T., Warren, R.F., Wickiewicz, T.L., and O'Brien, S.J. (1998). 
Osteonecrosis of the knee: current clinical concepts. Knee Surg. Sports Traumatol. Arthrosc. 6, 2-11. 
Pelttari, K., Winter, A., Steck, E., Goetzke, K., Hennig, T., Ochs, B.G., Aigner, T., and Richter, W. (2006). 
Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells 
correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis 
Rheum. 54, 3254-3266. 
Phinney, D.G., and Sensebe, L. (2013). Mesenchymal stromal cells: misconceptions and evolving concepts. 
Cytotherapy 15, 140-145. 
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., 
Simonetti, D.W., Craig, S., and Marshak, D.R. (1999). Multilineage potential of adult human mesenchymal 
stem cells. Science 284, 143-147. 
Poole, A.R., Kojima, T., Yasuda, T., Mwale, F., Kobayashi, M., and Laverty, S. (2001). Composition and 
structure of articular cartilage: a template for tissue repair. Clin Orthop Relat Res 391 Suppl, S26-33. 
Poole, C.A. (1997). Articular cartilage chondrons: form, function and failure. J. Anat. 191 ( Pt 1), 1-13. 
 - 105 -
Radice, M., Brun, P., Cortivo, R., Scapinelli, R., Battaliard, C., and Abatangelo, G. (2000). Hyaluronan-
based biopolymers as delivery vehicles for bone-marrow-derived mesenchymal progenitors. J. Biomed. 
Mater. Res. 50, 101-109. 
Retting, K.N., Song, B., Yoon, B.S., and Lyons, K.M. (2009). BMP canonical Smad signaling through 
Smad1 and Smad5 is required for endochondral bone formation. Development 136, 1093-1104. 
Reyes, M., Lund, T., Lenvik, T., Aguiar, D., Koodie, L., and Verfaillie, C.M. (2001). Purification and ex 
vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98, 2615-2625. 
Ringe, J., Burmester, G.R., and Sittinger, M. (2012). Regenerative medicine in rheumatic disease-progress 
in tissue engineering. Nature reviews. Rheumatology 8, 493-498. 
Roberts, S., Menage, J., Sandell, L.J., Evans, E.H., and Richardson, J.B. (2009). Immunohistochemical 
study of collagen types I and II and procollagen IIA in human cartilage repair tissue following autologous 
chondrocyte implantation. The Knee 16, 398-404. 
Robinton, D.A., and Daley, G.Q. (2012). The promise of induced pluripotent stem cells in research and 
therapy. Nature 481, 295-305. 
Ross, M.H., Pawlina, W., and Kaye, G.I. (2003). Histology: a text and atlas. Lippincott Williams & 
Wilkins: Baltimore. 
Rothwell, A.G., and Bentley, G. (1973). Chondrocyte multiplication in osteoarthritic articular cartilage. J. 
Bone Joint Surg. Br. 55, 588-594. 
Ryan, J.M., Barry, F.P., Murphy, J.M., and Mahon, B.P. (2005). Mesenchymal stem cells avoid allogeneic 
rejection. J Inflamm (Lond) 2, 8. 
Sadler, T.W., Langman, J., and Ecker, P.M. (2006). Langman's medical embryology. Lippincott Williams 
& Wilkins: Philadelphia. 
Saris, D., Price, A., Drogset, J.O., Podskubka, A., Tsuchida, A., Bezuidenhoudt, M., Kili, S., Levine, D.W., 
and Brittberg, M. (2013). SUMMIT Prospective, Randomized, Controlled Trial: Response Rates To 
Matrix-induced Autologous Chondrocyte Implant (MACI) Versus Microfracture (MFX) By Lesion 
Characteristics. Orthopaedic Journal of Sports Medicine 1. 
Saris, D.B., Vanlauwe, J., Victor, J., Almqvist, K.F., Verdonk, R., Bellemans, J., Luyten, F.P., Tig/Act, and 
Group, E.X.T.S. (2009). Treatment of symptomatic cartilage defects of the knee: characterized chondrocyte 
implantation results in better clinical outcome at 36 months in a randomized trial compared to 
microfracture. Am. J. Sports Med. 37 Suppl 1, 10S-19S. 
Saris, D.B., Vanlauwe, J., Victor, J., Haspl, M., Bohnsack, M., Fortems, Y., Vandekerckhove, B., Almqvist, 
K.F., Claes, T., Handelberg, F., Lagae, K., van der Bauwhede, J., Vandenneucker, H., Yang, K.G., Jelic, M., 
Verdonk, R., Veulemans, N., Bellemans, J., and Luyten, F.P. (2008). Characterized chondrocyte 
implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a 
randomized controlled trial versus microfracture. Am. J. Sports Med. 36, 235-246. 
Schallmoser, K., and Strunk, D. (2009). Preparation of pooled human platelet lysate (pHPL) as an efficient 
supplement for animal serum-free human stem cell cultures. Journal of visualized experiments : JoVE. 
Schenck, R.C., Jr., and Goodnight, J.M. (1996). Osteochondritis dissecans. J. Bone Joint Surg. Am. 78, 
439-456. 
Schnabel, L.V., Fortier, L.A., McIlwraith, C.W., and Nobert, K.M. (2013). Therapeutic use of stem cells in 
horses: which type, how, and when? Vet. J. 197, 570-577. 
 - 106 -
Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., and Selbach, M. 
(2011). Global quantification of mammalian gene expression control. Nature 473, 337-342. 
Schwartz, S.D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C.K., Ostrick, R.M., Mickunas, 
E., Gay, R., Klimanskaya, I., and Lanza, R. (2012). Embryonic stem cell trials for macular degeneration: a 
preliminary report. The Lancet 379, 713-720. 
Seibel, M.J., Robins, S.P., and Bilezikian, J.P. (2006). Dynamics of bone and cartilage metabolism. 
Academic Press: San Diego. 
Sekiya, I., Colter, D.C., and Prockop, D.J. (2001). BMP-6 enhances chondrogenesis in a subpopulation of 
human marrow stromal cells. Biochem. Biophys. Res. Commun. 284, 411-418. 
Sekiya, I., Larson, B.L., Vuoristo, J.T., Reger, R.L., and Prockop, D.J. (2005). Comparison of effect of 
BMP-2, -4, and -6 on in vitro cartilage formation of human adult stem cells from bone marrow stroma. Cell 
Tissue Res. 320, 269-276. 
Seo, M.J., Suh, S.Y., Bae, Y.C., and Jung, J.S. (2005). Differentiation of human adipose stromal cells into 
hepatic lineage in vitro and in vivo. Biochem. Biophys. Res. Commun. 328, 258-264. 
Serafini, M., and Verfaillie, C.M. (2006). Pluripotency in adult stem cells: state of the art. Seminars in 
reproductive medicine 24, 379-388. 
Shahdadfar, A., Loken, S., Dahl, J.A., Tunheim, S.H., Collas, P., Reinholt, F.P., Engebretsen, L., and 
Brinchmann, J.E. (2008). Persistence of collagen type II synthesis and secretion in rapidly proliferating 
human articular chondrocytes in vitro. Tissue Eng Part A 14, 1999-2007. 
Shelbourne, K.D., Jari, S., and Gray, T. (2003). Outcome of untreated traumatic articular cartilage defects 
of the knee: a natural history study. J. Bone Joint Surg. Am. 85-A Suppl 2, 8-16. 
Shellock, F.G., Hiller, W.D., Ainge, G.R., Brown, D.W., and Dierenfield, L. (2003). Knees of Ironman 
triathletes: magnetic resonance imaging assessment of older (>35 years old) competitors. J. Magn. Reson. 
Imaging 17, 122-130. 
Shi, S., and Gronthos, S. (2003). Perivascular niche of postnatal mesenchymal stem cells in human bone 
marrow and dental pulp. J. Bone Miner. Res. 18, 696-704. 
Shoji, T., Nakasa, T., Yamasaki, K., Kodama, A., Miyaki, S., Niimoto, T., Okuhara, A., Kamei, N., Adachi, 
N., and Ochi, M. (2012). The effect of intra-articular injection of microRNA-210 on ligament healing in a 
rat model. Am. J. Sports Med. 40, 2470-2478. 
Shum, L., and Nuckolls, G. (2002). The life cycle of chondrocytes in the developing skeleton. Arthritis 
research 4, 94-106. 
Smidsrod, O., and Skjak-Braek, G. (1990). Alginate as immobilization matrix for cells. Trends Biotechnol. 
8, 71-78. 
Smits, P., Li, P., Mandel, J., Zhang, Z., Deng, J.M., Behringer, R.R., de Crombrugghe, B., and Lefebvre, V. 
(2001). The Transcription Factors L-Sox5 and Sox6 Are Essential for Cartilage Formation. Developmental 
cell 1, 277-290. 
Solchaga, L.A., Gao, J., Dennis, J.E., Awadallah, A., Lundberg, M., Caplan, A.I., and Goldberg, V.M. 
(2002). Treatment of osteochondral defects with autologous bone marrow in a hyaluronan-based delivery 
vehicle. Tissue Eng. 8, 333-347. 
 - 107 -
Solchaga, L.A., Johnstone, B., Yoo, J.U., Goldberg, V.M., and Caplan, A.I. (1999). High variability in 
rabbit bone marrow-derived mesenchymal cell preparations. Cell Transplant. 8, 511-519. 
Solchaga, L.A., Temenoff, J.S., Gao, J., Mikos, A.G., Caplan, A.I., and Goldberg, V.M. (2005). Repair of 
osteochondral defects with hyaluronan- and polyester-based scaffolds. Osteoarthritis Cartilage 13, 297-309. 
Solter, D. (2005). Politically correct human embryonic stem cells? N. Engl. J. Med. 353, 2321-2323. 
Sorensen, A.L., Timoskainen, S., West, F.D., Vekterud, K., Boquest, A.C., Ahrlund-Richter, L., Stice, S.L., 
and Collas, P. (2010). Lineage-specific promoter DNA methylation patterns segregate adult progenitor cell 
types. Stem Cells Dev 19, 1257-1266. 
St-Jacques, B., Hammerschmidt, M., and McMahon, A.P. (1999). Indian hedgehog signaling regulates 
proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13, 2072-
2086. 
Steadman, J.R., Rodkey, W.G., Briggs, K.K., and Rodrigo, J.J. (1998). The microfracture procedure: 
Rationale, technique, and clinical observations for treatment of articular cartilage defects. Sports, 
Traumatol Rel Res 20, 61-70. 
Steck, E., Fischer, J., Lorenz, H., Gotterbarm, T., Jung, M., and Richter, W. (2009). Mesenchymal stem cell 
differentiation in an experimental cartilage defect: restriction of hypertrophy to bone-close neocartilage. 
Stem Cells Dev 18, 969-978. 
Steinwachs, M., and Kreuz, P.C. (2007). Autologous chondrocyte implantation in chondral defects of the 
knee with a type I/III collagen membrane: a prospective study with a 3-year follow-up. Arthroscopy 23, 
381-387. 
Stickens, D., Behonick, D.J., Ortega, N., Heyer, B., Hartenstein, B., Yu, Y., Fosang, A.J., Schorpp-Kistner, 
M., Angel, P., and Werb, Z. (2004). Altered endochondral bone development in matrix metalloproteinase 
13-deficient mice. Development 131, 5883-5895. 
Stockwell, R.A. (1971). The interrelationship of cell density and cartilage thickness in mammalian articular 
cartilage. J. Anat. 109, 411-421. 
Sumiyoshi, K., Kubota, S., Ohgawara, T., Kawata, K., Abd El Kader, T., Nishida, T., Ikeda, N., Shimo, T., 
Yamashiro, T., and Takigawa, M. (2013). Novel role of miR-181a in cartilage metabolism. J. Cell. 
Biochem. 114, 2094-2100. 
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell 126, 663-676. 
Tallheden, T., Brittberg, M., Peterson, L., and Lindahl, A. (2006). Human articular chondrocytes--plasticity 
and differentiation potential. Cells Tissues Organs 184, 55-67. 
Tandogan, R.N., Taser, O., Kayaalp, A., Taskiran, E., Pinar, H., Alparslan, B., and Alturfan, A. (2004). 
Analysis of meniscal and chondral lesions accompanying anterior cruciate ligament tears: relationship with 
age, time from injury, and level of sport. Knee Surg. Sports Traumatol. Arthrosc. 12, 262-270. 
Tang, Q.O., Carasco, C.F., Gamie, Z., Korres, N., Mantalaris, A., and Tsiridis, E. (2012). Preclinical and 
clinical data for the use of mesenchymal stem cells in articular cartilage tissue engineering. Expert Opin 
Biol Ther 12, 1361-1382. 
Tatard, V.M., D'Ippolito, G., Diabira, S., Valeyev, A., Hackman, J., McCarthy, M., Bouckenooghe, T., 
Menei, P., Montero-Menei, C.N., and Schiller, P.C. (2007). Neurotrophin-directed differentiation of human 
adult marrow stromal cells to dopaminergic-like neurons. Bone 40, 360-373. 
 - 108 -
Terada, N., Hamazaki, T., Oka, M., Hoki, M., Mastalerz, D.M., Nakano, Y., Meyer, E.M., Morel, L., 
Petersen, B.E., and Scott, E.W. (2002). Bone marrow cells adopt the phenotype of other cells by 
spontaneous cell fusion. Nature 416, 542-545. 
Thai, T.H., Christiansen, P.A., and Tsokos, G.C. (2010). Is there a link between dysregulated miRNA 
expression and disease? Discov Med 10, 184-194. 
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, 
J.M. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147. 
Tognana, E., Borrione, A., De Luca, C., and Pavesio, A. (2007). Hyalograft C: hyaluronan-based scaffolds 
in tissue-engineered cartilage. Cells Tissues Organs 186, 97-103. 
Toiyama, Y., Takahashi, M., Hur, K., Nagasaka, T., Tanaka, K., Inoue, Y., Kusunoki, M., Boland, C.R., 
and Goel, A. (2013). Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl. 
Cancer Inst. 105, 849-859. 
Tome, M., Lopez-Romero, P., Albo, C., Sepulveda, J.C., Fernandez-Gutierrez, B., Dopazo, A., Bernad, A., 
and Gonzalez, M.A. (2011). miR-335 orchestrates cell proliferation, migration and differentiation in human 
mesenchymal stem cells. Cell Death Differ. 18, 985-995. 
Tonnesen, H.H., and Karlsen, J. (2002). Alginate in drug delivery systems. Drug Dev. Ind. Pharm. 28, 621-
630. 
Treilleux, I., Mallein-Gerin, F., le Guellec, D., and Herbage, D. (1992). Localization of the expression of 
type I, II, III collagen, and aggrecan core protein genes in developing human articular cartilage. Matrix 12, 
221-232. 
Tuddenham, L., Wheeler, G., Ntounia-Fousara, S., Waters, J., Hajihosseini, M.K., Clark, I., and Dalmay, T. 
(2006). The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett. 580, 
4214-4217. 
van Rooij, E., Purcell, A.L., and Levin, A.A. (2012). Developing microRNA therapeutics. Circ. Res. 110, 
496-507. 
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and Speleman, F. 
(2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple 
internal control genes. Genome Biol 3, RESEARCH0034. 
Vanlauwe, J., Almqvist, F., Bellemans, J., Huskin, J.P., Verdonk, R., and Victor, J. (2007). Repair of 
symptomatic cartilage lesions of the knee: the place of autologous chondrocyte implantation. Acta Orthop. 
Belg. 73, 145-158. 
Vanlauwe, J., Saris, D.B., Victor, J., Almqvist, K.F., Bellemans, J., and Luyten, F.P. (2011). Five-year 
outcome of characterized chondrocyte implantation versus microfracture for symptomatic cartilage defects 
of the knee: early treatment matters. Am. J. Sports Med. 39, 2566-2574. 
Vasiliadis, H.S., and Wasiak, J. (2010). Autologous chondrocyte implantation for full thickness articular 
cartilage defects of the knee. Cochrane Database Syst Rev, CD003323. 
Vasudevan, S. (2012). Posttranscriptional upregulation by microRNAs. Wiley interdisciplinary reviews. 
RNA 3, 311-330. 
Verzijl, N., DeGroot, J., Thorpe, S.R., Bank, R.A., Shaw, J.N., Lyons, T.J., Bijlsma, J.W., Lafeber, F.P., 
Baynes, J.W., and TeKoppele, J.M. (2000). Effect of collagen turnover on the accumulation of advanced 
glycation end products. J. Biol. Chem. 275, 39027-39031. 
 - 109 -
Vista, E.S., and Lau, C.S. (2011). What about supplements for osteoarthritis? A critical and evidenced-
based review. Int J Rheum Dis 14, 152-158. 
Wagers, A.J., and Weissman, I.L. (2004). Plasticity of adult stem cells. Cell 116, 639-648. 
Wagner, T.U. (2007). Bone morphogenetic protein signaling in stem cells--one signal, many consequences. 
The FEBS journal 274, 2968-2976. 
Wagner, W., Wein, F., Seckinger, A., Frankhauser, M., Wirkner, U., Krause, U., Blake, J., Schwager, C., 
Eckstein, V., Ansorge, W., and Ho, A.D. (2005). Comparative characteristics of mesenchymal stem cells 
from human bone marrow, adipose tissue, and umbilical cord blood. Exp. Hematol. 33, 1402-1416. 
Wakitani, S., Goto, T., Pineda, S.J., Young, R.G., Mansour, J.M., Caplan, A.I., and Goldberg, V.M. (1994). 
Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. J. Bone Joint Surg. Am. 
76, 579-592. 
Wakitani, S., Imoto, K., Yamamoto, T., Saito, M., Murata, N., and Yoneda, M. (2002). Human autologous 
culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in 
osteoarthritic knees. Osteoarthritis Cartilage 10, 199-206. 
Wakitani, S., Mitsuoka, T., Nakamura, N., Toritsuka, Y., Nakamura, Y., and Horibe, S. (2004). Autologous 
bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human 
patellae: two case reports. Cell Transplant. 13, 595-600. 
Walczak, B.E., McCulloch, P.C., Kang, R.W., Zelazny, A., Tedeschi, F., and Cole, B.J. (2008). Abnormal 
findings on knee magnetic resonance imaging in asymptomatic NBA players. J Knee Surg 21, 27-33. 
Wang, L., Li, G., and Sugita, S. (2004). RalA-exocyst interaction mediates GTP-dependent exocytosis. J. 
Biol. Chem. 279, 19875-19881. 
Watt, F.M., Lo Celso, C., and Silva-Vargas, V. (2006). Epidermal stem cells: an update. Curr. Opin. Genet. 
Dev. 16, 518-524. 
Weiss, S., Hennig, T., Bock, R., Steck, E., and Richter, W. (2010). Impact of growth factors and PTHrP on 
early and late chondrogenic differentiation of human mesenchymal stem cells. J. Cell. Physiol. 223, 84-93. 
Whittaker, J.P., Smith, G., Makwana, N., Roberts, S., Harrison, P.E., Laing, P., and Richardson, J.B. (2005). 
Early results of autologous chondrocyte implantation in the talus. J. Bone Joint Surg. Br. 87, 179-183. 
Widuchowski, W., Widuchowski, J., Faltus, R., Lukasik, P., Kwiatkowski, G., Szyluk, K., and Koczy, B. 
(2011). Long-term clinical and radiological assessment of untreated severe cartilage damage in the knee: a 
natural history study. Scand. J. Med. Sci. Sports 21, 106-110. 
Widuchowski, W., Widuchowski, J., and Trzaska, T. (2007). Articular cartilage defects: study of 25,124 
knee arthroscopies. The Knee 14, 177-182. 
Wilk, K.E., Briem, K., Reinold, M.M., Devine, K.M., Dugas, J., and Andrews, J.R. (2006). Rehabilitation 
of articular lesions in the athlete's knee. J. Orthop. Sports Phys. Ther. 36, 815-827. 
Winter, A., Breit, S., Parsch, D., Benz, K., Steck, E., Hauner, H., Weber, R.M., Ewerbeck, V., and Richter, 
W. (2003). Cartilage-like gene expression in differentiated human stem cell spheroids: a comparison of 
bone marrow-derived and adipose tissue-derived stromal cells. Arthritis Rheum. 48, 418-429. 
Winter, J., Jung, S., Keller, S., Gregory, R.I., and Diederichs, S. (2009). Many roads to maturity: 
microRNA biogenesis pathways and their regulation. Nature cell biology 11, 228-234. 
 - 110 -
Wondrasch, B., Aroen, A., Rotterud, J.H., Hoysveen, T., Bolstad, K., and Risberg, M.A. (2013). The 
feasibility of a 3-month active rehabilitation program for patients with knee full-thickness articular cartilage 
lesions: the Oslo Cartilage Active Rehabilitation and Education Study. J. Orthop. Sports Phys. Ther. 43, 
310-324. 
Woods, A., Wang, G., and Beier, F. (2007). Regulation of chondrocyte differentiation by the actin 
cytoskeleton and adhesive interactions. J. Cell. Physiol. 213, 1-8. 
Wu, L., Bluguermann, C., Kyupelyan, L., Latour, B., Gonzalez, S., Shah, S., Galic, Z., Ge, S., Zhu, Y., 
Petrigliano, F.A., Nsair, A., Miriuka, S.G., Li, X., Lyons, K.M., Crooks, G.M., McAllister, D.R., Van 
Handel, B., Adams, J.S., and Evseenko, D. (2013). Human developmental chondrogenesis as a basis for 
engineering chondrocytes from pluripotent stem cells. Stem cell reports 1, 575-589. 
Xia, X., Zhang, Y., Zieth, C.R., and Zhang, S.C. (2007). Transgenes delivered by lentiviral vector are 
suppressed in human embryonic stem cells in a promoter-dependent manner. Stem Cells Dev 16, 167-176. 
Yamashita, A., Nishikawa, S., and Rancourt, D.E. (2010). Identification of five developmental processes 
during chondrogenic differentiation of embryonic stem cells. PloS one 5, e10998. 
Yamashita, S., Miyaki, S., Kato, Y., Yokoyama, S., Sato, T., Barrionuevo, F., Akiyama, H., Scherer, G., 
Takada, S., and Asahara, H. (2012). L-Sox5 and Sox6 proteins enhance chondrogenic miR-140 microRNA 
expression by strengthening dimeric Sox9 activity. J. Biol. Chem. 287, 22206-22215. 
Yamazaki, H., Tsuneto, M., Yoshino, M., Yamamura, K., and Hayashi, S. (2007). Potential of dental 
mesenchymal cells in developing teeth. Stem Cells 25, 78-87. 
Yang, B., Guo, H., Zhang, Y., Chen, L., Ying, D., and Dong, S. (2011a). MicroRNA-145 regulates 
chondrogenic differentiation of mesenchymal stem cells by targeting Sox9. PloS one 6, e21679. 
Yang, D., and Jones, K.S. (2009). Effect of alginate on innate immune activation of macrophages. Journal 
of biomedical materials research. Part A 90, 411-418. 
Yang, J., Qin, S., Yi, C., Ma, G., Zhu, H., Zhou, W., Xiong, Y., Zhu, X., Wang, Y., He, L., and Guo, X. 
(2011b). MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to target Sp1 in 
maintaining the chondrocyte proliferation. FEBS Lett. 585, 2992-2997. 
Yang, Y.C., Piek, E., Zavadil, J., Liang, D., Xie, D., Heyer, J., Pavlidis, P., Kucherlapati, R., Roberts, A.B., 
and Bottinger, E.P. (2003). Hierarchical model of gene regulation by transforming growth factor beta. Proc. 
Natl. Acad. Sci. U. S. A. 100, 10269-10274. 
Yap, S.P., Xing, X., Kraus, P., Sivakamasundari, V., Chan, H.Y., and Lufkin, T. (2011). Generation of 
mice with a novel conditional null allele of the Sox9 gene. Biotechnology letters 33, 1551-1558. 
Ying, Q.L., Nichols, J., Evans, E.P., and Smith, A.G. (2002). Changing potency by spontaneous fusion. 
Nature 416, 545-548. 
Yoon, Y.S., Wecker, A., Heyd, L., Park, J.S., Tkebuchava, T., Kusano, K., Hanley, A., Scadova, H., Qin, 
G., Cha, D.H., Johnson, K.L., Aikawa, R., Asahara, T., and Losordo, D.W. (2005). Clonally expanded 
novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. 
J. Clin. Invest. 115, 326-338. 
Yoshida, C.A., and Komori, T. (2005). Role of Runx proteins in chondrogenesis. Crit. Rev. Eukaryot. Gene 
Expr. 15, 243-254. 
 - 111 -
Ytrehus, B., Andreas Haga, H., Mellum, C.N., Mathisen, L., Carlson, C.S., Ekman, S., Teige, J., and 
Reinholt, F.P. (2004a). Experimental ischemia of porcine growth cartilage produces lesions of 
osteochondrosis. J. Orthop. Res. 22, 1201-1209. 
Ytrehus, B., Carlson, C.S., Lundeheim, N., Mathisen, L., Reinholt, F.P., Teige, J., and Ekman, S. (2004b). 
Vascularisation and osteochondrosis of the epiphyseal growth cartilage of the distal femur in pigs--
development with age, growth rate, weight and joint shape. Bone 34, 454-465. 
Ytrehus, B., Ekman, S., Carlson, C.S., Teige, J., and Reinholt, F.P. (2004c). Focal changes in blood supply 
during normal epiphyseal growth are central in the pathogenesis of osteochondrosis in pigs. Bone 35, 1294-
1306. 
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, 
G.A., Ruotti, V., Stewart, R., Slukvin, II, and Thomson, J.A. (2007). Induced pluripotent stem cell lines 
derived from human somatic cells. Science 318, 1917-1920. 
Zhang, J., Tu, Q., Bonewald, L.F., He, X., Stein, G., Lian, J., and Chen, J. (2011). Effects of miR-335-5p in 
modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J. Bone Miner. 
Res. 26, 1953-1963. 
Zhao, Y., Glesne, D., and Huberman, E. (2003). A human peripheral blood monocyte-derived subset acts as 
pluripotent stem cells. Proc. Natl. Acad. Sci. U. S. A. 100, 2426-2431. 
Zuk, P.A., Zhu, M., Mizuno, H., Huang, J., Futrell, J.W., Katz, A.J., Benhaim, P., Lorenz, H.P., and 
Hedrick, M.H. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. 
Tissue Eng. 7, 211-228. 
 
I

II

III

IV

 p. 1 
Analysis of the effects of five factors relevant to in vitro chondrogenesis 
of human mesenchymal stem cells using factorial design and high 
throughput mRNA-profiling. 
 
Rune B. Jakobsen1,2, Esben Østrup1,3, Xiaolan Zhang4, Tarjei S. Mikkelsen4,5, Jan E. 
Brinchmann1,2,6*.  
 
1 Norwegian Center for Stem Cell Research, Oslo University Hospital, Rikshospitalet, 
Oslo, Norway 
 
2 Department of Biochemistry, Institute of Basic Medical Sciences, The Medical Faculty, 
University of Oslo, Oslo, Norway 
 
3 Department of Biomaterials, Institute of Clinical Dentistry, University of Oslo, Norway 
 
4 Broad Institute, Cambridge, Massachusetts, USA 
 
5 Harvard Stem Cell Institute and Department of Stem Cell and Regenerative Biology, 
Harvard University, Cambridge, Massachusetts, USA 
 
6 Institute of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway 
 
 p. 2 
 
Contact info:  
Rune Bruhn Jakobsen, Telephone: +47 92092973, Fax: +47 22851058,  
Email: r.b.jakobsen@medisin.uio.no 
 
Esben Østrup, Telephone: +47 94219943, Fax: +47 22851058 
Email: esben.ostrup@odont.uio.no 
 
Xiaolan Zhang, Telephone: +1 617-714-7813, Fax: + 1 617-714-8102 
Email: xzhang@broadinstitute.org 
 
Tarjei S. Mikkelsen, Telephone: + 1 617-714-7772, Fax: + 1 617-714-8102,  
Email: tarjei@broadinstitute.org 
 
*CORRESPONDING AUTHOR:  
Jan E. Brinchmann, Telephone: +47 22840489, Fax: +47 22851058,  
E-mail: jan.brinchmann@rr-research.no,  
Postal address: Norwegian Center for Stem Cell Research, Pb. 1112 Blindern, N-0317 
Oslo, Norway. 
  
 p. 3 
Abstract 
The in vitro process of chondrogenic differentiation of mesenchymal stem cells for tissue 
engineering has been shown to require three-dimensional culture along with the addition 
of differentiation factors to the culture medium. In general, this leads to a phenotype 
lacking some of the cardinal features of native articular chondrocytes and their 
extracellular matrix.  
The factors used vary, but regularly include members of the transforming growth factor β 
superfamily and dexamethasone, sometimes in conjunction with fibroblast growth factor 
2 and insulin-like growth factor 1, however the use of soluble factors to induce 
chondrogenesis has largely been studied on a single factor basis.  
In the present study we combined a factorial quality-by-design experiment with high-
throughput mRNA profiling of a customized chondrogenesis related gene set as a tool to 
study in vitro chondrogenesis of bone marrow derived mesenchymal stem cells in 
alginate. 48 different conditions of transforming growth factor β 1, 2 and 3, bone 
morphogenetic protein 2, 4 and 6, dexamethasone, insulin-like growth factor 1, fibroblast 
growth factor 2 and cell seeding density were included in the experiment.   
The analysis revealed that the best of the tested differentiation cocktails included 
transforming growth factor β 1 and dexamethasone. Dexamethasone acted in synergy 
with transforming growth factor β 1 by increasing many chondrogenic markers while 
directly downregulating expression of the pro-osteogenic gene osteocalcin. However, all 
factors beneficial to the expression of desirable hyaline cartilage markers also induced 
undesirable molecules, indicating that perfect chondrogenic differentiation is not 
achievable with the current differentiation protocols. 
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Introduction 
Mesenchymal stem cells (MSCs) have been advocated as a useful cell source for tissue 
engineering. MSCs were originally isolated from bone marrow, but has later been found 
in and isolated from numerous tissues[1,2]. They can be readily expanded in vitro and 
differentiated into tissues of mesodermal and, in some instances, ectodermal lineages[3,4]. 
Clinically MSCs have shown promising potential in treatments of graft-versus-host-
disease and in repair of full-thickness cartilage defects[5,6].  
The in vitro process of directed differentiation of mesenchymal stem cells has been 
widely studied. Chondrogenic differentiation of MSCs has been shown to require the use 
of either high-density cell pellet, micro-mass cultures or a scaffold allowing for three-
dimensional culture[7-9] along with the addition of differentiation factors to the culture 
medium[10-13].  
The differentiation factors have traditionally included factors from the TGF superfamily 
such as transforming growth factor β (TGFβ)[7,14,15] and/or bone morphogenetic 
protein (BMP)[9,16,17] along with the steroid hormone dexamethasone (DEX). Other 
factors used are fibroblast growth factor 2 (FGF2)[15,18,19] and insulin-like growth 
factor 1 (IGF1)[20,21]. Traditionally, the use of soluble factors to induce chondrogenesis 
has largely been studied on a single factor basis or with simple combinations of a few 
factors. However, optimizing differentiation conditions one factor at a time is time 
consuming, and does not take into account interdependency between factors, which is 
likely to play a role in growth factor mediated differentiation. Factorial analysis is 
commonly used in industrial processes as a statistically and scientifically sound way of 
analyzing interplay between several factors on a predefined outcome. Factorial design 
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(often termed quality-by-design) has been used for optimization of protocols in a variety 
of industries and research areas including pharmaceutical studies and manufacturing, 
stem cell biology, polymer production and tissue engineering[22-24].  
Previously, expression profiling of medium to large sets of genes on multiple samples has 
been done using microarray hybridization technology with a relative high cost per 
individual sample. Smaller sets of genes have often been investigated using quantitative 
polymerase chain reactions (qPCR), though upscaling of qPCR experiments rapidly 
exceeds practically and economically feasible numbers of reactions. However, the 
introduction of digital and highly multiplexed mRNA-profiling (Nanostring nCounter) 
has made it possible and cost-effective to analyze large number of samples on predefined 
gene sets of up to 800 genes with an accuracy equal to single-plex qPCR[25]. This may 
be performed directly on cell lysates, thus bypassing the variability introduced by RNA 
isolation and conversion to cDNA which is necessary in microarrays and RT-qPCR[26]. 
 
In the present study we undertook a detailed comparison of all possible combinations of 
five commonly used differentiation factors in a fully humanized culture system: TGFβ1, 
BMP2, dexamethasone, FGF2 and IGF1 used for in vitro chondrogenesis of MSCs 
established in 3D culture in alginate hydrogels, including a comparison of the three 
isoforms of the TFGβ growth factor (TGFβ1, TGFβ2 and TGFβ3) and three of the 
isoforms of BMP (BMP2, BMP4 and BMP6). Our aim was to explore factorial design 
and digital mRNA profiling as tools to characterize directed differentiation of MSCs and 
to validate the most commonly used chondrogenic growth factors.  
 p. 6 
Methods and materials 
 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. 
Ethics statement 
The harvest of bone marrow from voluntary donors was approved by the Regional 
Committee for Medical Research Ethics, Southern Norway. Informed consent was 
obtained from all donors before the harvest procedure. 
Cell harvest and culture 
Bone marrow aspirates were obtained from the iliac crest of three healthy donors as 
previously described[27]. The isolation and culture procedure is given in the Supporting 
Information Methods and materials.  
Medium and supplements 
Growth medium for monolayer cultures contained 2 U/mL heparin, 100 U/mL penicillin, 
100μg/mL streptomycin and 2,5 μg/mL amphotericin B in DMEM F-12, with 20 % 
human platelet lysate (hPL) (Supporting Information Methods and materials) added for 
the first passage and 10 % for all subsequent passages. 
Basic chondrogenic differentiation medium (bCDM) contained 1 mM sodium pyruvate, 
0.1 mM ascorbic-acid-2-phosphate, 1 % ITS (25 mg insulin, 25 mg transferrin and 25 μg 
sodium selenite) and 1,25 mg/mL human serum albumin in high-glucose DMEM-F12 
(4,5 g/L). bCDM was supplemented with 500 ng/mL BMP2 (InductOs; Wyeth, Taplow, 
UK), BMP4 or BMP6 (R&D Systems, Minneapolis, MN), 10 ng/mL TGFβ1, TGFβ2 or 
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TGFβ3 (R&D Systems), 100 nM dexamethasone, 10 ng/mL FGF2 (R&D Systems) 
and/or 100 ng/mL IGF1. 
Validation of cells as MSC 
Cells used for experiments in passage 2 or 3 were validated as MSCs by flow cytometry 
and differentiation assays as described in Supporting Information Methods and materials. 
3D cell culture 
Cells in passage 2 or 3 were trypsinized, counted, washed in PBS and seeded into a self-
gelling alginate scaffold (NovaMatrix, Sandvika, Norway) as described previously and in 
Supporting Information Methods and materials[28]. 
Experimental design 
We investigated a total of 48 different conditions (Figure 1A). Five factors: TGFβ1, IGF1, 
DEX, FGF2 and BMP2 were investigated in two-level (present or not) full 25 factorial 
design experiments. Concentrations were based on typical use in the literature[7,15-
17,21]. This gave a total of 32 conditions in each experiment, which was repeated with 
cells from three donors at two time points each: days 1 and 7. In addition a modified 
design investigating TGFβ isoforms 1, 2 and 3 and BMP isoforms 2, 4 and 6 was also 
performed, including an experiments where the cell density was varied between 1.25x106 
and 2x107 cells/mL at log(2)-intervals. Design of the experiments was done with 
MiniTAB 16 (Minitab Inc, State College, PA). At the end of the experiments discs were 
divided in halves, snap-frozen in liquid nitrogen and stored at -80°C. Negative control 
disc cultures were performed in the same way using bCDM only, while positive controls 
were discs supplemented with our to date standard chondrogenic differentiation cocktail 
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consisting of TGFβ1, BMP2 and DEX. Positive control samples were collected at day 7, 
14 and 21 with additions of extra discs fixed in 4% paraformaldehyde for 
immunohistochemistry. 
Digital mRNA profiling and quantitative polymerase chain reaction  
Frozen discs were crushed in liquid nitrogen with a pestle (Argos Technologies, Elgin, 
IL), lysed in RLT buffer and homogenized (QiaShredder, Qiagen, Venlo, Netherlands). 
Samples were then either directly used for digital mRNA profiling with the Nanostring 
nCounter technology[25] (NanoString Technologies, Seattle, WA) or RNA was extracted 
(RNeasy Mini kit, Qiagen). For qPCR, after DNase I treatment (Ambion; Life 
Technologies, Carlsbad, CA), reverse transcription (RT) was performed according to 
protocol (High-Capacity cDNA archive Kit; Applied Biosystems, Foster City, CA) using 
200 ng total RNA per RT reaction and analyzed with the primers for peroxisome 
proliferator-activated receptor gamma and osteomodulin (PPARG Hs01115513_m1, 
OMD Hs00192325_m1, Applied Biosystems). 
For the digital mRNA profiling, a custom chondrogenic gene set consisting of 364 genes 
(Table S1) including endogenous controls was established on the background of genes 
known or suspected to be affected by chondroskeletogenesis[28]. For analysis of lysate 
vs. purified mRNA performance, the pre-designed NanoString 48-plex Customer Assay 
Evaluation (CAE) kit was used instead. Sample preparation and hybridization was 
performed according to the manufacturer's instructions with either 100 ng of total RNA 
or lysate equivalent to 10.000 cells. All hybridizations were incubated at 65°C purified 
and counted on the nCounter Prep Station and Digital Analyzer (NanoString 
Technologies).  
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Data analysis and statistics 
Normalization for lane-to-lane variation and positive spike-in-control series were 
performed according to the manufactures protocol[29] using Microsoft Excel (Microsoft , 
Redmond, WA). The geometric mean of the five best endogenous control genes 
identified by NormFinder was used to normalize the data[30]. Further data normalization 
was performed in the R statistical application (http://www.R-project.org/) including log 
transformation using the "vsn" package[31]. 
MiniTAB was used to fit a statistical regression model to analyze main effects, two and 
three factor interactions with significance assumed for p-values less than 0.05 in a 
multivariate analysis of variance on the normalized data. If needed, transformation of the 
responses was used to make the residuals exhibit normality as judged by normality plots. 
Pearson´s correlation between expression values in lysates and RNA and Spearman´s 
correlation between rankings of conditions day 1 and day 7 were calculated with Prism 6 
(Graphpad, San Diego, CA). 
To make graphical representations of wanted and unwanted genes the data were 
Studentized subtracting the mean expression of each gene across all conditions divided 
by the standard deviation. For analysis of significantly changed genes and gene set 
enrichment analysis the data were analyzed in R using the "Limma" package[32] to fit a 
linear model to the data. Cut-off values were set to twofold difference in expression 
values with a false discovery rate of 5% (FDR < 0.05). The "ade4"[33] package in R was 
used to perform a two-dimensional principal component analysis on the normalized data. 
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Results 
Characterization of cells and validation of the use of lysates for mRNA profiling 
Surface antigen profiles were obtained of the expanded cells at passage 2 (Figure S1A). 
Cells readily differentiated into adipogenic and osteogenic lineages verified by extensive 
staining of lipid droplets and calcium deposits and upregulation of PPARG and OMD 
(Figure S1B and C). Cells also showed differentiation into the chondrogenic lineage with 
upregulation of gene expression and synthesis of proteins representing key chondrogenic 
markers (Figure S1D and E). To evaluate if lysate of cells in alginate discs could be used 
instead of RNA, lysate and RNA isolated from matching samples at three timepoints 
grown under standard chondrogenic conditions were analyzed. Results showed highly 
significant correlations (p <0.0001) for all pairs with coefficients of determination (R2) 
ranging from 0.92 to 0.97 (Figure S2). This validated the use of lysate through the rest of 
the study. 
Principal component analysis on the full gene set 
Principal component analysis (PCA) is a powerful way of reducing the dimensionality of 
a large data set in an unbiased way to identify clustering behaviour[34]. To see if the 
mRNA profiling of the full chondrogenic gene set reflected the studied conditions both 
regarding factors and temporal spatialization, we performed a PCA on the full dataset in 
all conditions at all timepoints (Figure 1B).  This revealed that day 1 and day 7 samples 
clustered together, with larger differences observed within the day 7 cluster. We next 
limited the the PCA to only day 0 (untreated cells) and the full 25-factorial design at day 
1 (Figure 1C) or day 7 (Figure 1D) to allow for a more detailed analysis of the individual 
factors and combinations. At both timepoints it was readily apparent that conditions 
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clustered according to TGFβ1 exposure, with unexposed conditions being closer to 
undifferentiated MSCs. On day 7 (Figure 1D) it was also evident that adding IGF1 led to 
only very minor differences (see for example conditions 25 and 27, 2 and 4 or 9 and 11). 
Notably, the 6 conditions found in the lower right quadrant of the plot all included 
TGFβ1 and DEX.  
Interactions between TGFβ1, DEX, BMP2, IGF1 and FGF2 evaluated by changes in 
selected gene subsets 
The full custom-made chondrogenic gene set comprised 364 genes including endogenous 
reference genes. It included both genes that are hallmarks of hyaline cartilage, but also 
genes that mark other differentiation processes such as adipogenesis or osteogenesis. To 
study the effects of the individual factors specifically on chondrogenesis we prespecified 
two subsets of genes: a "wanted" marker group comprised of genes coding for 
extracellular matrix (ECM) molecules known to be hallmarks of native hyaline 
cartilage[35], and the negative "unwanted" marker group comprised of genes coding for 
extracellular molecules distinctive for other cartilage types, but also genes coding for 
major transcription factors of other lineages such as adipose tissue or bone (Table 1). The 
mean expression of "wanted" or "unwanted" markers was used as responses when fitting 
a statistical regression model to the full factorial design. This allowed us to study the 
main effects of individual factors and significant interactions between factors on 
chondrogenesis. The normal plots of standardized effects using wanted and unwanted 
markers on day 1 (Figure S3A and D) and day 7 (Figure 2A and D) show the factors and 
interactions that significantly affected the wanted and unwanted responses. Focusing on 
day 7, TGFβ1, DEX and BMP2 affected the wanted markers significantly in the desired 
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direction and FGF2 in the opposite direction (Figure 2B). A more complete description is 
seen when analyzing the significant two-way interactions of TGFβ1 with DEX and 
TGFβ1 with BMP2 (Figure 2C). The effect on wanted markers of TGFβ1 was dependent 
on the presence of DEX. TGFβ1 on its own had a much smaller effect than when added 
in the presence of DEX. For the interaction of TGFβ1 with BMP2 the opposite was true: 
adding TGFβ1 in the presence of BMP2 led to a smaller absolute increase in wanted 
marker expression than when TGFβ1 was added alone (Figure 2D). Only one three-way 
interaction, that of TGFβ1, DEX and BMP2, was found to significantly affect wanted 
markers. However, the standardized effect was small, and showed that both the 
TGFβ1/BMP2 and the TGFβ1/DEX interaction was affected by the addition of the third 
factor, which in both cases decreased the total effect slightly (Table S2). The effects of 
the differentiation factors on the expression of the unwanted marker genes were very 
similar to that seen for the wanted genes, with a few notable differences (Figure 2E, F, G 
and H). First, DEX alone did not have a significant effect (Figure 2F, Table S2).  Second, 
both TGFβ1 and BMP2 alone increased unwanted marker expression, but in combination 
TGFβ1 or BMP2 did not increase unwanted expression above that seen for each of them 
alone (Figure 2G).  FGF2 seemed to reduce the expression of wanted genes considerably, 
while IGF1 did not impact on this gene set at all (Figure 2B and F)  
Identifying optimal differentiation conditions from the expression of wanted and 
unwanted genes 
As the PCA was done on the full gene set, we next wanted to explore if the changes in 
gene expression that segregated the different conditions reflected a desired change in 
terms of the expression of the wanted or unwanted gene subsets (Figure 3A). 
 p. 13 
Interestingly, we found a highly significant (P < 0.0001) correlation between the ranking 
of conditions on day 1 and day 7 (Figure 3B), which shows that the changes in mRNA 
expression that arise soon after induction of differentiation can predict the direction of 
later changes. Corroborating the PCA, plots of the summary score of wanted and 
unwanted markers show larger separation in the day 7 samples (Figure 3B). In the 
detailed view of day 0 and the full 25-factorial design on day 7 (Figure 3C) it is clear that 
conditions 9 and 11 are the most favorable, with low scores for unwanted markers and the 
highest scores of wanted markers overall. It is also apparent from the color coding that 
TGFβ1 is substantially affecting expression of wanted markers in the desired direction, 
yet also increasing the expression of unwanted markers. DEX, on the other hand, seems 
to increase only expression of wanted markers if added in the presence of TGFβ1.  
To support these findings we performed a gene set enrichment analysis for the wanted 
and unwanted gene sets. Conditions significantly enriched for the wanted gene set (FDR 
< 0.05), but not significantly enriched for the unwanted gene set, are highlighted in bold 
sorted by the FDR (Table 2). The top ranked conditions match the previous findings and 
a heatmap of the expression of wanted and unwanted markers of the top ten conditions 
(Figure 4) further visually confirms the changes with lower expressions of unwanted 
markers and higher expression of wanted markers in conditions 9, 11, 10 and 12. 
However, from the heatmap it is also apparent that individual unwanted and wanted 
genes such as LUM, ALPL, COL10A1 and PPARG did not change in the desired direction. 
The three TGFβ isoforms tested did not show substantial differences in the mean 
expression of wanted and unwanted markers. Figure S4A shows that addition of any 
TGFβ isoform increased both wanted and unwanted markers, addition of DEX to any of 
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these increased wanted markers further and addition of BMP2 in the presence of TGFβ 
and DEX decreased unwanted marker expression slightly. In the comparison of BMP 
isoforms we found that addition of any of the three BMP isoforms alone increased both 
wanted and unwanted marker expression, and addition of TGFβ1 further increased the 
expression of wanted markers (Figure S4B). Cell density upon induction of 
chondrogenesis affected expression both on day 1 and day 7 (Figure S4C). The 
expression of wanted markers on day 7 increased as the cell density was increased from 
1.25 x 106 to 10 x 106 cells/mL. However, further increasing the cell density to 2 x 107 
cells/mL reduced the expression of wanted genes substantially. 
Genes uniformly affected by single factors across all conditions 
To elucidate effects of individual factors on genes other than the selected wanted or 
unwanted marker genes we performed an analysis of differentially expressed genes 
between the bCDM and all other conditions (Figure S5). Figure 5 shows the genes that 
were consistently up or down regulated in all conditions with any one of the five factors. 
It is evident that the expression for several genes is completely dependent on the presence 
of a specific factor. The pro-osteoblastic gene BGLAP, for example, which codes for 
osteocalcin, was downregulated in all conditions containing DEX, but not affected in any 
other conditions. The matrix metallopeptidase MMP1, which specifically degrades type I, 
II and III collagen, was also almost exclusively downregulated in conditions containing 
DEX. Genes consistently upregulated by DEX included MMP7, previously shown to 
correlate with chondrocyte maturation[36] and the tissue inhibitor of metalloproteinases 4 
(TIMP4), known to be upregulated in response to cartilage injury and degradation[37]. 
Another example worth special attention is the WNT-signalling modulator SFRP4, 
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known to be upregulated during adipogenesis[38], shown here to be consistently 
downregulated by DEX, and upregulated in conditions with BMP2 and no DEX, except 
where BMP2 was added alone or with IGF1 only. COL10A1, a known marker of 
hypertrophy[39] was consistently and exclusively upregulated in conditions with TGFβ1. 
Unlike practically all the other molecules upregulated by TGFβ1, for COL10A1 the 
absence of TGFβ1 could not be compensated for by the addition of BMP2. COL2A1, 
which encodes for the major collagen of hyaline collage, is somewhat surprisingly not 
upregulated consistently by any one factor, though it is consistently upregulated in all 
conditions containing TGFβ1 and DEX (Figure S5). Interestingly, FGF2 could be seen to 
inhibit the upregulatory effect of TGFβ1 or BMP2 on COL2A1 in all conditions where 
DEX was not also added. Further substantiating that DEX plays an important role in 
chondrogenesis is that PRG4, encoding the surface lubricant lubricin [40], was only 
upregulated in conditions with DEX without TGFβ-superfamily ligands (Figure S5). 
Genes differentially regulated between key conditions 
Finally, we examined genes differentially expressed between key conditions. In particular, 
we focused on the effect of adding DEX to either TGFβ1 or to TGFβ1+BMP2, or adding 
BMP2 to either TGFβ1 or TGFβ1+DEX (Figure 6A and B and Figure S6). Adding DEX 
to TGFβ1 changed 115 genes significantly, and adding DEX to TGFβ1 with BMP2 
changed 110 genes, with an overlap of 77 genes (Figure S7 and Table S3). Several 
desired genes were upregulated by DEX such as ACAN, COL2A1 and SOX9 while 
undesired genes such as the collagen degrading metallopeptidase MMP13 and the 
osteogenic transcription factor RUNX2 were downregulated by DEX.  
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As expected, adding BMP2 as the second TGFβ-superfamily signalling molecule to 
either TGFβ1 alone or TGFβ1 with DEX changed only 17 and 14 genes respectively 
Surprisingly, only the upregulated gene SOCS2 was common between these gene sets, 
showing that DEX importantly affects the way TGFβ1 stimulated MSCs respond to 
BMP2.   
Given that the beneficial effect of DEX has been amply proven, and IGF1 and FGF2 have 
been shown to not have effects or even predominantly negative effects, the remaining 
question was whether BMP2 should be added to the combination of TGFβ1 and DEX. 
The answer to this question, at the single gene expression level, is found in Figure 6D. 
The most highly upregulated gene, NOG, encodes a polypeptide noggin that binds and 
inactivates BMPs belonging to the TGFβ-superfamily, particularly BMP4[41,42]. Also 
the addition of BMP2 on a background of TGFβ1 + DEX leads to downregulation of 
BMP4 at the mRNA level, which could be a direct effect of BMP2 or perhaps an effect 
by noggin also on BMP4 mRNA expression. NOTCH1, which has been shown to be 
required in early chondrogenesis but must be turned off for full chondrogenesis to 
occur[43,44], was also downregulated. In addition, several other downregulated genes 
such as DPT, FGFR1 and TGFB1 are likely to have pro-chondrogenic effects [15,45]. 
One positive effect of BMP2 was the downregulation of COL3A1, a collagen frequently 
coexpressed with type I collagen in connective tissues[46].  
In total, these data indicate that addition of BMP2 to a chondrogenic cocktail already 
consisting of TGFβ1 and DEX will not improve cartilage formation, at least judging by 
the expression of genes of relevance for chondrogenesis.  
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Discussion 
Directed differentiation of stem cells into chondrocytes in vitro has been shown to require 
both three-dimensional culture and environmental ques in the form of growth 
factors[7,16,17,47]. These cocktails of growth factors have largely been studied by 
manipulating one factor at a time, which is laborous and time consuming. We show here 
that high-throughput gene profiling makes it feasible to perform larger scale experiments 
with statistical design of experiments, allowing for sound conclusions on the involvement 
of many simultaneously investigated factors[24,48,49].  
In the present study we used this approach to dissect the expression of a chondrogenesis 
relevant gene set during in vitro chondrogenesis of MSCs subjected to 48 different 
conditions of growth factors and cell densities. We found that only three of the factors 
(TGFβ1, DEX, and BMP2) directly increased the expression of chondrogenic markers 
significantly. Adding FGF2 or IGF1, either alone or in combination with other factors, 
had either no effect or predominantly negative effects on the expression of chondrogenic 
genes. 
TGFβ1 is the most extensively used factor for inducing chondrogenesis in directed 
differentiation of MSCs[10]. The present data show that the related factors TGFβ2 and 3, 
but no single other factor studied here, can replace its positive effects on chondrogenic 
differentiation of human MSCs. Next, we found that adding DEX to TGFβ1 changed 
more that 100 of the investigated genes significantly, with the vast majority of changes 
being favourable for chondrogenesis. This is in line with the use of DEX in most of the 
published literature[7,10,14], although a recent publication actually concluded that DEX 
should be omitted [50]. The present study extends current knowledge by describing 
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which of a large set of relevant genes are changed by each of these factors, and then by 
two together.    
BMPs can, like the TGFβ isoforms, promote MSC differentiation into chondrocytes 
[51,52]. However, BMPs and TGFβ have also been described to exhibit antagonistic 
activities in many tissues[53]. We found that both factors increased wanted chondrogenic 
markers on their own. Interestingly, the two combinations identified with the best ratio of 
wanted to unwanted genes and highest mean expression of wanted markers contained 
both TGFβ1 and BMP2. However the effect of adding either factor together with the 
other was marginal and not synergistical on either wanted or unwanted markers. This is 
most likely explained by the molecular mechanism for the actions of these factors. Both 
BMP2 and TGFβ1 are ligands of the transformings growth factor β superfamily and act 
by binding to specific type II receptors, which recruits the corresponding type I receptor, 
ultimately leading to phosporylation of receptor-SMADs. Even though BMP2 works 
mainly through SMAD1, 5 and 8 and TGFβ1 through SMAD2 and 3, there are known 
interactions between the two systems such as the competitive occupation of the common 
downstream effector SMAD4[53]. Also it seems that adding BMP2 to TGFβ1 and DEX 
does not lead to a significant upregulation of any genes positively related to 
chondrogenesis, but rather to an endogenous modulation of BMP4. Taken together, there 
may be more reasons to exclude BMP2 than to include it in a chondrogenic 
differentiation cocktail, although it could have a role in a system with sequential cocktails 
for different parts of chondrogenesis, as illustrated by the effect on PRG4. 
The FGF2 treatment did not lead to an increase in the chondrogenic gene expression. On 
the contrary, a significant reduction was seen in the general gene expression of both 
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wanted and unwanted genes when FGF2 was added to the basic differentiation cocktail. 
In line with our finding, it has been published that FGF2 may abolish chondrogenesis 
when combined with TGFβ1 and BMP-6[54]. On the other hand, FGF2 has recently been 
described to enhance the potential of MSCs for use in tissue engineering of 
cartilage[18,55] when used as a mitogen in the expansion phase prior to the 
differentiation. 
We found that IGF1 did not change the general expression of either wanted or unwanted 
genes significantly, which is contrary to some previous publications[21]. IGF1 has been 
shown to be expressed in articular cartilage and regulate proteoglycan metabolism[56] 
and it has a distinct expression profile during embryogenic chondrogenesis[57]. However 
our finding is in line with other publications failing to find effects of using IGF1 to 
induce chondrogenesis[58,59].  
There are limitations to our approach. We only considered gene expression on the level 
of transcribed mRNA, which does not necessarily correlate with protein synthesis[60]. 
We also utilized a two-level factorial design with either absence or presence of the 
investigated growth factors, which did not allow an assesment of the role that different 
factor concentrations might play. Considering these limitations, we propose that the 
method presented here could be adapted to screen large numbers of molecules that could 
enhance chondrogenesis. We also believe that the method described could be valuably 
expanded to testing several concentrations of factors, which would also allow a statistical 
analysis with response optimization to be performed[24]. Further supporting the 
feasibility of our approach in larger screening experiments, is our finding that gene 
profiling can be performed directly on lysates without any loss in assay quality. Also the 
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finding that changes in gene expression seen just one day after induction predicts later 
changes, potentially allows for a simpler design with just one time point, likely earlier 
than the one week mark chosen in the present study. Combined, the implications of these 
findings could decrease both cost and workload considerably in future experiments. 
Finally, larger screening experiments could be efficiently performed in a fractionalized 
factorial design allowing for sound conclusions without increasing the number of 
experiments[23,61], for example in order to test temporal spatialization of chondrogenic 
factors to more exactly mirror the conditions known from embryogenesis of cartilage. 
Conclusion 
In this study we have shown that high-throughput mRNA profiling can be efficiently 
performed on lysates of MSCs during in vitro chondrogenesis in alginate. A thorough 
analysis revealed that the cocktail of growth factors leading to the most efficient 
upregulation of wanted chondrogenic markers was a combination of TGFβ and DEX. 
Adding BMP2 lead to a slightly higher mean expression of wanted markers but did not 
significantly upregulate key positive genes and led to a downregulation of endogenous 
BMP4 and TGFβ1 expression, and may therefore be expendable. DEX, on the other hand, 
worked synergistically with TGFB1 in increasing wanted marker expression and was also 
directly downregulating expression of the unwanted marker BGLAP. All factors 
beneficial to the expression of wanted hyaline cartilage markers also introduced an 
induction of unwanted markers, with the exception of DEX alone. Upregulation of 
COL10A1 was seen in all conditions containing TGFβ1 indicating that perfect 
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differentiation to hyaline cartilage is not achievable with the current differentiation 
protocols.   
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Figure legends 
 
Figure 1: Experimental setup and principal component analysis (PCA) 
A. Experimental setup with numbering of the different conditions. When not stated, the 
cell density was 107 cells per mL. B. PCA on all conditions labelled by days in culture. C. 
PCA limited to conditions 1 - 32 on days 0 and 1.  D. PCA limited to conditions 1-32 on 
days 0 and day 7. 
 
Figure 2: Statistical analysis of main effects and interactions at day 7 
A. Normal plot of the standardized effects with the response set to mean expression of 
wanted markers. B. Corresponding main effects plot of all factors. C and D. 
Corresponding plots of significant second order interactions. E. Normal plot of the 
standardized effects with the response set to mean expression of unwanted markers. F. 
Corresponding main effects plot of all factors. G and H. Corresponding plots of 
significant second order interactions.   
 
Figure 3: Analysis of wanted and unwanted gene expression 
A. Gene sets used to compute mean expression of wanted and unwanted markers. B. 
Scatter-plot of the mean expression (studentized values) of wanted (x-axis) and unwanted 
(y-axis) markers at day 0, 1 and 7 of all conditions. C. Scatter-plot of the mean 
expression (studentized values) of wanted and unwanted markers at day 0 and 7 for 
condition 1 - 32. 
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Figure 4: Heatmap of top ranking conditions. 
Heatmap of wanted and unwanted genes in all conditions significantly enriched for 
wanted, but not unwanted markers, color coded by the studentized score.    
 
Figure 5: Genes uniformly affected by single factors across conditions 1 - 32 at day 7. 
A. Experimental setup conditions 1 - 32. B. Heatmap of genes significantly 
downregulated in all conditions contaning any one of the factors compared to condition 
32. C. Heatmap of genes significantly upregulated in all conditions contaning any one of 
the factors compared to condition 32. Values are log2-transformed mean expressions (n = 
3) 
 
Figure 6: Genes significantly regulated between key conditions (day 7) 
A. Top 20 upregulated and top 20 downregulated genes when adding DEX to TGFB1. B. 
Top 20 upregulated and top 20 downregulated genes when adding DEX to 
TGFB1+BMP2. C. All regulated genes when adding BMP2 to TGFB1. D. All regulated 
genes when adding BMP2 to TGFB1+DEX.  
Values represent log2 to the fold change between the gene expression in the condition 
without and the condition with the specified factor added. 
 
Supplementary Figure 1: Quality control of MSCs 
A. Light microscopy picture of MSCs and surface marker profiles of MSCs as measured 
by flow cytometry before differentiation (passage 2 or 3). B. Light microscopy pictures 
of stained control (CTRL) and differentiated (DIFF) MSCs on day 21. Upper panel; 
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adipogenic differentiated cells stained with Oil Red-O: Lower panel: osteogenic 
differentiation of MSCs stained with Alizarin Red. C. Fold change of the expression of 
PPARG in adipogenic differentiated cells and OMD in osteogenic differentiated relative 
to control treated cells (mean±SE, n=3). D. Chondrogenically differentiated MSCs in 
alginate with TGFB1, DEX and BMP2 as shown by mRNA expression changes in key 
chondrogenic markers (n=3, mean±SE) with corresponding protein synthesis (E.) in a 
representative sample on day 21. Nuclei counterstained with DAPI (blue). Scale bar = 50 
μM. 
 
Supplementary Figure S2: Correlation between gene expression analyzed in lysates 
and in isolated total RNA from corresponding samples. 
Correlation plots of the expression of genes analyzed in lysates and in total RNA in two 
donors at day 1, 7 and 14 with coefficients of determination (Pearson´s correlation).  
  
Supplementary Figure S3: Statistical analysis of main effects and interactions at day 
1. 
A. Normal plot of the standardized effects with response set to mean expression of 
wanted markers. B. Corresponding main effects plot of all factors. C. Corresponding 
plots of significant second order interactions. D. Normal plot of the standardized effects 
with response set to mean expression of unwanted markers. E. Corresponding main 
effects plot of all factors. F. Corresponding plots of significant second order interactions. 
 
Supplementary Figure S4: Analysis of wanted and unwanted gene expression 
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A. Scatter-plot of the mean expression (studentized values) of wanted and unwanted 
markers at day 0 and 7 for conditions containing isoforms of TGFB (n = 2). B. Scatter-
plot of the mean expression (studentized values) of wanted and unwanted markers at day 
0 and 7 for conditions with isoforms of BMP. (n = 2) B. Scatter-plot of the mean 
expression (studentized values) of wanted and unwanted markers at day 0 and 7 for 
condition with varying cell seeding density. (n = 2) 
 
Supplementary Figure S5: Genes significantly up- or downregulated  
Heatmap of all genes significantly changed compared to condition 32 at day 7. Values are 
log2-transformed mean expressions (n = 3) 
 
Supplementary Figure S6: Genes significantly regulated between key conditions 
(day 7) 
Upper panel:  All significantly regulated genes (>2-fold) when adding DEX to TGFB1. 
Lower panel: All significantly regulated genes (>2-fold) when adding DEX to 
TGFB1+BMP2. Values represent log2 to the fold change between the gene expression in 
the condition without and the condition with the specified factor added. 
 
Supplementary Figure S7: Overlapping regulated genes when adding DEX to TGF 
or to TGFB1 with BMP2. 
Venn diagram illustrating the overlap of genes significantly up- or downregulated 
corresponding to Supplementary Figure S6. 
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Table 1: Selected wanted and unwanted gene sets. 
 Gene symbol Gene name Functional role 
WANTED ACAN aggrecan Major proteoglycan in hyaline cartilage 
 BGN biglycan Small leucine rich proteoglycans, pericellular 
location and links to chondroitin sulfate in 
hyaline cartilage 
 COL11A1/2 collagen, type XI, 
alpha1/2 
Fibril forming collagen found associated with 
type 2 collagen in hyaline cartilage 
 COL2A1 collagen, type II, 
alpha 1 
The major fibril forming collagen almost 
exclusively found in hyaline cartilage 
 COL9A1/2/3 collagen, type IX, 
alpha 1/2/3 
Fibril associated collagen with interrupted 
triple helix found covalently linked to 
collagen type 2 in hyaline cartilage  
 COMP cartilage oligomeric 
matrix protein 
Prominent component in the ECM of hyaline 
cartilage possibly stabilizing the collagen 
fibril assembly and network 
 DCN decorin Small leucine rich proteoglycan, binds to 
collagen fibrils and aids in assembly 
 FMOD fibromodulin Small leucine rich proteoglycan, aids in 
collagen assembly in cartilage in early 
development 
 HAPLN1 hyaluronan and 
proteoglycan link 
protein 1 
Abundant protein in cartilage, stabilizes 
aggregates of hyaluronan and aggrecan 
 LUM lumican Leucine rich proteoglycan, aids in collagen 
assembly in cartilage in early development 
 MATN3 matrilin 3 Matrix protein restricted to cartilage and  
binds tightly to aggrecan and/collagen fibrils 
UNWANTED ALPL alkaline 
phosphatase, 
liver/bone/kidney 
Major enzyme leading to mineralization of 
bone 
 COL10A1 collagen type X, 
alpha 1 
Network forming collagen found 
predominantly in hypertrophic or diseased 
cartilage 
 COL1A1/2 collagen type I, 
alpha 1/2 
Fibril forming cartilage abundant in bone 
ECM and virtually absent in hyaline cartilage 
 COL3A1 collagen type III, 
alpha 1 
Fibril forming collagen often found in mixed 
fibrils with collagen type 1 
 OGN osteoglycin Small leucine rich proteoglycan, induces 
bone formation 
 PPARG peroxisome 
proliferator-
activated receptor 
gamma 
Nuclear receptor, promotes adipogenesis,  
stimulates lipid uptake and glucose 
metabolism  
 RUNX2 runt related 
transcription factor 
2 
Transcription factor required for bone 
formation 
 SP7 osterix Transcription factor essential for 
osteoblastogenesis 
 SPP1 osteopontin Bone protein, potentiates osteoclast adhesion 
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to mineral surfaces 
 VCAN versican Proteoglycan present in fibrous and elastic 
cartilage, upregulated in dedifferentiating 
chondrocytes 
Gene symbol and name of all genes comprising the wanted and unwanted marker gene 
sets. Based on references [35,62-66] 
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Table 2: Gene set enrichment analysis for wanted and unwanted markers. 
 False discovery rate 
Condition Wanted Unwanted 
11 <0.0001 0.452 
10 <0.0001 0.273 
9 <0.0001 0.484 
12 <0.0001 0.296 
1 <0.0001 0.135 
3 <0.0001 0.138 
13 <0.0001 0.052 
4 <0.0001 0.080 
2 <0.0001 0.056 
5 0.003 0.067 
7 0.035 0.051 
15 <0.0001 0.044 
14 0.001 0.014 
19 0.017 0.018 
17 0.020 0.016 
29 0.030 0.023 
31 0.033 0.023 
All conditions enriched for wanted markers are listed and ranked by the false discovery 
rate for wanted markers (exact FDR values are not stated for FDR <0.0001). Conditions 
enriched for wanted but not for unwanted markers are marked in bold and stated first. 
 
 
A. Experimental setup with numbering of the different conditions. When not stated, the cell 
density was 107 cells per mL. B. PCA on all conditions labelled by days in culture. C. PCA 
limited to conditions 1 - 32 on days 0 and 1. D. PCA limited to conditions 1-32 on days 0 and 
day 7.
Figure 1: Experimental setup and principal component analysis (PCA)
Figure 2: Statistical analysis of main effects and interactions at day 7
A. Normal plot of the standardized effects with the response set to mean expression 
of wanted markers. B. Corresponding main effects plot of all factors. C and D. 
Corresponding plots of significant second order interactions. E. Normal plot of the 
standardized effects with the response set to mean expression of unwanted markers. 
F. Corresponding main effects plot of all factors. G and H. Corresponding plots of 
significant second order interactions.
Figure 3: Analysis of wanted and unwanted gene expression
A. Gene sets used to compute mean expression of wanted and unwanted markers. B. Scatter-plot of 
the mean expression (studentized values) of wanted (x-axis) and unwanted (y-axis) markers at day 0, 
1 and 7 of all conditions. C. Scatter-plot of the mean expression (studentized values) of wanted and 
unwanted markers at day 0 and 7 for condition 1 - 32.
Figure 4: Heatmap of top ranking conditions.
Heatmap of wanted and unwanted genes in all conditions 
significantly enriched for wanted, but not unwanted markers, 
color coded by the studentized score.
Figure 5: Genes uniformly affected by single factors across conditions 1 - 32 at day 7.
A. Experimental setup conditions 1 - 32. B. Heatmap of genes significantly downregulated in all 
conditions contaning any one of the factors compared to condition 32. C. Heatmap of genes 
significantly upregulated in all conditions contaning any one of the factors compared to condition 32. 
Values are log2-transformed mean expressions (n = 3)
Figure 6: Genes significantly regulated between key conditions (day 7)
A. Top 20 upregulated and top 20 downregulated genes when adding DEX to TGFB1. B. Top 20 
upregulated and top 20 downregulated genes when adding DEX to TGFB1+BMP2. C. All 
regulated genes when adding BMP2 to TGFB1. D. All regulated genes when adding BMP2 to 
TGFB1+DEX.
Values represent log2 to the fold change between the gene expression in the condition without and 
the condition with the specified factor added.
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Supporting information Methods and materials 
Cell harvest and culture 
Bone marrow aspirates were obtained in heparin-coated syringes and immediately diluted 
1:4 with DMEM-F12 (Gibco) and centrifuged on a density gradient (Lymphoprep, Axis 
Shield, Oslo, Norway). The mononuclear layer was washed twice and seeded into 175 
cm2 culture flask (Nunc, Roskilde, Denmark). Cells were allowed to adhere for 72 hours 
before the first medium change. Medium was then changed every 3-4 days. Cells were 
passaged when approximately 75% confluent and reseeded at a density of 5000 cells/cm2.  
Medium and supplements 
Human platelet lysate (hPL) was prepared as published previously[1,2]. Briefly, 1 unit of 
pooled platelets (4 donors) in platelet additive solution was spun at 1700 g at room 
temperature. The resulting pellet was resuspended in 10 mL Octaplas AB (Octapharma 
AS, Jessheim, Norway) and frozen at -20°C. After thawing, platelets from 19 units were 
pooled and adjusted to a final volume of 4,8 L with Octaplas AB, subjected to a second 
freeze-thaw-cycle, centrifuged at 4000 g at 4°C for 15 minutes to remove platelet 
fragments and frozen in aliquotes. 
Validation of cells as MSC 
Characterization was performed as previously described[3]. Fluorochrome conjugated 
antibodies used for surface marker characterization were CD19-APC, CD105-APC, 
HLA-DR-APC, CD14-FITC (all Diatec, Oslo, Norway), CD34-FITC, CD44-FITC, 
CD45-PE, CD73-PE (all BD-Biosciences, San Jose, CA) and CD90-PE (Serotec, Oxford, 
UK) and appropriate IgG control antibodies. Multipotency was validated by osteogenic 
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and adipogenic differentiation[4]. For osteogenic differentiation cells were seeded at 
3000 cells/cm2 and differentiated with DMEM-F12 containing 10 % hPL, 10 mM β-
glycerophosphate, 100 nM DEX and 0.05 mM ascorbic acid-2-phosphate. Medium was 
changed twice a week. For adipogenic differentiation cells were seeded at 50,000 
cells/cm2 and differentiated with DMEM-F12 containing 10 μg/mL insulin (Novo 
Nordisk, Bagsvaerd, Denmark), 0.5 μM 1-methyl-3-isobutylxanthine, 1 μM DEX and 
100 μm indomethacin (Dumex-Alpharma, Copenhagen, Denmark). Medium was changed 
twice a week. For both differentiation assays, after 3 weeks, the cells were washed with 
phosphate-buffered saline (PBS), fixed for 1 h with 4% paraformaldehyde, and rinsed 
with PBS. Mineralisation of osteogenic cultures was confirmed by staining with 40 mM 
Alizarin Red (ph 4.2) for 5 min. Lipid droplets in adipogenic cultures were confirmed by 
staining with Oil Red O for 10 min. Appropiate control cultures receiving standard 
growth medium were also stained and evaluated. 
3D cell culture 
Briefly, cells were resuspended into a 1% Pronova-LVG solution. 62,5 μL were 
transferred to 16-well chamberslides (Labtek, Nunc, Denmark) and mixed with an equal 
volume of 1% Pronova-calcium-alginate containing slow releasing calcium particles, 
giving a final cell density of 1x107 cells/mL. After stabilisation for 15 minutes, discs 
were transferred to 24-well culture plates (Nunc) where gelling was consolidated by 
washing with 50 mM SrCl2, followed by three times of washing with regular DMEM 
before addition of bCDM with or without additional growth factors according to the 
experimental factorial design. Medium was changed three times per week. 
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Immunohistochemical stainings 
Primary and secondary antibodies and all final concentrations are specified in Table S4. 
Formalin-fixed, paraffin-embedded samples of cells in alginate were sectioned and 
deparaffinized using standard laboratory procedures and postfixed for 10 minutes in 4% 
paraformaldehyde in PBS. Tissue sections were boiled for 20 minutes in 0.05% citraconic 
anhydride in ddH2O (pH 7.4), incubated with primary antibodies diluted in PBS/1.25% 
bovine serum albumin with 0.1% saponin for permeabilization overnight at 4°C, followed 
by secondary reagents for 1.5 hour at room temperature. Stained sections were mounted 
using ProLong Gold antifading reagent with DAPI (Invitrogen, Carlsbad, CA). 
Microscopy was performed with a Nikon Eclipse E-600 fluorescence microscope 
equipped with Nikon Plan-Fluor objective lenses and a Color View III digital camera 
controlled by Cell-B software (Olympus, Center Valley, PA).  
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Supplementary Figure 1: Quality control of MSCs
A. Light microscopy picture of MSCs and surface marker profiles of 
MSCs as measured by flow cytometry before differentiation (passage 2 or 
3). B. Light microscopy pictures of stained control (CTRL) and 
differentiated (DIFF) MSCs on day 21. Upper panel;
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adipogenic differentiated cells stained with Oil Red-O: Lower panel: 
osteogenic differentiation of MSCs stained with Alizarin Red. C. Fold 
change of the expression of PPARG in adipogenic differentiated cells and 
OMD in osteogenic differentiated relative to control treated cells (mean
±SE, n=3). D. Chondrogenically differentiated MSCs in alginate with 
TGFB1, DEX and BMP2 as shown by mRNA expression changes in key 
chondrogenic markers (n=3, mean±SE) with corresponding protein 
synthesis (E.) in a representative sample on day 21. Nuclei counterstained 
with DAPI (blue). Scale bar = 50 μM.
Supplementary Figure S2: Correlation between gene 
expression analyzed in lysates and in isolated total 
RNA from corresponding samples.
Correlation plots of the expression of genes analyzed in lysates 
and in total RNA in two donors at day 1, 7 and 14 with 
coefficients of determination (Pearson ́s correlation).
Supplementary Figure S3: Statistical analysis of main effects and interactions at day 1.
A. Normal plot of the standardized effects with response set to mean expression of wanted markers. 
B. Corresponding main effects plot of all factors. C. Corresponding plots of significant second 
order interactions. D. Normal plot of the standardized effects with response set to mean expression 
of unwanted markers. E. Corresponding main effects plot of all factors. F. Corresponding plots of 
significant second order interactions.
Supplementary Figure S4: Analysis of wanted and unwanted gene expression
A. Scatter-plot of the mean expression (studentized values) of wanted and unwanted markers at day 0 
and 7 for conditions containing isoforms of TGFB (n = 2). B. Scatter- plot of the mean expression 
(studentized values) of wanted and unwanted markers at day 0 and 7 for conditions with isoforms of 
BMP. (n = 2) B. Scatter-plot of the mean expression (studentized values) of wanted and unwanted 
markers at day 0 and 7 for condition with varying cell seeding density. (n = 2)
CONDITION 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
TGFB1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + factor
FGF2 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 - factor
DEX 1 1 1 1 0 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 0 0 0 0
IGF1 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0 0 1 1 0 0
BMP2 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0
GENE
ACAN 12.9 10.4 12.6 10.5 8.1 5.8 7.4 5.7 14.2 13.1 14.1 13.3 10.8 8.8 10.5 8.4 10.7 4.1 10.4 3.9 8.3 5.6 8.3 5.1 11.8 5.0 11.8 4.5 10.5 6.0 10.3 6.4 More than 10 fold upregulated
ACTA1 1.9 2.3 2.5 1.7 2.5 2.2 3.3 1.8 3.7 3.0 3.4 3.0 2.5 2.5 0.7 2.6 0.8 1.9 1.5 0.8 2.2 1.9 2.4 1.7 1.9 2.2 1.9 1.6 2.6 2.0 2.0 2.3 2-10 fold upregulated
ACTA2 7.1 9.1 7.3 9.1 7.4 8.8 7.2 9.4 6.6 7.1 6.2 6.9 7.1 8.9 6.8 8.8 9.0 8.7 9.0 8.7 7.7 8.7 7.7 8.6 8.5 9.0 8.4 9.0 8.4 9.7 8.0 10.0 0-2 fold upregulated
ADAMTS1 5.6 4.8 5.2 5.0 5.3 6.4 5.7 6.1 4.9 4.7 4.9 4.8 5.9 4.9 5.4 5.2 7.7 8.2 7.8 8.3 7.8 6.8 7.8 6.8 8.1 9.2 8.1 9.2 8.2 6.6 8.4 6.0 Not significantly regulated 
ADAMTS5 4.2 4.3 4.3 4.2 5.3 6.3 5.5 6.2 3.5 3.6 3.3 3.8 4.8 4.7 4.6 5.0 4.4 4.7 4.4 4.3 4.8 4.4 5.4 4.3 4.8 4.9 4.6 5.6 5.0 4.5 4.9 3.9 0-2 fold downregulated
ADAMTS7 6.1 6.1 6.2 6.1 6.3 6.3 6.6 6.2 5.4 6.0 5.4 6.2 6.2 6.3 6.1 6.5 7.5 5.7 7.5 5.8 7.1 6.0 7.1 6.3 7.8 6.6 7.9 6.5 7.6 7.1 7.5 7.2 2-10 fold down-regulated
ADAMTSL1 2.7 3.6 2.8 3.7 2.4 3.9 3.1 3.6 3.4 3.0 3.1 2.6 2.6 3.1 2.5 2.9 4.6 6.8 4.4 6.7 5.0 5.6 5.1 5.4 3.5 6.0 4.6 6.0 5.3 6.3 4.2 6.6 More than 10 fold downregulated
ADAMTSL4 4.1 4.4 4.5 4.5 3.9 3.7 4.3 3.7 4.5 3.8 4.2 3.9 4.0 4.2 3.7 3.9 5.3 7.5 5.2 7.4 4.3 4.5 4.4 4.1 5.6 7.4 5.9 7.4 5.0 5.4 4.8 3.3
AGT 3.6 3.4 3.3 3.2 3.2 4.0 3.7 4.3 3.7 4.0 3.4 4.4 4.6 4.5 4.3 4.2 4.4 2.0 4.4 2.5 3.5 4.3 3.6 3.6 5.1 4.5 4.7 3.7 3.1 3.2 3.3 5.0
AGTR1 4.1 3.9 3.9 3.8 4.1 3.8 4.6 4.1 2.9 3.2 3.3 2.5 3.6 3.9 2.6 3.9 9.2 7.3 9.3 7.4 7.1 4.8 7.0 4.8 7.8 8.4 7.7 8.3 6.2 6.0 6.3 5.5
AGTR2 3.5 3.2 3.4 3.3 3.4 3.4 3.9 3.4 3.3 2.6 2.5 3.1 3.4 3.8 3.6 3.5 2.9 2.3 3.9 1.5 3.9 2.0 3.3 1.7 2.7 2.2 3.6 2.9 3.4 3.3 2.8 2.3
AGTRAP/C11orf2 6.9 7.2 6.8 7.2 6.4 6.7 6.5 6.6 6.6 6.7 6.7 6.9 6.7 6.7 6.8 6.7 6.5 6.1 6.3 6.1 6.5 6.1 6.4 6.2 6.3 6.3 6.4 6.3 6.7 6.6 6.2 6.9
ALPL 10.5 8.0 10.0 7.7 6.2 2.8 5.8 3.4 11.2 10.8 11.2 11.1 9.8 7.9 9.6 7.8 10.4 6.9 10.5 6.7 8.2 1.8 8.0 2.5 12.0 5.4 12.2 5.8 9.7 5.2 9.6 5.1
ANG 5.2 5.0 5.0 4.5 4.0 3.7 3.8 3.4 5.9 5.0 5.6 5.3 4.0 3.8 4.1 3.7 4.8 5.4 4.9 5.4 4.2 3.6 4.4 3.7 5.0 6.2 5.1 6.1 4.4 3.7 4.4 4.3
ANG2 3.6 3.3 3.3 2.9 2.9 3.1 3.4 3.0 2.3 2.8 2.3 2.7 3.2 3.9 1.8 3.7 5.6 3.3 5.6 3.4 3.5 2.2 3.6 2.9 5.2 4.8 5.3 4.9 2.7 2.2 4.2 1.1
ANGPTL2 11.3 8.3 11.2 8.4 11.7 8.8 11.8 8.6 10.2 9.9 10.5 9.9 11.7 9.1 11.6 9.2 7.2 5.7 7.3 5.9 11.4 6.4 11.2 6.7 7.7 6.5 7.8 6.6 11.7 7.0 11.8 6.6
ANGPTL4 6.1 6.1 6.0 5.7 6.5 6.1 6.5 5.7 6.4 4.6 5.3 4.8 5.1 5.5 5.9 5.7 6.3 6.7 6.5 6.6 5.9 5.6 6.0 5.1 6.1 6.6 6.4 6.8 7.3 6.9 6.7 7.4
ANGPTL5 4.4 3.2 4.2 3.4 2.9 3.1 3.6 2.7 5.4 4.8 5.4 4.7 3.7 3.1 3.4 3.3 2.9 3.7 3.3 3.6 2.8 2.6 3.5 2.2 4.2 4.9 4.3 4.4 3.0 1.5 2.6 2.0
ANGPTL7 8.5 7.0 8.2 7.3 4.1 3.0 2.8 2.4 10.7 9.8 10.6 9.9 6.0 4.7 4.5 4.2 2.8 2.3 2.7 2.5 3.2 3.0 2.8 2.5 4.0 3.7 4.2 3.5 3.0 3.7 3.4 4.2
APOD 10.6 10.3 10.8 10.6 5.3 5.6 5.7 5.5 10.3 10.1 10.0 9.9 5.5 5.2 5.0 4.8 10.1 11.1 10.1 11.2 7.1 8.7 6.9 8.8 8.8 10.9 8.6 10.9 6.2 7.0 6.3 6.2
APOE 3.4 2.8 2.7 3.1 3.1 3.1 3.5 3.2 2.0 2.6 2.1 2.5 2.7 1.6 3.3 2.7 5.9 8.7 5.8 8.7 5.5 4.1 5.3 4.3 6.4 9.7 6.2 9.7 5.0 4.7 5.5 5.0
ARHGEF19 7.5 7.2 7.2 7.0 6.5 5.3 6.5 5.5 6.1 6.4 6.0 6.5 6.7 6.4 6.4 6.3 7.0 5.1 6.9 5.3 6.2 3.6 6.0 2.7 7.6 6.8 7.2 6.7 6.6 3.3 6.8 4.5
ARHGEF3 5.1 5.5 5.3 5.3 7.4 7.9 7.7 7.6 4.1 3.8 4.0 3.7 5.5 6.5 5.6 6.8 5.4 5.3 5.7 5.1 7.7 8.3 7.6 8.4 4.5 5.3 4.5 5.4 6.5 8.0 6.0 7.7
ARNT2 3.2 4.1 3.4 3.7 3.7 4.1 3.4 3.9 2.8 3.3 2.5 2.8 3.6 3.3 3.9 3.7 3.8 3.6 3.9 3.4 4.2 4.3 4.5 3.4 4.1 4.3 3.7 4.0 4.6 4.6 4.9 3.5
BAPX1 6.0 3.9 5.0 4.0 2.6 3.3 3.6 3.6 6.7 5.8 6.7 6.0 4.0 3.5 3.3 3.9 3.9 2.5 3.5 1.7 3.4 2.8 3.6 2.0 2.6 2.3 3.6 3.4 4.3 2.9 2.4 2.8
BCL6 7.5 7.6 7.5 7.5 6.6 7.3 6.7 7.2 7.7 7.0 7.1 7.2 6.8 7.2 6.4 7.3 8.3 7.0 8.5 6.9 6.0 6.5 6.2 6.4 8.5 8.1 8.5 8.1 6.1 6.7 6.5 6.2
BDKRB1 5.1 3.2 4.8 3.6 3.2 4.1 3.4 3.4 7.1 5.8 6.5 5.7 3.5 3.2 2.6 2.4 2.6 2.9 3.0 3.1 3.3 5.2 1.7 5.3 2.8 3.1 3.1 3.1 3.4 5.2 1.8 4.9
BEX1 4.5 4.3 4.6 4.6 4.8 4.1 4.9 4.5 4.8 4.5 4.2 4.7 4.5 4.5 4.3 4.3 4.5 3.7 4.6 3.4 4.8 3.8 5.3 4.1 5.0 4.1 4.2 4.3 5.0 4.5 5.2 4.8
BGLAP 5.0 4.6 4.6 4.5 7.4 6.9 7.4 7.1 4.3 4.3 4.2 4.3 6.7 7.0 6.4 6.7 5.2 4.4 5.2 4.3 8.3 8.0 8.7 8.2 5.5 4.7 5.5 4.3 7.8 7.1 7.6 7.5
BGN 13.1 13.5 13.0 13.4 13.2 13.2 13.3 13.3 12.7 13.3 12.6 13.5 13.6 13.7 13.7 13.7 11.5 10.8 11.5 10.7 12.3 10.9 12.3 10.9 11.2 10.9 11.3 10.9 12.1 11.8 12.1 12.1
BID 4.5 4.6 4.5 4.6 4.3 4.4 4.3 4.5 4.6 4.3 3.8 4.4 4.4 4.3 3.3 4.5 4.5 4.7 5.0 4.8 4.3 4.5 4.4 4.3 4.8 4.6 4.9 4.7 4.6 4.6 5.0 4.9
BMP2 9.0 10.0 9.0 9.9 10.1 10.9 10.4 10.8 7.7 8.6 7.8 8.6 8.8 9.8 9.2 10.2 7.5 4.3 7.4 4.6 6.6 8.6 6.5 8.7 8.1 5.2 8.1 5.4 6.2 7.8 6.1 8.4
BMP4 5.3 6.2 5.2 6.2 5.8 5.7 5.7 6.0 4.3 7.1 4.1 7.2 7.3 7.6 7.3 7.6 5.2 5.1 5.2 4.6 4.6 6.1 4.6 6.3 5.7 6.1 5.8 6.0 4.4 6.2 3.7 6.9
BMP6 3.8 4.4 3.7 4.0 3.7 3.5 3.6 2.8 4.1 3.3 3.6 3.4 3.8 2.6 3.4 2.7 5.7 3.4 6.2 3.0 3.7 5.6 4.1 5.5 6.7 4.6 6.8 4.7 2.1 4.1 3.5 5.1
BMP7 3.3 2.6 2.8 2.8 4.1 2.2 4.3 2.4 3.1 3.3 3.1 3.9 4.1 3.7 4.2 3.4 2.1 1.2 1.5 1.4 3.5 1.5 3.8 2.0 3.0 2.2 2.8 1.4 3.9 2.0 3.7 1.5
BMPR1A 7.3 7.1 7.1 7.0 7.4 7.2 7.3 7.3 6.3 6.7 6.2 6.7 7.3 7.4 7.4 7.4 8.1 7.1 8.1 7.1 8.2 6.9 8.3 6.9 8.0 7.5 8.0 7.6 8.7 7.3 8.6 7.2
BMPR1B 2.9 3.2 3.0 2.9 2.0 3.3 3.3 3.0 3.1 3.7 2.9 3.6 3.4 3.3 2.8 3.1 2.7 5.4 2.6 5.6 4.3 3.7 4.2 3.2 2.4 4.9 2.8 4.7 3.4 3.9 4.3 4.4
BMPR2 7.3 7.2 7.4 7.2 7.9 7.4 7.9 7.4 6.6 6.6 6.5 6.7 7.3 7.4 7.4 7.4 7.7 6.4 7.6 6.3 8.4 6.5 8.5 6.6 7.6 6.6 7.5 6.6 8.9 6.9 8.9 6.8
BST1 2.9 3.4 2.8 2.5 3.0 3.0 2.5 3.2 3.3 2.8 2.8 2.7 3.0 3.1 3.5 3.1 4.8 5.3 5.2 5.5 4.3 3.9 4.3 3.7 5.4 6.0 5.0 5.8 4.4 4.8 4.9 4.5
C1QTNF3 11.1 8.8 10.8 9.0 5.6 4.4 4.5 4.9 12.4 11.5 12.4 11.4 7.6 6.2 7.3 5.9 6.4 4.4 6.3 4.2 5.3 3.7 5.4 3.2 8.1 5.3 7.9 5.4 5.6 4.5 5.6 5.1
CA12 8.8 8.1 8.5 7.9 6.2 7.1 6.1 7.0 9.3 9.1 9.3 9.4 8.3 7.8 8.0 8.1 6.8 8.5 6.6 8.4 6.0 8.6 5.9 8.5 6.7 7.5 6.7 7.6 5.8 8.6 5.5 8.5
CA5B 5.6 5.3 5.5 5.2 6.6 5.7 6.5 5.4 4.7 4.6 4.6 4.7 5.7 5.8 5.7 5.6 5.8 4.1 5.9 4.5 6.3 5.2 6.1 5.4 6.2 4.9 6.4 4.9 5.4 4.7 5.8 5.1
CA9 7.9 7.5 7.8 7.4 4.8 3.6 4.8 3.1 8.8 7.6 8.4 7.8 4.9 3.7 5.2 4.1 3.9 4.1 2.6 3.2 4.1 1.9 4.2 1.8 4.4 2.8 4.4 3.3 4.6 3.9 4.5 2.8
CARD10 2.6 2.0 2.5 1.9 2.7 2.3 2.6 2.7 2.6 2.6 2.5 2.3 2.6 2.1 2.7 1.7 2.3 3.7 2.8 4.2 3.3 3.6 2.4 4.1 2.9 2.8 2.9 3.5 3.4 4.1 3.5 3.1
CASC3 7.3 7.2 7.2 7.1 7.2 7.2 7.2 7.2 6.7 6.9 6.7 7.0 7.3 7.3 7.3 7.4 7.8 7.3 7.7 7.2 7.8 7.2 7.9 7.0 7.7 7.9 7.6 7.8 7.9 7.2 7.9 6.7
CASP3 5.1 5.7 5.0 5.4 6.0 5.6 5.8 5.6 5.0 4.9 4.8 5.1 5.7 5.9 5.4 5.6 6.2 6.1 6.4 6.2 6.2 6.3 6.5 6.0 5.9 6.8 6.1 7.0 6.3 7.0 6.8 6.7
CASP4 5.0 5.6 4.9 5.6 5.7 5.8 5.6 5.9 3.5 4.2 3.0 4.3 5.2 5.7 5.3 5.7 5.8 6.0 5.9 6.0 6.2 5.6 6.4 5.4 5.9 6.6 5.9 6.7 6.4 5.6 6.7 6.4
CBFB 9.3 8.8 9.3 8.9 9.3 8.7 9.4 8.6 9.0 9.1 9.1 9.1 9.3 8.8 9.3 8.9 9.5 7.5 9.4 7.5 10.2 8.1 10.2 8.1 9.2 7.8 9.1 7.9 10.2 8.2 10.2 8.2
CCL2 1.6 2.2 1.8 2.2 3.0 4.2 3.1 4.0 2.0 2.2 1.5 1.4 3.0 2.7 3.3 3.4 2.9 3.7 3.3 3.8 3.8 5.4 3.1 5.1 2.4 3.6 2.3 3.6 4.1 6.4 4.1 4.2
CCNA2 5.4 6.2 5.3 6.1 3.9 4.3 4.3 4.6 4.1 5.2 4.6 4.9 5.0 4.8 4.9 4.7 4.4 3.4 4.3 3.3 4.1 3.7 3.9 2.8 4.4 3.6 4.5 3.8 4.3 4.6 4.3 3.4
CCNB1IP1 4.0 4.4 4.2 4.1 4.3 3.9 3.5 3.6 4.5 3.9 4.1 4.1 4.2 4.2 3.8 4.0 4.9 4.7 5.0 4.6 4.8 4.4 5.1 4.3 4.9 5.3 4.6 5.6 4.8 4.7 4.8 2.5
CCNB2 5.8 6.3 5.5 6.3 4.3 4.6 3.9 4.3 4.2 5.3 4.4 5.0 4.5 4.7 4.4 4.6 4.4 2.8 4.4 2.4 4.1 3.3 3.7 3.4 4.5 3.8 4.5 3.2 4.7 2.5 4.2 4.0
CCND1 9.3 9.7 9.1 9.7 9.7 10.0 9.7 10.0 9.0 9.3 9.0 9.2 9.4 9.7 9.4 9.7 9.4 9.6 9.5 9.5 9.7 10.7 9.6 10.7 9.3 7.9 9.2 8.1 9.6 10.5 9.6 10.4
CCND2 7.8 6.5 7.6 6.6 6.2 5.2 5.0 5.2 8.1 7.6 8.1 7.6 6.5 5.9 6.8 5.8 6.5 7.6 6.6 7.4 6.3 5.8 6.4 5.7 6.0 6.0 5.9 6.2 6.4 4.9 5.8 5.1
CCNF 4.8 5.2 4.8 5.3 3.7 4.1 3.8 4.1 5.1 4.9 4.7 4.7 4.0 4.1 4.2 4.7 4.4 3.9 4.3 3.8 3.7 3.6 3.9 3.2 4.0 3.7 4.2 4.0 4.2 3.9 3.9 4.2
CCNYL1 5.2 4.8 4.9 5.2 4.9 4.5 4.8 4.7 4.8 5.2 4.9 5.3 5.1 5.3 5.3 4.8 5.5 5.1 5.3 5.0 4.8 4.6 4.8 4.8 5.3 5.2 5.4 5.2 5.5 5.5 5.5 5.4
CD109 8.5 8.1 8.3 8.1 7.2 7.2 7.2 7.2 9.6 8.5 9.3 8.6 7.3 7.1 7.1 7.1 7.6 7.9 7.4 8.0 7.1 8.1 7.0 8.0 8.0 8.0 7.8 7.9 6.8 8.0 6.8 8.0
CD24 7.8 6.6 7.4 6.7 8.7 6.5 8.8 6.9 8.3 8.7 8.2 8.9 9.6 8.1 9.5 8.1 5.6 4.3 5.7 4.2 10.9 4.8 10.7 3.9 6.9 4.3 7.0 5.0 11.0 5.9 11.2 6.5
CD248 6.6 7.3 6.7 7.3 6.1 6.8 6.1 6.9 5.6 6.6 5.5 6.7 6.3 7.1 6.3 7.1 8.2 9.3 8.1 9.3 7.5 7.4 7.5 7.1 8.6 9.7 8.4 9.8 7.9 8.1 8.0 8.0
CD44 7.0 7.9 6.9 8.0 8.2 8.4 8.3 8.2 6.9 6.6 6.8 6.6 7.3 7.9 7.8 8.0 7.2 8.3 7.1 8.2 7.6 8.5 7.4 8.5 7.0 8.3 7.0 8.3 6.6 8.5 6.5 8.5
CD55 2.9 3.2 2.5 2.3 2.9 3.0 3.4 3.4 4.1 3.5 3.4 3.7 3.6 3.6 2.6 3.4 2.8 3.1 3.3 3.5 3.5 3.9 3.2 3.2 4.1 2.8 3.3 3.6 4.4 2.7 3.7 3.0
CD59 9.8 9.9 9.7 9.9 9.5 9.5 9.5 9.5 9.2 9.7 9.4 9.8 9.4 9.5 9.3 9.5 9.4 10.2 9.5 10.1 9.8 9.5 9.8 9.6 9.3 9.4 9.2 9.5 9.4 9.5 9.6 9.7
CD74 5.8 5.1 5.7 5.0 6.4 6.5 6.1 6.6 6.0 5.7 5.8 5.8 6.2 6.5 6.4 6.5 6.0 6.1 6.1 6.1 7.7 8.7 7.6 8.6 6.1 6.2 6.0 6.0 7.5 8.7 7.3 8.6
CD9 9.0 8.9 9.0 8.9 8.2 8.3 8.3 8.2 8.9 8.7 9.0 8.7 8.0 8.1 7.9 8.2 8.0 8.6 8.1 8.7 7.8 8.6 7.7 8.6 8.8 8.4 8.7 8.4 6.5 8.2 7.1 8.4
CDH11 11.1 11.5 11.1 11.5 11.3 11.0 11.3 11.1 9.1 10.5 9.1 10.4 11.4 11.6 11.4 11.6 11.9 10.5 11.9 10.5 12.1 10.8 12.1 10.7 11.9 11.3 11.8 11.3 12.4 11.4 12.3 11.4
CDH13 4.0 4.5 4.0 4.2 2.8 2.9 2.7 3.2 3.1 2.4 2.1 3.2 2.0 2.2 1.8 2.7 4.3 4.6 4.3 4.9 3.3 5.0 2.8 5.2 3.8 4.2 3.6 4.6 4.0 5.0 2.3 5.7
CDH15 7.0 6.1 6.8 5.9 7.1 5.3 7.2 5.9 6.3 6.8 6.0 6.7 8.3 7.6 7.9 7.5 4.9 1.2 5.3 1.6 5.4 3.4 5.5 2.8 7.2 2.1 7.0 3.0 6.2 4.1 6.5 4.1
CDH2 6.4 6.5 6.1 6.5 6.6 5.9 6.4 6.1 6.9 6.9 6.7 6.9 7.4 6.8 7.4 7.0 7.4 5.2 7.4 5.1 8.0 6.1 8.2 5.9 8.4 5.3 8.5 5.6 8.8 6.7 8.8 7.0
CDKN1A 8.7 8.9 8.7 8.9 9.8 9.9 9.8 9.8 8.8 8.5 8.7 8.5 9.4 9.3 9.6 9.6 8.9 9.7 8.9 9.7 9.4 10.3 9.4 10.2 9.1 9.8 9.1 10.0 9.2 10.2 9.2 10.3
CDKN1B 4.2 4.2 4.6 4.1 4.7 4.1 4.3 3.7 4.1 3.9 4.0 4.2 4.2 4.3 4.3 3.8 5.1 3.9 4.7 4.0 5.0 3.6 5.0 3.9 4.9 5.4 4.8 4.7 4.8 4.2 4.6 4.7
CDKN1C 8.3 5.4 7.7 5.0 3.8 3.9 3.9 3.4 10.1 9.0 10.0 9.2 6.5 5.9 6.3 5.7 5.2 4.4 5.4 4.5 5.6 3.3 5.4 4.0 7.0 6.1 7.1 6.1 7.1 5.1 6.8 5.2
CDKN2A 5.0 5.0 5.2 5.3 5.1 5.4 5.7 5.7 4.5 4.9 4.6 4.7 5.2 5.3 5.5 5.3 5.9 6.1 6.0 5.9 6.1 6.0 6.3 6.3 5.6 5.5 5.8 5.3 6.4 5.5 6.3 5.9
CDKN2B 5.7 5.0 5.7 5.3 7.2 7.2 7.6 7.2 4.6 5.3 4.6 5.0 6.4 6.5 6.6 6.5 6.9 6.6 6.8 6.4 7.2 7.8 7.3 8.1 6.4 5.6 6.5 5.6 6.9 6.8 6.7 6.7
CDKN2C 5.2 5.3 5.0 5.3 4.5 4.1 4.0 4.2 4.5 4.5 4.5 4.4 4.3 3.7 4.2 4.4 5.2 4.3 5.2 4.4 3.9 3.9 4.0 4.2 5.7 5.3 5.7 5.3 4.9 4.9 4.3 3.4
CDKN2D 4.2 4.3 4.3 4.3 3.9 3.6 4.5 4.1 3.9 3.7 3.9 4.0 3.6 4.1 4.2 3.6 4.4 3.8 4.3 3.7 4.3 4.1 4.5 4.6 3.9 3.5 3.5 3.9 4.1 3.8 4.5 2.4
CEBPA 1.2 0.5 1.9 1.3 1.0 1.5 2.7 1.2 2.2 1.6 1.6 1.3 2.0 1.6 1.6 2.2 5.0 1.9 5.1 2.4 2.7 2.6 3.6 2.3 6.2 4.0 5.8 4.4 3.7 2.3 3.8 3.0
CEBPB 8.6 8.5 8.5 8.4 8.8 9.1 9.0 9.0 7.7 7.6 7.6 7.7 8.2 8.7 8.4 8.9 9.1 7.7 9.1 7.6 8.7 8.6 8.8 8.5 9.3 8.3 9.2 8.5 9.1 8.8 9.1 8.6
CHAD 10.2 6.6 9.5 6.5 5.3 3.6 4.4 3.3 11.6 9.9 11.6 10.4 8.5 6.1 8.3 5.4 4.6 3.1 4.4 2.3 4.7 2.3 4.6 2.7 8.5 3.9 8.9 5.3 5.2 3.2 6.1 5.0
CHST1 6.7 7.3 6.8 7.3 6.9 6.9 7.1 7.0 6.0 7.1 5.8 7.3 6.8 7.5 6.8 7.1 5.2 4.5 4.8 4.4 5.9 6.0 6.2 6.1 4.8 4.2 4.6 4.1 5.6 5.3 5.5 5.8
CHST3 8.3 7.6 8.1 7.5 7.1 6.6 6.9 6.4 8.8 9.1 8.8 9.2 8.3 7.5 8.3 7.5 6.1 5.8 5.9 5.8 6.2 5.7 6.4 6.1 6.9 6.3 6.9 6.4 6.1 6.0 6.6 6.4
CHST6 6.2 5.9 6.1 6.0 5.9 6.0 5.4 6.2 6.2 7.0 6.4 6.8 7.1 7.1 6.8 7.0 3.4 2.0 3.5 1.3 3.9 3.2 4.1 2.1 3.2 2.4 4.3 1.6 3.9 1.7 4.4 3.3
CITED2 6.8 6.9 6.8 6.7 7.3 6.7 7.4 6.8 6.3 6.1 6.2 6.4 7.2 7.1 7.0 7.3 9.5 9.1 9.6 9.1 8.4 7.9 8.4 7.9 9.5 9.7 9.4 9.7 8.5 8.2 8.6 8.2
CITED4 3.2 3.9 3.3 3.9 2.9 4.0 3.9 3.4 4.0 4.0 4.6 3.8 3.7 4.2 2.5 4.0 2.4 6.1 2.5 5.7 3.8 4.5 2.6 4.9 2.5 3.5 2.2 3.5 2.9 4.2 2.9 4.7
CNN1 3.9 3.9 4.1 3.7 3.3 3.0 2.2 3.1 5.5 4.2 5.0 4.3 3.5 2.8 3.3 3.7 4.3 4.0 4.4 4.3 4.1 2.5 3.7 3.2 4.1 4.1 4.1 4.7 4.2 3.8 3.7 3.0
CNN2 8.1 9.3 8.2 9.2 8.1 8.6 8.3 8.9 7.0 8.2 6.8 8.1 8.5 9.0 8.4 8.9 9.2 9.5 9.2 9.4 8.9 8.3 8.9 8.2 9.0 10.0 8.9 10.0 9.1 9.1 8.8 9.3
COL10A1 14.9 14.3 14.4 14.3 14.0 13.3 13.9 13.0 15.6 15.3 15.6 15.7 14.4 13.8 14.4 13.9 3.5 2.3 3.6 2.4 5.0 6.0 5.0 5.8 9.0 2.8 9.0 2.0 5.7 6.4 5.9 6.8
COL11A1 12.9 11.5 12.5 11.5 8.9 8.0 7.7 7.8 14.1 13.6 13.9 13.7 11.7 10.3 11.2 9.8 9.4 7.9 9.4 7.4 7.3 6.1 7.4 6.1 11.1 9.4 11.2 9.5 8.9 7.2 8.8 8.1
COL11A2 10.8 7.7 10.3 8.0 5.9 3.2 5.0 3.0 12.4 11.4 12.2 11.5 9.8 6.9 9.1 6.4 4.2 1.4 4.2 1.4 3.3 2.5 4.1 1.7 7.5 2.9 7.5 1.6 4.6 1.5 5.6 1.3
COL12A1 12.1 11.7 11.8 11.6 10.9 9.8 10.9 10.0 12.7 13.1 12.5 13.3 12.2 11.5 11.8 11.1 11.0 8.7 11.0 8.6 10.8 8.4 10.8 8.3 12.1 9.8 12.0 9.8 11.3 9.8 11.4 10.1
COL14A1 4.5 5.0 4.3 5.1 5.5 7.9 5.9 8.3 4.6 5.3 4.4 5.4 5.1 7.5 5.2 7.8 4.0 8.8 4.2 8.8 5.8 10.2 6.2 10.3 4.7 8.5 4.2 8.3 6.9 10.6 6.6 10.5
COL18A1 6.4 6.7 6.3 6.7 7.3 6.9 7.4 6.8 4.5 5.5 4.4 5.0 6.1 6.5 6.1 6.7 6.3 8.3 6.0 8.3 6.7 7.2 6.5 7.1 5.3 8.6 5.1 8.6 6.1 7.3 5.9 7.4
COL1A1 15.9 15.9 15.7 15.7 14.8 14.0 14.6 14.2 16.0 16.6 15.8 16.8 16.2 15.8 16.0 15.7 14.1 12.5 14.3 12.4 14.8 11.6 15.0 11.4 15.1 13.3 15.2 13.4 14.9 13.2 14.7 13.8
COL1A2 15.2 15.1 15.0 15.0 14.4 13.5 14.3 13.7 15.3 15.8 15.0 16.0 15.6 15.2 15.4 15.1 14.0 13.4 14.1 13.3 14.5 12.3 14.6 12.2 14.8 14.2 14.9 14.2 14.7 13.4 14.5 13.7
COL27A1 8.4 6.7 8.0 6.4 6.5 6.8 6.4 6.6 9.2 8.3 9.2 8.2 7.7 6.9 7.5 7.0 6.8 6.0 6.9 5.9 7.2 6.5 6.8 6.4 7.8 7.0 7.4 6.9 7.3 7.6 7.1 7.5
COL2A1_1 11.4 8.7 10.9 8.9 7.0 4.1 5.7 3.9 12.6 12.2 12.3 12.2 10.5 7.8 9.9 7.1 4.3 1.6 4.8 1.6 4.2 1.5 4.5 2.7 7.1 2.1 7.5 2.2 5.8 2.0 5.6 3.9
COL2A1_2 13.4 9.7 12.8 9.9 6.7 3.7 5.3 3.6 15.2 14.2 15.0 14.2 11.1 7.6 10.4 6.7 3.7 0.9 4.3 1.3 2.4 2.3 1.4 2.3 7.6 2.7 8.8 2.4 6.2 2.0 5.8 3.3
COL2A1_common 15.0 11.6 14.4 11.9 9.1 5.0 7.1 4.5 16.7 15.8 16.6 15.9 13.1 9.9 12.7 9.1 4.6 0.9 5.6 2.5 3.0 2.2 3.7 2.2 9.9 2.6 10.3 2.5 6.6 2.6 7.9 4.6
COL3A1 16.2 16.2 16.0 16.1 15.9 15.6 16.1 15.7 13.0 14.1 12.7 14.1 14.9 15.6 15.1 15.9 17.7 15.8 17.7 15.8 17.3 14.1 17.2 14.0 16.4 16.7 16.4 16.8 17.0 15.0 16.9 15.1
COL4A1 6.4 7.5 6.1 7.4 6.2 6.7 6.2 6.9 5.9 5.7 5.7 5.4 4.2 5.0 4.3 5.1 7.9 7.3 8.0 7.3 5.9 5.6 5.7 5.6 6.9 8.2 7.0 8.4 4.7 6.0 5.1 6.2
COL4A2 5.0 6.4 5.1 6.1 4.8 5.4 4.9 5.5 4.5 4.3 4.4 3.7 3.2 3.8 3.7 4.5 6.7 6.4 6.7 6.4 4.9 5.1 4.5 5.1 5.8 7.2 5.5 7.4 4.1 5.5 3.6 5.8
COL6A1 11.2 11.9 11.1 11.8 11.1 11.9 11.1 12.0 11.2 10.8 11.1 10.7 10.4 11.4 10.7 11.5 11.7 12.4 11.6 12.2 11.3 12.6 11.2 12.6 11.0 12.2 11.0 12.3 10.7 12.8 10.5 13.0
COL7A1 8.9 9.9 8.8 9.8 9.7 9.6 9.8 9.5 8.0 8.1 7.6 8.3 8.9 8.9 8.5 9.2 7.5 7.9 7.7 7.8 7.9 7.7 7.7 7.6 7.4 8.2 7.2 8.4 7.0 7.7 7.2 7.9
COL8A1 9.6 10.3 9.4 10.3 9.6 9.9 9.6 9.9 8.2 9.2 8.0 9.2 9.6 9.8 9.4 9.8 9.5 7.6 9.6 7.6 9.5 8.3 9.3 8.5 10.3 7.3 10.3 7.5 11.1 8.8 11.3 8.8
COL9A1 8.7 3.9 8.0 4.0 1.8 0.9 0.9 1.7 10.8 9.5 10.8 9.6 5.3 3.1 4.6 1.5 0.9 0.8 1.9 1.4 1.5 2.2 1.2 1.4 4.5 1.7 5.0 1.4 2.6 2.0 1.8 2.1
COL9A2 10.8 8.6 10.3 8.6 8.2 5.1 7.6 4.6 11.7 11.1 11.7 11.2 9.9 7.6 9.5 7.2 6.9 2.6 7.1 2.4 8.9 2.3 9.1 2.4 8.4 3.8 8.3 3.9 9.1 3.2 9.3 3.3
COL9A3 10.5 7.8 10.1 8.2 6.3 4.4 6.0 4.0 12.0 10.9 11.8 10.9 8.9 6.5 8.4 6.1 5.2 1.6 4.9 1.6 4.3 2.0 4.0 0.8 7.6 1.5 7.5 3.2 6.2 3.2 5.6 0.8
COMP 14.3 14.6 14.3 14.6 12.3 12.1 12.2 11.7 12.9 13.8 12.9 14.0 12.8 12.4 12.7 12.4 9.3 6.3 9.1 6.1 5.2 4.1 5.5 4.9 9.4 8.2 9.1 7.9 6.9 5.7 6.9 5.9
CP 2.3 2.6 2.4 2.4 2.5 1.9 2.6 2.0 2.7 2.6 2.7 2.8 1.9 2.9 2.5 2.5 3.6 2.8 3.1 2.4 2.9 2.2 1.9 2.4 3.6 3.7 3.9 3.3 2.2 3.8 2.6 1.1
CRLF1 9.7 8.7 9.7 8.7 9.7 8.4 9.8 8.3 8.9 7.7 8.8 8.1 9.5 8.2 9.4 8.2 6.6 3.1 6.5 3.4 7.3 3.2 6.8 3.6 6.8 4.5 6.8 4.4 7.2 4.1 7.7 3.9
CRTAC1 5.0 5.5 4.7 5.4 5.5 5.6 5.0 4.9 4.3 5.5 4.1 5.5 5.2 5.6 5.4 5.6 5.2 1.6 5.0 1.8 4.0 2.8 4.0 2.7 5.9 2.2 5.6 2.9 4.8 2.9 5.4 3.0
CRTAP 4.7 4.9 4.8 4.7 5.0 4.5 4.9 4.7 4.4 4.9 4.5 5.2 4.9 5.1 4.6 4.8 4.7 4.7 4.7 4.5 4.7 3.7 5.0 2.6 5.2 5.0 4.9 4.8 4.9 4.1 4.8 5.0
Supplementary Figure S5: Genes significantly up- or downregulated
CRYGS 6.9 5.5 6.9 5.4 5.7 5.7 5.5 5.7 6.8 6.4 7.1 6.3 6.2 6.0 6.0 5.8 5.4 3.4 5.3 3.7 5.6 4.3 5.8 3.7 6.6 4.0 6.2 4.3 6.6 4.5 7.6 3.0
CTGF 12.2 11.5 12.0 11.5 9.3 8.6 9.0 8.8 13.5 12.8 13.1 12.9 10.9 9.5 10.8 9.3 8.6 7.5 8.7 7.4 8.9 8.2 8.6 8.1 9.7 8.5 9.6 8.6 9.0 9.1 8.6 9.1
CTNNB1 12.3 12.5 12.2 12.5 11.2 11.3 11.2 11.4 11.9 12.5 11.8 12.7 11.8 11.8 11.7 11.7 11.3 10.4 11.3 10.4 11.1 11.1 11.1 11.0 11.9 10.9 11.8 10.9 11.5 11.2 11.4 11.5
CXCL12 3.8 4.6 3.7 4.5 7.3 8.8 7.6 8.9 3.0 3.7 3.3 3.4 5.1 7.3 6.1 8.0 5.5 7.9 5.0 7.8 6.4 8.3 6.4 8.1 5.6 9.1 5.9 9.2 6.6 10.1 6.1 10.1
CXCL14 8.2 5.9 7.7 5.8 3.0 1.9 3.0 2.2 9.6 9.0 9.5 9.3 6.5 6.3 6.1 5.6 1.3 1.0 3.2 1.3 2.3 2.2 3.1 2.2 4.1 1.3 3.6 1.2 3.9 2.0 3.5 1.1
CXCL16 3.5 3.5 3.6 3.5 4.2 3.9 4.2 3.9 3.8 3.4 3.2 3.8 3.1 4.1 3.6 3.5 4.2 4.0 4.0 3.5 5.4 4.8 5.2 4.4 3.7 4.2 3.0 3.6 5.6 4.8 5.1 4.9
CYB5B 7.8 7.7 7.7 7.8 7.4 7.4 7.5 7.6 7.6 8.0 7.8 7.8 7.8 7.7 7.8 7.6 7.9 7.5 7.9 7.5 8.0 7.7 8.0 7.6 7.6 7.5 7.7 7.4 7.9 7.4 8.2 7.4
CYC1 6.3 6.3 6.4 6.4 5.9 5.8 6.0 5.7 6.3 6.6 6.6 6.5 6.8 6.5 6.6 6.3 6.1 5.8 6.2 6.0 6.0 5.9 6.3 5.5 6.0 5.6 6.3 6.0 6.2 5.4 6.3 6.0
DCN 12.8 13.1 12.9 13.0 11.2 11.2 11.3 11.2 12.3 12.1 12.1 12.2 10.9 11.5 11.0 11.7 13.3 12.2 13.3 12.2 10.7 9.8 10.8 9.6 13.1 13.0 13.1 13.0 10.7 10.6 10.6 10.8
DDIT3 5.7 5.7 5.9 5.7 6.5 6.4 6.6 6.5 6.9 6.0 6.3 6.2 6.6 6.2 6.3 6.4 6.4 6.5 6.4 6.4 7.1 6.7 7.3 6.5 6.7 7.2 6.9 7.5 7.4 7.3 7.4 6.7
DKK1 6.3 4.4 5.4 4.6 4.7 2.9 4.9 2.3 6.7 6.2 6.7 6.0 6.7 4.5 6.2 4.2 6.1 2.3 6.4 2.9 6.7 2.0 7.2 2.5 5.4 4.1 5.7 4.4 4.9 3.1 5.4 2.7
DKK2 3.0 4.2 2.1 3.8 3.9 3.0 4.3 3.3 2.6 2.8 2.1 2.6 4.0 3.3 4.1 2.4 2.9 1.8 3.1 2.7 3.9 2.3 3.5 1.7 3.0 3.0 3.3 2.3 3.3 3.6 4.6 2.9
DLX5 8.4 8.5 8.4 8.4 7.4 6.4 7.5 6.4 7.7 8.0 7.5 8.2 7.8 7.7 7.8 7.7 9.0 5.3 9.1 5.4 9.2 5.1 9.2 4.6 8.8 6.3 8.9 6.3 9.8 5.4 9.9 5.6
DPT 9.0 9.7 9.0 9.5 7.3 5.6 7.4 5.4 7.1 9.1 7.1 9.3 7.7 7.3 7.4 7.1 7.3 8.0 7.4 8.0 6.3 3.3 6.3 2.9 8.3 10.1 8.1 10.0 6.5 4.5 6.6 4.7
EFNA1 5.6 5.7 5.6 5.4 5.4 4.5 5.5 4.4 6.4 5.8 6.1 6.1 5.5 5.4 5.4 5.2 5.5 3.8 5.9 4.1 5.0 3.7 5.2 3.5 6.3 4.7 6.3 4.4 5.3 4.6 5.4 2.7
EFNB2 3.2 4.3 3.3 4.3 3.6 3.5 3.6 3.2 3.9 3.2 3.5 3.2 3.1 3.5 3.6 4.0 2.3 5.3 3.3 5.1 3.8 3.7 3.9 3.4 2.4 3.1 3.7 3.6 5.0 3.7 5.3 2.9
EIF2B1 7.3 7.3 7.5 7.3 7.4 7.0 7.1 7.0 7.2 7.3 7.1 7.2 7.3 7.3 7.4 7.2 7.7 7.3 7.7 7.2 7.3 6.8 7.4 6.8 7.6 7.5 7.5 7.4 7.5 7.1 7.6 7.2
ELF1 7.1 6.8 7.0 6.8 6.8 6.9 7.0 6.8 6.4 6.4 6.4 6.7 6.5 6.8 6.8 6.8 7.6 6.8 7.6 6.8 7.0 6.3 7.3 6.6 7.6 7.2 7.6 7.1 7.5 6.7 7.3 7.1
ELN 4.4 5.8 4.3 5.4 3.8 4.0 3.8 3.9 4.8 5.4 4.7 5.5 4.8 6.3 5.1 5.7 3.8 2.9 3.5 3.1 3.5 2.6 3.6 3.1 4.5 4.5 3.8 3.3 4.7 3.5 4.3 4.2
EPHA2 6.8 7.2 6.7 7.1 7.7 6.9 7.7 7.3 5.8 5.8 5.3 5.8 7.9 7.6 7.8 7.8 5.9 5.0 6.2 4.9 7.4 5.4 7.4 5.9 6.3 5.2 6.3 5.8 7.9 5.8 7.6 6.2
EPYC 8.4 6.4 8.1 7.0 6.4 5.0 5.9 5.3 9.6 9.2 9.5 9.0 7.0 6.4 6.6 6.6 3.1 1.4 2.6 1.1 3.0 1.0 3.2 0.9 4.5 1.5 4.5 1.4 3.5 2.1 4.0 3.5
ERF 8.1 7.8 8.1 7.8 7.8 7.7 7.7 7.6 8.0 8.4 8.2 8.3 8.6 8.5 8.6 8.4 8.3 6.7 8.2 6.5 8.2 6.8 8.0 7.2 8.2 6.7 8.1 6.6 8.0 6.9 8.0 7.1
FGF11 6.9 6.4 6.6 6.1 5.2 4.8 4.9 4.9 6.9 6.9 7.0 7.1 5.9 5.4 5.6 5.3 4.2 2.6 4.3 2.7 4.4 1.8 4.0 3.1 4.7 3.6 4.6 3.6 4.4 3.7 5.0 2.4
FGF2 6.2 5.7 5.8 5.8 5.8 5.2 5.9 5.1 6.6 6.3 6.5 6.3 5.8 4.8 5.9 5.0 4.9 5.3 4.9 4.9 5.9 5.4 5.8 5.5 5.3 5.2 4.9 4.8 6.1 5.4 6.4 5.5
FGF7 6.5 6.9 6.5 6.7 7.7 8.1 8.2 8.0 5.5 5.5 5.5 5.9 5.6 6.9 5.9 7.0 8.6 7.2 8.6 7.0 9.1 8.0 9.0 8.0 8.7 8.0 8.6 7.9 8.7 8.8 8.7 8.9
FGFBP2 8.0 6.7 7.7 6.6 5.1 3.8 4.5 3.2 9.9 9.7 9.7 9.9 7.4 6.6 7.3 6.0 3.9 2.6 3.9 2.7 2.9 3.0 3.2 3.2 5.5 3.8 5.6 3.9 3.4 3.3 4.0 3.6
FGFR1 9.6 9.7 9.4 9.6 11.0 10.9 11.0 11.2 7.9 9.0 7.7 9.1 10.0 10.8 10.0 10.8 8.8 9.1 8.9 9.0 10.9 10.6 10.8 10.5 9.0 9.7 8.9 9.8 10.6 10.3 10.5 10.5
FGFR2 4.7 4.7 4.6 4.5 3.3 3.7 3.2 3.4 4.1 4.6 4.0 4.3 4.8 5.2 5.2 4.4 4.0 2.4 4.2 2.0 4.4 3.7 4.5 1.6 4.8 3.7 5.1 4.0 5.1 4.5 5.0 4.3
FGFR3 10.0 7.1 9.9 7.1 8.5 5.5 8.4 5.5 10.6 9.2 10.8 9.2 9.3 7.2 9.2 7.0 8.8 2.3 8.9 2.0 10.0 1.1 9.9 2.4 9.5 2.6 9.6 2.7 11.4 3.5 11.3 3.6
FGFR4 5.8 4.1 6.0 4.0 3.8 2.6 3.5 2.9 6.2 5.4 6.1 5.4 5.0 3.8 4.7 3.2 3.1 2.5 3.3 2.3 4.2 2.1 3.4 2.3 4.3 3.2 4.4 3.1 3.8 3.0 4.8 4.0
FGFRL1 9.3 8.1 9.2 8.3 9.0 8.3 8.9 8.2 10.0 9.4 10.1 9.4 9.5 8.7 9.3 8.7 7.6 7.3 7.6 7.1 8.0 7.1 7.8 7.1 8.1 7.7 8.0 7.6 8.3 7.3 8.3 7.0
FMOD 12.4 11.0 12.2 11.0 9.5 8.2 8.9 7.9 13.8 13.0 13.6 13.0 11.5 9.9 11.3 9.5 8.1 7.1 8.0 7.1 7.7 5.2 7.5 5.6 9.1 7.7 9.1 7.6 8.7 6.7 8.3 6.7
FN1 16.3 16.5 16.2 16.6 16.4 16.3 16.5 16.2 16.8 16.5 16.4 16.6 16.4 16.5 16.3 16.6 14.6 15.6 14.4 15.5 14.3 15.3 14.3 15.4 14.0 15.1 13.9 14.9 14.0 15.8 13.9 15.7
FOXA2 5.8 2.7 5.2 3.1 3.6 2.1 2.8 3.2 7.4 6.2 7.4 6.3 4.2 2.7 3.5 2.8 2.3 1.6 2.8 1.9 2.8 1.0 2.9 2.4 4.3 1.7 4.2 1.8 3.8 2.0 3.4 1.1
FOXA3 3.6 3.0 3.7 2.8 3.4 2.4 2.9 2.8 4.5 4.3 4.3 4.4 3.9 3.6 4.2 3.2 2.1 1.3 2.4 1.6 3.0 1.6 2.7 1.4 3.3 2.8 3.2 2.7 3.9 2.2 3.4 1.3
FOXC1 5.5 5.7 5.6 5.5 5.1 5.1 5.5 5.0 5.8 5.9 5.9 5.7 6.0 5.8 5.8 5.6 5.6 5.4 5.0 5.6 5.7 5.7 5.2 5.5 5.4 5.6 5.2 6.1 6.0 5.6 6.1 5.2
FOXC2 6.6 6.0 6.7 5.8 7.8 6.2 7.6 6.4 6.2 5.7 6.2 5.8 7.4 6.5 7.3 6.6 7.5 6.5 7.5 6.5 8.7 6.1 8.7 6.4 7.1 6.4 7.1 6.6 9.0 5.9 8.8 5.9
FOXD1 7.4 7.4 7.3 7.3 7.6 7.1 7.7 7.3 7.0 7.5 7.1 7.7 8.0 8.2 8.1 8.2 7.1 6.6 7.0 6.5 7.1 7.2 7.2 7.2 7.0 6.9 6.9 7.1 7.3 7.6 7.3 7.9
FOXD2 2.7 2.4 3.0 2.6 2.0 1.6 2.3 2.2 2.8 3.2 3.1 3.2 2.0 1.5 2.3 2.6 3.4 2.6 3.0 2.4 2.9 2.0 3.2 1.3 4.1 3.0 3.3 3.6 1.6 2.4 1.8 0.2
FOXM1 6.2 6.6 6.1 6.8 4.8 5.1 4.9 5.1 5.2 5.8 5.3 5.4 5.4 5.3 5.1 5.2 4.7 3.3 4.6 3.3 4.5 3.5 3.4 3.8 4.7 4.4 4.6 4.2 5.2 4.6 5.1 5.1
FOXO1 8.3 9.2 8.4 9.2 8.8 9.3 8.9 9.1 6.6 7.2 6.4 7.2 8.0 8.4 8.2 8.8 6.8 7.3 6.4 7.3 5.4 5.7 5.6 5.5 6.9 8.3 6.7 8.4 5.6 5.6 5.1 6.2
FOXQ1 3.3 6.0 3.7 5.9 3.2 3.5 3.2 4.0 2.9 3.1 2.4 2.8 3.0 2.9 2.2 3.1 2.1 2.6 2.9 2.6 3.0 5.7 2.6 5.6 2.8 2.9 3.0 3.2 3.6 6.4 3.6 6.0
FRZB 5.6 4.4 5.5 4.6 5.6 2.9 5.9 3.0 6.3 6.0 6.2 5.7 6.0 4.0 5.6 4.2 6.9 1.9 6.9 2.0 6.2 2.3 6.3 2.2 7.3 2.3 7.3 2.8 6.4 2.6 6.7 2.0
FZD2 5.2 5.2 5.1 5.3 5.1 5.4 5.2 5.5 5.0 4.8 4.7 5.1 4.9 5.4 4.9 5.6 5.7 6.1 5.8 6.0 6.4 5.7 6.5 5.8 5.5 6.2 5.5 6.7 6.4 6.3 6.1 6.5
FZD4 4.8 4.1 4.9 4.4 4.5 4.2 4.6 5.0 4.6 4.4 4.2 3.9 4.2 4.8 3.5 4.3 6.9 6.0 6.9 6.1 5.2 4.6 5.5 4.6 7.6 6.8 7.5 6.9 5.9 5.0 5.8 3.2
FZD6 5.7 6.8 5.9 6.7 6.3 6.0 6.2 6.0 4.6 5.4 4.6 5.5 5.8 5.7 6.0 5.9 5.2 6.5 5.2 6.4 6.1 6.2 5.8 6.2 4.9 6.2 4.8 6.3 5.8 6.0 6.1 6.4
FZD7 6.6 6.9 6.8 6.9 7.4 7.3 7.6 7.6 6.2 6.6 5.9 6.9 6.8 7.7 6.9 7.9 9.1 6.6 9.1 6.6 8.6 7.5 8.6 7.7 8.3 7.4 8.2 7.3 7.5 7.7 7.4 7.5
FZD8 7.3 6.7 7.3 6.8 8.5 7.3 8.3 7.3 6.1 6.4 6.5 6.2 8.2 7.8 8.4 7.7 8.0 4.5 7.9 4.5 8.6 7.2 8.6 7.6 7.9 5.4 7.9 5.5 8.7 7.2 8.8 6.9
FZD9 4.4 2.9 4.1 2.7 3.4 2.1 2.1 2.3 5.2 5.0 5.1 5.1 3.5 3.1 4.9 3.7 0.8 1.7 1.7 1.1 1.0 1.4 0.8 1.2 1.7 0.8 2.3 1.6 0.9 1.5 2.4 1.1
GLI1 4.0 3.7 3.9 3.5 2.6 3.4 3.0 3.4 4.2 4.6 4.1 4.8 4.5 4.9 4.4 4.5 1.8 1.6 1.8 1.5 1.8 2.7 2.9 2.8 2.2 2.4 1.9 1.2 3.6 1.5 3.6 2.7
GLI2 3.4 3.5 3.2 3.4 3.7 4.1 3.8 3.5 2.9 3.3 3.0 3.7 4.3 4.3 4.2 4.3 3.3 2.7 3.7 2.8 3.5 2.2 3.3 1.5 3.2 3.7 3.1 3.3 3.6 2.4 4.4 4.0
GLI3 5.7 6.6 5.7 6.6 6.5 6.8 6.6 6.7 5.0 5.4 5.0 5.7 6.4 6.7 6.5 6.8 6.5 6.4 6.6 6.4 6.9 7.2 7.1 7.1 6.4 7.0 6.4 6.9 7.4 7.5 7.2 7.8
GLI4 2.3 2.5 3.0 2.4 2.6 2.5 2.8 2.5 2.8 2.5 2.5 2.8 3.3 3.1 3.4 2.7 2.7 2.2 3.0 2.3 3.1 2.8 3.5 2.6 3.6 3.5 2.4 2.7 3.1 3.1 4.1 2.6
GLIS3 5.2 5.1 4.8 4.8 4.6 4.6 4.0 3.9 5.9 5.3 5.7 5.3 4.0 3.9 4.3 4.2 4.7 5.4 4.3 5.6 4.7 5.3 4.7 4.8 4.8 5.9 4.8 5.6 4.4 5.8 4.6 5.3
HAPLN1 12.6 9.9 12.3 10.1 6.5 4.7 5.6 4.5 14.0 13.0 13.9 13.1 10.0 7.2 9.5 6.7 6.6 2.4 6.5 2.7 4.7 2.0 4.3 2.9 9.5 4.5 9.7 3.1 6.9 4.3 6.7 4.9
HAPLN3 7.0 6.7 6.9 6.7 6.7 6.7 6.5 6.6 7.4 6.9 7.1 7.1 6.8 7.0 7.1 7.1 5.8 6.3 5.4 6.1 5.9 5.8 6.1 5.9 6.3 7.1 6.0 6.9 6.1 6.3 6.1 6.0
HAS1 7.8 8.8 7.5 8.8 5.6 7.1 5.6 7.0 5.6 5.9 5.3 5.9 4.8 6.0 4.7 6.2 5.9 5.6 6.1 5.2 4.1 5.4 3.0 5.2 4.3 4.1 4.8 4.0 4.3 4.6 4.1 5.6
HAS2 6.7 7.8 6.5 8.0 5.7 8.0 5.8 8.0 7.3 6.9 7.4 7.1 5.6 5.9 5.7 6.1 6.5 9.2 6.3 9.3 4.9 8.1 5.4 8.1 7.5 9.6 7.5 9.4 4.9 8.0 4.8 7.8
HAS3 1.6 1.8 2.1 2.7 2.6 2.0 3.2 2.2 1.9 1.7 1.9 2.4 2.3 2.7 2.8 2.3 3.0 2.2 3.0 1.5 3.6 2.7 2.9 2.8 2.3 2.3 2.0 3.2 3.7 2.9 3.6 4.2
HCLS1 4.7 3.5 4.3 3.9 3.5 3.6 3.7 3.4 5.5 4.7 5.5 4.8 3.9 3.6 4.0 3.6 3.3 3.0 3.1 2.5 3.2 2.8 2.6 1.4 3.6 3.6 2.9 2.6 3.4 3.1 3.6 2.6
HES1 5.5 5.4 5.4 5.3 6.7 6.9 6.9 7.0 5.8 4.6 5.5 4.7 5.7 6.0 5.7 6.5 6.1 3.3 5.8 3.4 6.9 6.7 6.8 6.7 6.0 3.8 6.2 3.1 5.9 7.0 5.8 7.2
HESX1 3.9 3.9 4.1 3.8 3.8 2.9 3.8 3.3 4.5 4.2 4.2 4.6 4.2 3.6 4.1 3.2 3.6 2.8 3.6 3.0 4.3 2.6 3.9 1.4 3.3 3.4 3.1 3.4 4.7 2.2 4.0 4.0
HEY1 8.5 4.6 8.4 4.8 7.3 2.5 7.4 3.1 5.7 4.5 6.0 4.5 7.6 4.3 7.7 3.6 10.6 1.3 10.7 1.7 11.1 1.0 11.1 1.4 10.2 2.3 10.3 2.4 11.5 3.5 11.5 1.4
HEY2 3.6 2.0 3.7 2.1 5.6 3.2 5.7 3.5 3.1 2.8 3.2 2.4 4.6 4.1 5.3 4.1 3.1 2.0 3.1 1.9 6.1 2.6 5.7 2.7 2.9 3.0 3.1 3.1 6.8 2.0 7.0 4.1
HIF1A 10.3 9.8 10.3 10.0 9.7 10.1 9.8 9.8 10.4 10.5 10.6 10.4 10.1 9.7 9.9 9.8 10.7 9.3 10.8 9.2 9.8 9.3 9.9 9.3 10.4 9.1 10.2 9.0 10.1 9.2 10.0 9.0
HIF2A 2.0 1.7 2.1 1.7 2.2 1.8 2.2 1.9 1.5 1.6 1.6 1.6 2.3 2.0 2.1 2.0 2.5 2.0 2.3 1.9 2.6 2.3 2.6 2.3 2.4 2.2 2.5 2.2 2.8 2.4 2.8 2.4
HMBS 5.5 5.4 5.2 5.5 5.2 5.2 5.4 5.2 4.9 5.3 5.2 5.5 5.6 5.5 4.5 5.0 5.2 4.8 5.0 4.9 5.4 4.7 5.4 4.6 5.6 4.6 5.3 4.6 5.3 4.8 6.0 5.4
HP 0.9 1.3 1.0 1.4 1.5 1.9 1.5 1.2 2.0 1.1 1.1 1.6 1.4 1.6 1.9 1.5 3.3 3.5 3.7 3.6 2.0 0.7 1.6 1.9 3.8 4.5 4.1 4.3 3.1 2.1 2.2 1.0
HPRT1 7.6 7.5 7.5 7.4 6.5 6.5 6.6 6.5 7.7 7.5 7.7 7.7 6.7 6.7 6.6 6.6 7.0 6.5 7.0 6.6 6.6 6.2 6.3 6.5 7.0 6.2 7.0 6.2 6.6 6.1 6.3 6.2
HYAL1 4.6 4.5 4.4 4.2 3.9 3.8 3.4 3.7 5.2 4.6 4.9 4.7 4.0 4.4 4.6 4.2 3.7 3.4 3.5 3.1 3.3 3.0 3.9 3.0 3.9 3.1 4.0 3.9 4.2 4.3 3.4 2.8
ICAM1 2.7 2.7 3.1 2.4 3.7 3.4 3.3 3.1 3.3 2.8 3.5 2.8 3.2 3.4 3.7 3.5 3.1 1.8 3.2 2.0 4.0 3.8 4.1 1.4 3.4 3.4 3.7 2.7 4.4 4.5 4.9 5.1
IFNA1 2.0 1.5 1.6 1.6 2.2 1.8 2.5 1.8 2.8 2.7 2.8 2.5 2.7 2.6 1.2 2.7 2.2 1.1 1.9 0.8 1.5 1.7 1.7 1.8 2.1 1.3 1.5 2.1 3.7 2.6 2.6 4.1
IFNB1 1.8 1.8 1.9 1.7 1.4 1.8 1.8 2.0 2.3 1.8 2.0 2.2 2.3 1.6 2.1 1.2 1.3 1.9 2.1 1.0 2.1 1.8 0.2 1.0 2.2 2.3 2.8 2.4 1.2 1.6 2.8 3.3
IFNG 2.5 2.1 2.3 2.2 1.0 1.8 2.3 1.5 2.8 2.9 2.2 2.7 2.1 2.2 1.7 1.7 1.4 0.5 1.5 1.5 2.0 1.1 2.4 2.0 1.8 2.0 2.4 1.7 2.3 2.6 2.8 1.4
IGFBP1 2.2 2.0 2.3 1.8 1.6 2.2 2.6 2.2 2.2 2.4 2.0 2.1 2.0 1.8 2.8 1.8 2.5 1.4 2.7 1.7 3.0 5.0 2.6 4.6 2.5 2.6 2.1 2.8 0.9 3.9 1.8 1.6
IGFBP2 5.8 5.5 5.8 5.5 5.7 5.5 5.8 5.5 5.8 5.9 5.8 6.1 6.2 6.4 5.9 6.4 7.2 9.9 7.3 9.7 7.0 6.2 7.0 6.0 7.1 8.1 7.3 8.0 6.7 7.2 6.9 6.9
IGFBP3 10.1 10.7 10.2 10.6 11.8 11.7 12.3 12.0 8.8 8.2 7.6 8.1 8.5 9.8 8.6 10.4 13.2 13.0 13.3 13.1 12.4 13.5 12.3 13.6 12.2 12.6 12.0 12.5 10.0 12.9 10.4 12.7
IGFBP4 10.0 11.4 9.9 11.4 9.9 10.8 10.2 10.6 8.0 8.3 7.9 8.4 9.2 9.7 9.4 10.1 9.9 12.0 10.1 12.1 10.6 11.7 10.5 11.8 9.8 11.9 9.6 11.9 10.6 12.2 10.6 11.8
IGFBP5 12.9 12.9 12.7 12.9 13.5 12.5 13.5 12.3 10.5 11.5 10.7 11.3 12.9 12.1 13.2 12.3 12.0 8.2 12.1 8.4 14.8 11.1 14.8 11.1 11.7 9.2 11.7 9.3 15.4 9.1 15.4 9.1
IGFBP6 8.5 8.6 8.5 8.6 7.8 7.2 7.8 7.1 8.1 7.1 7.8 7.3 7.4 7.2 7.4 7.1 9.2 9.9 9.3 9.8 9.0 8.1 9.1 8.2 8.9 7.9 9.1 8.0 8.4 8.7 8.3 8.4
IGFBP7 8.9 9.0 8.8 8.9 8.2 8.7 8.3 8.9 9.3 9.0 9.3 9.1 8.3 8.6 8.2 8.7 8.5 8.8 8.6 8.9 7.9 8.2 7.8 8.4 8.3 9.1 8.2 9.2 7.9 9.0 7.9 9.1
IHH 7.9 5.7 7.4 5.7 4.0 2.4 2.7 2.9 9.0 8.8 9.0 8.7 7.8 5.9 7.5 6.0 1.8 2.0 2.4 1.7 1.8 2.8 2.0 1.6 4.1 2.7 4.4 2.0 3.0 3.7 2.1 2.5
IL11 5.7 6.2 5.3 6.1 7.0 6.6 6.8 5.9 4.7 5.5 4.9 5.8 7.5 6.2 7.4 6.4 2.5 2.2 2.3 2.1 4.1 4.3 3.8 3.7 2.5 2.6 2.6 2.6 3.2 3.3 4.5 4.9
IL13RA1 8.8 7.6 8.8 7.6 8.1 7.2 8.2 7.1 9.2 8.1 9.0 8.4 7.7 7.1 7.6 7.1 8.3 6.5 8.5 6.3 9.6 6.7 9.5 6.5 9.0 6.2 8.8 6.4 9.6 7.1 9.5 7.2
IL16 6.6 7.5 6.4 7.3 5.1 6.8 5.3 6.7 7.3 7.1 7.0 7.2 5.4 6.0 5.5 6.0 4.3 4.3 4.6 4.6 3.1 6.4 2.9 6.4 5.7 5.6 5.3 5.9 4.3 6.5 3.7 6.3
IL1R1 8.3 8.4 8.2 8.3 7.3 6.9 7.4 7.0 7.6 8.2 7.5 8.4 8.3 7.9 8.1 8.0 7.7 7.6 7.7 7.5 7.1 7.0 7.0 6.9 7.9 8.6 7.8 8.6 7.5 7.3 7.6 6.8
IL20RB 5.8 3.5 5.2 3.5 2.3 1.3 2.1 2.3 7.7 6.5 7.0 6.5 4.2 2.4 4.2 2.7 2.7 2.3 3.2 2.0 1.5 2.5 2.5 2.3 4.2 3.2 2.8 3.2 1.8 3.4 3.3 2.1
IL6 2.8 3.3 2.6 3.0 3.5 2.9 3.4 2.9 3.7 3.0 3.0 3.0 3.7 3.8 3.5 3.5 3.1 2.6 2.9 2.6 3.8 2.9 3.0 3.3 2.9 2.9 3.3 3.6 4.0 4.4 4.0 4.7
IL7R 4.6 3.9 4.3 4.0 4.5 3.9 4.5 3.5 4.3 3.9 4.3 4.0 5.0 4.0 4.6 4.1 7.5 2.8 7.7 2.4 10.2 3.4 10.6 4.2 6.7 3.3 7.1 2.6 9.5 3.7 9.9 3.7
IRF6 5.9 4.0 5.5 3.5 3.0 3.1 3.7 3.8 8.1 7.1 8.0 7.3 4.1 3.5 4.0 3.7 3.5 2.4 3.0 2.1 4.3 3.0 3.9 4.1 4.0 2.4 4.2 2.6 4.2 2.8 3.7 4.7
IRF9 5.7 6.0 5.9 6.0 6.4 6.5 6.6 6.8 5.4 5.5 5.2 5.6 6.2 6.5 6.1 6.6 6.7 6.5 7.1 6.6 7.1 6.7 7.0 6.6 6.6 6.8 6.5 6.7 6.9 6.5 7.2 6.5
ITGA1 5.2 5.7 5.2 5.7 5.6 5.7 5.7 5.7 5.4 5.1 5.0 4.9 4.8 4.7 5.2 4.7 6.0 3.6 5.9 3.6 5.9 6.3 5.7 6.3 6.1 4.5 6.0 4.4 5.6 4.9 4.6 4.9
ITGA2 5.0 5.1 4.9 5.2 6.5 6.0 7.2 5.9 3.4 3.4 3.1 3.7 5.4 5.0 5.3 5.3 4.8 4.5 5.2 4.9 7.3 6.7 7.5 7.1 4.1 3.5 4.1 3.3 6.5 6.3 6.5 6.1
ITGA3 5.0 5.0 4.9 5.2 5.5 5.4 5.8 5.6 5.9 4.8 5.3 5.0 5.0 4.8 5.0 4.7 4.9 6.6 5.1 6.4 5.3 6.8 5.3 6.8 3.8 5.1 4.1 5.1 5.0 6.8 4.7 7.3
ITGA5 9.5 10.2 9.6 10.2 8.5 8.9 8.7 8.9 9.4 8.8 9.1 8.8 8.5 8.8 8.7 8.8 9.5 10.3 9.4 10.3 8.7 8.8 8.6 8.7 9.2 9.9 9.1 10.0 8.9 9.0 8.9 8.9
ITGB1 11.2 11.5 11.0 11.4 11.1 11.2 11.2 11.2 10.8 11.0 10.7 11.1 11.0 11.0 10.9 11.1 11.2 11.3 11.3 11.3 11.7 10.9 11.7 10.9 11.1 10.9 11.1 10.9 12.1 11.1 12.1 11.0
JAG1 6.7 6.1 6.6 6.4 8.7 7.9 8.7 8.1 5.8 5.8 5.7 5.8 7.5 7.7 7.5 7.6 6.3 5.3 6.4 5.4 8.7 5.1 8.6 5.5 6.4 6.0 6.3 6.1 8.6 5.3 8.7 5.2
JAG2 4.3 2.8 3.7 3.1 2.4 2.3 3.4 2.0 5.1 4.7 4.6 5.3 3.2 3.4 2.1 3.4 2.2 1.3 2.3 1.8 2.9 1.5 2.9 2.4 2.4 2.0 2.9 2.4 2.0 2.1 3.7 1.4
JUNB 8.8 8.2 8.9 8.2 7.9 7.7 7.9 7.5 8.7 8.8 8.8 9.0 8.5 8.3 8.5 8.2 7.6 5.9 7.9 6.1 7.8 7.4 7.4 7.2 7.7 5.8 7.9 6.3 7.4 7.9 7.1 8.2
KERA 3.1 2.8 2.8 2.6 2.8 2.9 3.1 2.8 4.2 3.3 3.9 3.7 2.8 2.8 3.4 1.7 1.7 1.0 1.2 1.7 1.4 2.0 2.4 2.2 2.5 1.2 2.4 1.6 2.1 2.2 2.8 2.8
KLF13 6.9 7.1 6.8 6.9 6.5 6.4 6.5 6.5 5.3 6.1 5.7 6.2 6.4 7.0 6.4 7.0 7.1 6.2 7.2 6.2 6.5 6.2 6.6 6.2 7.2 6.7 7.1 6.8 6.5 6.2 5.8 6.5
KLF15 4.4 3.4 4.4 3.2 2.2 2.5 3.1 1.9 6.0 4.8 5.4 4.8 2.5 2.5 2.7 2.1 4.5 4.6 4.8 4.7 3.4 3.1 3.2 2.6 6.0 6.4 5.6 6.4 1.6 3.8 2.8 3.7
KLF4 7.0 7.0 7.0 6.8 7.0 6.3 7.0 6.4 7.2 7.2 7.1 7.2 7.7 7.5 7.7 7.6 6.2 5.7 6.0 5.3 7.0 5.1 7.2 5.1 6.9 5.9 6.6 6.0 6.6 5.7 6.3 6.4
KLF6 6.8 7.8 6.6 7.7 6.7 7.1 6.7 7.0 6.6 6.7 6.2 6.8 6.5 7.2 6.5 7.2 8.7 9.3 8.8 9.2 7.9 7.2 7.9 7.3 8.2 9.3 8.2 9.4 8.3 7.6 7.8 8.0
LEF1 6.2 6.2 6.2 6.4 6.3 6.4 5.9 6.3 6.2 6.3 6.1 6.0 5.4 5.6 5.6 5.5 3.6 1.5 3.5 1.7 6.2 3.1 6.1 3.4 3.3 2.4 3.2 2.9 5.0 2.6 4.8 1.7
LGALS1 11.1 11.9 11.0 11.7 11.1 11.4 11.1 11.4 10.0 10.2 9.8 10.4 10.5 11.2 10.7 11.1 11.9 12.2 11.9 12.1 11.6 11.3 11.6 11.3 11.6 11.9 11.6 11.9 11.8 11.7 11.6 12.0
LGALS3 8.9 8.9 8.9 8.9 8.6 8.9 8.7 9.0 9.2 9.1 9.3 9.1 8.8 9.0 8.7 9.0 9.2 9.9 9.2 9.9 9.3 9.5 9.4 9.4 9.2 9.9 9.2 10.0 9.5 9.8 9.5 9.3
LGALS3BP 7.1 7.2 7.3 7.2 8.0 8.0 8.3 8.2 6.0 6.4 5.8 6.3 7.5 8.0 7.3 8.0 9.2 9.4 9.3 9.3 9.8 8.9 9.8 8.7 8.6 9.3 8.5 9.3 9.5 8.9 9.6 8.7
LPAR4 7.4 5.2 7.0 5.3 5.0 3.6 5.1 4.3 8.4 8.2 8.6 8.2 7.6 6.0 7.2 5.8 2.3 1.4 2.4 1.9 3.9 2.5 3.4 2.6 4.1 1.9 4.4 1.3 4.1 3.4 4.1 2.4
LRP5 5.4 5.6 5.1 5.5 5.5 5.5 5.8 5.7 4.9 5.7 4.9 5.9 5.7 6.0 6.0 5.7 5.4 5.0 4.9 4.8 5.8 6.4 5.9 6.7 5.3 5.8 5.8 5.3 5.9 6.5 6.0 6.7
LRP6 6.4 6.3 6.3 6.3 6.4 5.8 6.3 6.1 6.4 6.4 6.3 6.5 6.5 6.4 6.3 6.4 6.4 5.7 6.4 5.6 7.1 6.1 6.9 6.0 6.5 6.3 6.2 6.3 7.4 6.0 7.2 4.0
LUM 13.3 13.4 13.2 13.2 13.6 13.2 13.7 13.3 11.8 12.5 11.9 12.5 13.3 13.6 13.4 13.8 13.4 8.5 13.6 8.1 12.8 10.3 12.9 10.2 12.9 9.9 13.0 10.0 12.9 11.6 12.8 11.9
MAF 4.3 3.6 4.4 3.6 4.2 4.7 4.3 4.7 5.0 4.2 5.1 4.5 4.4 4.4 4.2 4.2 5.6 5.1 5.8 4.9 5.1 5.5 5.3 5.4 6.1 6.0 5.7 6.1 5.6 5.5 5.3 6.0
MAFB 6.4 6.0 6.4 6.0 6.8 6.3 6.8 6.5 5.3 5.9 5.4 5.8 6.8 7.1 6.7 6.6 6.1 5.8 6.0 5.8 7.0 6.5 7.1 6.4 6.6 6.9 6.3 6.8 7.2 7.3 7.1 7.4
MATN1 3.8 2.8 3.6 2.8 3.1 2.5 2.9 2.5 5.2 3.8 4.5 4.3 3.0 1.6 3.1 2.9 3.9 2.4 3.7 2.8 3.4 3.3 2.6 3.0 4.2 3.0 3.9 2.9 4.4 3.7 3.6 4.9
MATN2 6.7 7.3 6.5 7.3 6.9 7.4 6.7 7.5 6.2 7.4 6.0 7.4 7.3 8.1 7.2 7.8 5.2 4.2 5.3 4.0 5.4 5.6 5.2 6.0 6.3 5.9 6.2 5.9 6.1 5.9 6.3 6.3
MATN3 12.8 9.9 12.3 10.0 6.6 4.6 5.0 4.9 14.5 13.3 14.3 13.2 8.8 6.6 8.5 6.0 6.4 5.6 6.6 5.3 4.3 3.0 3.9 2.6 9.1 6.2 8.8 6.3 6.0 4.6 4.9 2.6
MATN4 8.2 6.5 8.0 6.8 5.3 3.4 4.7 2.5 9.4 9.5 9.4 9.5 8.1 6.3 7.7 5.5 2.9 0.9 3.3 1.5 3.4 1.0 3.0 1.6 4.8 1.9 4.2 2.4 4.5 2.3 3.6 1.4
MEF2C 8.4 7.5 8.2 7.3 7.8 6.0 7.7 6.3 8.6 8.6 8.6 8.7 9.1 8.1 9.0 8.0 6.5 4.8 6.8 4.9 7.5 5.3 7.5 5.2 7.9 5.4 7.7 5.6 8.2 5.6 8.0 6.0
MEF2D 5.9 6.3 6.2 6.2 6.6 6.3 6.4 6.4 6.4 5.9 6.3 6.0 6.1 6.4 6.0 6.5 5.9 5.5 5.7 5.4 6.1 5.7 6.2 6.2 6.1 5.7 5.7 6.0 6.0 6.0 6.0 5.6
MGP 10.4 9.6 10.3 9.8 11.4 10.1 11.5 9.8 9.4 9.7 9.5 9.6 10.8 10.1 11.1 10.1 9.1 9.3 9.1 9.3 10.2 8.3 10.1 8.4 9.4 10.9 9.2 11.1 10.0 6.7 10.1 6.7
MIA 8.3 6.7 8.0 6.9 6.0 4.5 5.6 4.2 9.2 8.8 9.1 9.0 7.3 5.8 7.4 6.0 5.0 2.3 5.2 2.3 5.4 4.2 5.5 4.3 6.4 3.5 6.1 3.4 5.4 4.1 5.9 5.0
MMP1 2.1 3.7 1.7 3.7 7.2 8.2 8.1 8.3 2.7 1.7 2.2 2.0 3.2 5.2 4.0 6.2 1.5 2.1 2.4 1.9 5.8 7.0 5.3 7.6 1.4 2.6 2.3 2.8 3.0 7.4 3.7 7.1
MMP13 9.3 10.8 9.4 11.1 12.8 13.7 13.3 13.8 6.6 6.5 6.7 6.5 10.5 11.9 10.7 12.5 9.8 3.3 9.8 3.0 11.2 11.2 11.3 11.0 9.2 4.7 8.9 4.5 10.3 11.1 9.9 11.0
MMP2 11.1 11.4 10.9 11.3 10.7 11.2 10.8 11.2 11.3 11.2 11.2 11.4 11.1 11.5 11.0 11.5 9.9 11.0 9.7 11.0 10.4 11.2 10.4 11.2 10.1 11.8 10.0 11.9 10.8 11.8 10.9 11.6
MMP28 6.0 5.4 6.2 5.7 4.3 4.5 4.2 4.4 6.5 6.0 6.4 6.2 4.3 4.8 4.8 4.8 7.2 6.7 7.1 6.7 4.3 3.3 4.0 3.0 7.9 7.9 7.8 8.1 3.8 4.4 4.1 4.6
MMP3 4.3 5.0 4.0 5.2 3.5 3.3 2.3 3.2 5.2 3.9 4.4 3.8 3.3 2.5 3.1 3.0 2.9 1.1 1.9 1.7 2.5 2.4 2.6 2.3 3.2 2.0 3.6 2.1 3.1 3.7 2.9 3.5
MMP7 5.3 6.6 5.9 6.5 2.8 2.4 2.0 2.4 6.3 6.9 6.0 7.0 3.1 2.6 2.1 1.5 8.8 8.0 8.7 7.9 4.1 1.8 3.6 2.9 8.5 9.9 8.3 10.0 3.6 3.2 4.3 2.7
MMP8 3.4 3.0 3.3 2.7 3.2 2.9 3.7 2.0 3.6 3.6 3.0 3.5 3.5 3.6 3.2 3.1 4.4 2.4 3.6 2.1 3.2 1.0 3.7 2.6 3.8 2.5 3.8 2.2 4.3 3.7 3.9 3.3
MMP9 3.7 3.5 3.4 3.5 4.6 3.2 4.9 3.5 3.2 3.6 3.3 3.5 4.5 5.0 4.5 4.7 2.9 1.7 3.4 2.0 4.0 3.3 4.6 3.8 3.7 2.8 3.4 3.0 4.5 5.4 5.2 4.6
MST1 4.2 3.6 4.0 3.8 4.3 3.7 3.8 3.3 4.4 3.7 3.6 3.8 3.6 3.8 3.4 4.0 5.3 4.7 5.3 4.5 5.5 3.4 5.7 4.2 5.3 5.1 5.6 5.7 5.6 4.5 5.8 4.5
MST4 7.5 5.8 7.3 5.6 5.4 4.5 5.2 4.5 8.7 8.1 8.9 8.2 6.8 5.2 6.5 4.9 4.1 3.6 4.1 3.5 4.8 3.8 4.8 3.5 5.4 3.9 5.5 4.3 5.2 4.7 5.1 4.6
MSX1 6.9 5.7 6.7 6.0 6.5 4.8 6.8 5.3 5.1 4.9 5.2 5.2 6.0 5.4 5.7 5.6 7.7 3.4 8.1 3.6 8.4 4.1 8.5 4.0 6.4 4.3 6.6 4.1 8.1 4.8 8.1 4.9
MYC 7.5 7.8 7.4 7.7 5.6 5.6 5.1 5.6 8.1 8.0 8.1 8.0 6.5 6.6 6.6 6.3 6.5 7.9 6.4 8.0 4.9 5.5 5.0 5.5 7.0 7.7 7.1 7.8 5.4 5.8 4.8 5.9
NFAT5 7.3 6.8 7.2 6.8 7.2 7.0 7.4 7.0 7.3 7.4 7.4 7.4 7.5 7.2 7.3 7.0 6.7 6.5 6.9 6.7 7.5 6.8 7.3 7.0 6.8 6.8 6.8 6.9 7.6 6.8 7.2 7.0
NFE2 1.4 0.9 0.4 1.1 0.9 1.2 1.8 0.9 1.7 1.2 1.4 1.7 1.4 0.7 1.1 1.5 0.2 0.8 0.9 1.0 1.1 1.6 1.5 0.2 2.1 1.5 1.0 1.4 2.7 0.9 1.5 2.1
NFIB 3.5 3.5 3.8 3.9 2.9 3.2 3.5 3.5 3.7 3.7 3.5 3.3 3.0 3.3 3.6 3.5 6.6 6.5 6.9 6.6 6.0 5.8 5.7 5.8 6.2 7.2 6.0 7.0 5.4 6.6 5.4 6.0
NFIL3 6.3 6.3 6.6 6.2 4.9 5.2 5.3 5.0 6.9 6.4 6.6 6.5 5.5 5.4 5.3 5.2 7.1 8.0 6.9 8.0 6.5 6.3 6.7 5.8 7.2 8.7 7.0 8.9 6.9 6.4 6.8 6.4
NFKBIA 7.7 7.2 7.7 7.2 6.3 5.8 6.6 5.6 6.9 6.6 6.7 6.8 6.5 6.3 6.4 6.3 8.9 7.6 8.9 7.7 7.3 6.0 7.3 6.0 9.0 8.5 8.9 8.4 7.8 6.8 7.8 6.7
NGEF 6.9 6.3 6.9 6.5 6.5 5.8 6.5 5.7 7.4 7.6 7.3 7.7 7.3 7.0 7.1 6.9 4.0 2.6 4.0 2.4 4.7 5.1 4.7 4.8 5.7 2.4 5.7 2.8 3.9 5.0 4.8 5.0
NOG 5.9 3.1 6.0 2.8 2.6 2.2 2.7 0.9 7.0 4.1 7.0 4.3 3.9 1.6 4.0 2.7 6.8 2.1 6.4 1.6 6.7 2.8 6.8 3.3 6.9 1.4 6.9 2.6 8.1 2.7 8.4 2.6
NOS2 5.9 4.3 5.5 4.2 3.3 1.9 2.9 1.9 6.3 6.6 6.7 6.5 4.5 3.2 4.4 3.4 3.2 1.6 3.1 1.9 2.0 2.6 3.2 2.3 3.6 3.0 4.0 2.7 4.0 3.6 3.7 4.0
NOTCH1 3.7 4.2 3.9 4.2 5.1 5.5 5.3 5.6 3.5 3.9 3.5 3.9 4.5 5.0 3.2 5.1 4.3 3.5 4.6 3.8 5.2 5.2 5.2 5.3 4.7 4.2 4.4 4.1 3.2 5.5 4.9 5.5
NOTCH2 9.2 9.3 9.2 9.4 9.0 8.7 9.0 8.6 8.3 8.7 8.1 8.7 8.9 8.8 9.2 8.8 9.9 8.6 9.8 8.6 9.7 8.4 9.8 8.7 9.6 9.0 9.5 9.0 10.3 8.8 10.2 9.1
NOTCH3 8.7 8.7 8.7 8.7 9.6 8.8 9.7 8.9 6.7 6.9 6.3 6.7 8.5 8.6 8.8 8.7 9.0 7.4 8.8 7.5 9.6 7.8 9.4 7.9 8.2 7.3 8.2 7.5 9.5 7.9 9.5 7.3
NOX1 2.6 2.1 2.2 2.1 3.1 2.2 2.7 2.9 2.7 2.2 2.4 2.1 2.5 1.9 2.0 2.7 2.8 1.5 2.9 2.0 3.4 3.0 2.6 3.2 2.8 3.1 3.1 1.9 3.7 2.9 3.1 4.8
NPAS2 5.7 6.1 5.4 5.9 3.5 3.8 3.3 3.5 7.0 6.4 6.7 6.5 3.7 4.1 2.5 4.0 4.8 6.4 4.9 6.1 3.5 4.8 3.7 4.5 5.4 6.2 5.5 6.4 4.1 5.3 4.1 5.3
NR4A2 4.4 4.0 4.2 3.9 5.0 4.3 4.9 4.0 4.0 4.4 3.9 4.3 5.2 4.8 4.5 4.1 3.7 2.5 3.7 2.3 4.6 4.8 4.9 5.4 4.3 3.6 3.8 2.9 4.4 4.0 4.6 3.5
NRG1 4.4 4.2 4.0 4.1 4.4 4.4 4.8 4.4 4.8 4.5 4.3 4.5 4.3 4.4 4.3 4.2 3.5 3.8 3.3 3.4 5.1 4.7 6.0 4.3 3.8 4.7 4.2 4.3 5.0 3.8 5.3 3.2
OAF 8.5 6.3 8.3 6.5 6.2 5.2 5.9 5.2 9.1 8.4 9.2 8.3 7.8 6.4 7.7 6.1 6.5 4.6 6.1 4.5 6.4 5.8 6.3 6.0 7.5 4.4 7.3 4.9 5.6 6.3 6.7 5.7
OGN 8.9 8.8 8.7 8.4 7.1 6.9 7.2 7.2 7.9 8.7 7.7 8.8 8.6 9.1 8.4 8.9 9.0 6.1 9.2 5.8 7.6 3.0 8.2 3.2 10.0 7.5 10.1 7.5 8.9 4.9 8.5 5.6
OMD 11.0 10.4 10.9 10.4 10.1 7.8 10.0 8.0 9.4 10.3 9.2 10.6 11.7 10.3 11.4 10.2 10.3 5.4 10.6 5.1 10.2 2.4 10.4 2.4 11.6 7.1 11.6 6.9 11.6 5.2 11.4 4.8
PANX3 9.8 8.1 9.3 7.6 4.3 3.6 4.0 3.4 9.6 11.3 10.0 11.4 9.3 8.1 8.5 6.9 3.3 1.7 4.1 1.3 2.7 1.5 2.4 2.4 8.1 1.8 8.0 3.3 3.1 1.7 3.9 3.9
PBX1 5.1 5.0 5.0 4.9 6.1 5.9 6.1 5.8 3.6 4.3 3.7 4.3 5.8 5.9 5.3 5.8 6.6 6.2 6.7 6.2 7.5 5.7 7.8 6.0 6.3 6.8 6.1 6.7 8.1 6.1 8.0 6.0
PCOLCE2 9.0 7.4 8.7 7.5 6.9 6.2 6.6 5.5 9.7 8.7 9.7 8.8 7.7 6.7 7.5 6.4 7.3 6.2 7.2 6.0 7.9 4.5 8.3 3.6 8.4 5.6 8.4 5.1 8.8 4.8 8.8 4.5
PDPN 7.0 6.6 6.5 6.5 5.9 7.6 6.1 7.2 8.7 7.1 8.8 7.2 6.3 6.5 6.4 7.1 3.5 7.5 3.7 7.7 3.9 8.3 3.7 8.2 5.5 7.9 5.6 8.0 4.1 8.6 4.7 8.3
PGK1 12.1 12.0 11.8 11.6 9.8 9.6 9.5 9.4 12.5 12.0 12.5 12.3 10.3 9.8 10.2 9.7 9.8 9.5 10.0 9.4 9.4 8.8 9.4 8.9 10.3 8.9 10.0 8.9 9.6 9.2 9.4 9.2
PLCD1 9.6 8.6 9.4 8.5 7.7 6.8 7.5 6.9 10.5 10.1 10.3 10.2 9.4 8.7 9.2 8.6 8.0 7.5 8.0 7.5 7.1 6.4 7.3 6.6 8.8 7.7 8.7 7.8 7.6 7.0 7.5 7.5
PLCG2 2.8 2.0 2.8 2.1 2.3 3.5 3.1 3.2 3.0 3.0 2.8 3.1 3.5 2.0 1.2 3.0 2.5 1.3 2.0 1.5 3.2 2.8 3.2 3.4 2.9 1.2 2.6 2.6 3.7 2.7 3.1 2.6
PMP2 5.2 3.0 4.9 3.3 2.4 1.4 2.8 1.9 6.3 5.3 6.3 5.5 3.6 2.8 3.6 2.9 2.8 1.9 2.8 1.7 2.2 1.6 2.9 2.9 3.2 2.4 2.7 2.3 2.2 3.5 3.2 4.0
PPARG 3.2 3.0 3.4 2.9 1.2 2.5 1.8 2.2 4.1 3.6 3.9 3.5 2.7 2.0 1.9 1.8 6.5 7.3 6.7 7.2 3.3 3.5 3.8 3.7 7.2 7.3 7.1 7.4 4.0 4.3 4.1 4.0
PPP1R14C 5.6 5.1 5.4 4.9 4.5 4.1 4.6 4.2 6.5 5.6 6.1 5.6 5.4 3.1 4.8 3.9 2.0 2.6 2.5 2.1 3.0 3.2 3.3 3.1 3.2 1.6 2.8 1.6 3.1 2.6 3.1 3.0
PRELP 7.5 6.8 7.2 6.8 4.2 4.1 3.7 3.2 7.3 7.3 7.5 7.4 6.0 4.8 5.3 4.3 2.7 2.1 2.5 1.7 2.6 2.6 2.5 0.9 4.6 3.1 4.8 2.6 2.7 3.1 3.6 2.2
PRG4 5.2 5.4 5.2 5.5 5.5 6.0 5.7 5.6 5.9 5.0 5.6 5.3 4.9 4.7 5.1 5.1 5.0 7.0 4.2 6.7 3.1 4.0 2.7 3.2 5.0 9.3 5.2 9.3 3.8 3.6 2.9 4.4
PSMC4 7.4 7.1 7.1 7.1 7.0 7.1 7.0 7.1 6.8 7.3 7.1 7.3 7.3 7.4 7.4 7.3 6.7 6.3 7.0 6.5 7.0 6.8 7.0 6.8 6.8 6.3 7.1 6.2 7.3 6.9 7.1 7.0
PTCH1 7.2 6.5 6.8 6.3 5.7 5.0 5.7 5.0 7.2 7.9 7.2 8.1 7.3 6.5 6.9 6.8 5.4 4.4 5.3 4.3 6.1 3.4 6.3 2.4 6.2 5.2 5.7 5.1 6.3 3.7 6.5 3.1
PTCH2 2.5 2.5 2.2 2.4 3.3 2.7 3.6 2.5 2.6 2.6 0.8 2.6 3.4 3.5 2.1 2.9 2.8 2.3 2.7 2.7 3.7 2.6 3.5 2.5 2.9 2.9 2.7 3.1 3.4 3.3 3.4 2.2
PTHLH 2.7 2.0 2.9 2.2 2.9 2.7 3.4 3.0 4.0 2.7 3.3 3.2 3.4 2.7 2.8 3.0 2.2 1.1 2.4 1.8 4.9 5.1 5.2 5.7 1.6 1.9 1.8 0.9 5.0 4.2 5.4 3.3
PTHR1 9.4 8.3 9.0 8.1 6.3 4.9 5.9 5.2 10.3 10.2 10.3 10.4 8.8 8.6 8.8 8.2 7.1 4.0 7.3 3.8 3.9 2.7 4.0 2.7 8.5 5.5 8.4 5.7 5.4 2.4 5.1 4.6
RASL11B 8.3 9.2 8.3 9.0 8.0 7.2 8.1 7.4 5.7 7.5 5.7 7.8 7.4 8.0 7.3 7.9 5.4 4.7 5.6 4.7 6.8 2.7 6.5 2.3 5.6 6.3 5.5 6.4 6.8 2.4 6.8 4.5
RCOR2 7.4 6.5 7.1 6.2 4.9 4.1 5.0 3.9 7.6 7.8 7.6 7.9 7.2 6.3 7.1 6.0 4.2 2.7 4.1 3.2 4.5 2.5 4.1 3.1 5.9 3.3 6.0 3.2 3.7 3.4 4.1 4.8
RNF144 7.4 7.8 7.4 7.5 5.9 6.3 5.7 6.3 7.0 7.2 6.8 7.4 6.5 6.8 6.4 6.5 5.3 5.7 5.6 5.8 4.4 6.2 4.4 5.9 6.3 6.7 5.8 6.5 5.2 6.2 4.6 6.4
RPL37A 13.8 13.7 13.8 13.6 13.1 13.0 13.2 13.1 14.0 13.8 13.9 14.0 13.6 13.5 13.4 13.4 14.3 14.2 14.4 14.2 13.9 12.7 13.9 12.7 14.4 14.5 14.3 14.5 14.0 13.4 14.0 13.3
RPS27L 9.9 9.9 10.0 9.9 10.2 10.4 10.2 10.4 9.9 9.9 9.9 10.0 10.1 10.2 10.0 10.3 9.8 10.3 9.8 10.3 10.0 10.2 10.2 10.2 10.0 10.2 9.9 10.3 10.1 10.4 10.1 10.2
RUNX1 8.5 8.9 8.3 8.9 9.2 9.4 9.3 9.4 7.7 8.2 7.7 8.3 8.9 9.5 8.9 9.4 7.8 6.9 7.7 6.9 8.4 8.1 8.1 8.2 7.6 7.6 7.2 7.7 8.7 8.4 8.6 8.4
RUNX2 8.0 8.2 7.9 8.1 8.5 8.2 8.7 8.2 7.1 7.3 7.1 7.5 8.6 8.8 8.6 8.8 8.5 6.5 8.5 6.4 8.7 7.4 8.7 7.4 8.5 7.3 8.4 7.3 8.8 7.5 8.8 8.0
RUNX3 6.2 5.9 6.2 5.8 5.4 5.0 5.5 4.6 6.6 6.4 6.2 6.3 5.9 5.1 5.7 5.1 5.2 4.2 5.2 4.3 5.3 3.3 5.6 3.5 5.0 4.9 5.4 5.0 5.6 4.7 5.5 3.8
RYK 7.2 6.9 7.3 6.9 7.4 7.2 7.4 7.3 6.8 7.0 7.0 7.1 7.2 7.2 7.0 7.2 8.1 7.1 8.2 7.1 7.6 7.0 7.6 7.2 7.8 7.4 7.7 7.3 7.7 7.4 7.6 7.1
S100A1 10.0 7.9 9.7 8.1 7.1 4.8 6.5 4.6 10.8 10.4 10.9 10.5 9.0 7.2 8.9 6.9 3.9 1.8 3.8 1.4 3.9 1.5 3.8 1.8 6.3 2.0 6.3 3.2 3.6 1.7 4.4 1.6
S100B 7.1 5.3 6.9 5.6 5.2 4.1 4.6 4.5 7.2 7.0 7.2 6.9 6.0 5.3 5.9 4.8 6.5 3.9 6.3 3.4 5.4 3.4 5.4 2.7 7.6 4.1 7.6 4.6 5.4 4.2 5.8 1.9
S100P 11.5 7.1 11.0 7.2 5.7 2.9 4.1 2.2 13.3 10.6 13.2 11.2 8.7 4.9 8.1 4.7 4.8 1.7 5.4 2.0 4.4 2.9 3.7 2.0 8.6 3.2 8.4 2.9 5.8 3.5 6.0 3.3
SCIN 9.0 6.6 8.7 6.5 5.4 3.3 5.0 2.8 10.1 9.4 10.1 9.7 7.4 4.7 7.2 4.8 5.5 2.6 5.4 2.8 5.0 2.8 5.5 3.9 7.0 3.5 6.6 3.1 5.0 3.8 5.3 2.8
SCRG1 11.2 9.5 11.1 9.5 6.8 5.0 6.8 4.8 11.9 11.2 11.8 11.4 9.1 7.5 8.7 7.0 11.2 8.3 11.3 8.0 7.6 3.4 7.9 1.7 11.4 9.7 11.2 9.8 7.9 2.9 8.0 2.7
SDC3 6.9 6.2 6.9 6.3 6.1 5.2 5.8 4.8 6.8 6.7 6.8 6.8 6.6 5.9 6.6 5.6 8.8 7.0 8.9 7.0 7.6 6.1 7.8 6.1 8.5 7.1 8.5 7.2 8.2 6.1 8.0 6.5
SERPINA1 4.0 3.5 4.0 3.6 3.4 4.6 4.2 4.7 5.6 4.0 5.2 4.6 4.7 3.6 3.9 3.3 2.6 2.6 3.3 2.8 3.0 2.3 3.4 3.0 3.1 2.1 3.1 2.2 0.9 3.5 1.7 1.1
SERPINA3 7.8 7.1 7.9 7.4 4.8 4.1 4.5 3.2 9.2 8.7 9.0 8.7 6.3 4.8 6.1 4.8 5.1 5.7 5.0 5.4 4.1 2.4 4.0 2.9 6.1 6.0 6.3 6.4 4.4 2.0 4.6 3.3
SERPINA5 5.0 4.7 5.2 4.8 3.5 3.0 4.2 3.8 5.4 5.3 5.2 5.4 4.0 3.9 4.2 4.2 4.1 3.5 3.9 3.2 4.2 2.0 3.9 1.5 4.3 4.3 4.1 4.0 3.8 3.2 4.0 2.9
SFRP1 5.3 4.1 4.9 3.7 1.2 3.5 2.4 2.7 6.8 5.7 6.2 5.7 3.6 3.0 2.2 2.8 3.4 4.2 3.4 4.1 3.8 5.0 2.0 5.5 4.3 5.1 4.0 4.9 3.7 4.0 3.4 4.4
SFRP2 2.6 3.0 2.5 2.5 2.7 2.9 2.4 2.1 3.1 2.7 2.8 2.5 2.7 2.4 1.4 2.3 2.4 1.9 2.7 1.6 2.5 1.5 2.1 2.9 1.4 2.1 2.3 2.4 1.4 1.4 3.2 1.8
SFRP4 3.7 2.1 3.6 2.4 9.3 6.9 9.8 7.4 2.2 2.6 2.6 2.8 8.4 7.5 8.4 7.8 2.2 1.9 1.7 2.2 7.9 6.8 7.9 6.6 1.9 2.4 3.3 3.6 4.9 6.6 5.6 5.9
SHC4 7.8 6.4 7.5 6.5 6.0 4.1 5.6 4.1 8.7 8.4 8.8 8.4 6.4 5.0 6.5 4.9 4.9 3.4 5.0 3.3 5.0 4.2 5.0 3.1 5.8 3.5 5.7 4.0 5.4 3.5 5.0 2.8
SLAMF9 4.7 3.4 4.6 3.5 2.6 1.8 2.3 1.5 6.5 4.1 5.8 4.7 2.9 2.6 3.3 1.2 1.8 1.1 1.4 1.4 2.2 1.9 3.1 2.1 2.5 1.9 2.4 1.0 3.4 1.7 2.6 1.8
SLC13A5 7.5 5.1 7.0 5.0 2.3 1.5 2.4 2.2 8.6 7.6 8.6 8.0 6.4 4.5 6.4 4.4 1.8 1.2 2.6 1.6 3.3 1.9 1.9 1.4 5.0 1.8 4.5 2.1 3.1 3.5 4.0 2.6
SMAD1 5.8 6.2 5.8 6.4 5.7 6.4 5.7 6.4 5.3 5.9 5.5 5.8 5.9 6.5 6.0 6.5 6.4 5.6 6.1 5.7 6.3 6.7 6.6 6.8 6.3 5.6 6.3 5.9 6.8 7.0 6.7 7.5
SMAD2 7.8 8.1 7.9 8.1 8.1 8.2 8.1 8.0 7.7 7.8 7.6 7.9 8.1 8.2 8.3 8.3 8.4 8.1 8.4 8.0 8.6 7.9 8.6 7.6 8.4 8.5 8.4 8.4 9.0 8.5 8.7 8.5
SMAD3 5.4 5.6 5.3 5.5 5.6 5.4 5.9 5.4 5.8 5.8 5.8 5.9 6.1 5.8 5.8 5.6 5.8 6.2 5.9 6.2 6.6 6.5 6.8 6.2 6.3 7.0 6.0 7.1 6.6 6.7 6.5 6.6
SMAD4 6.8 6.8 6.8 6.9 6.8 6.7 6.9 6.9 6.3 6.6 6.3 6.7 6.7 7.0 7.0 7.1 7.3 6.9 7.4 7.0 7.2 6.5 7.3 6.4 7.0 7.2 7.2 7.2 7.4 6.7 7.4 6.9
SMAD5 8.0 7.8 7.9 7.9 8.0 7.8 8.1 7.7 7.6 7.8 7.6 8.0 7.8 7.8 7.7 7.9 8.1 7.6 8.1 7.6 8.7 7.3 8.4 7.5 8.1 8.0 8.1 8.2 8.7 7.8 8.8 7.9
SMAD6 8.7 6.8 8.6 6.8 8.6 6.7 8.6 6.6 7.8 6.9 8.0 7.2 8.7 7.6 8.9 7.6 9.3 4.2 9.2 4.1 9.9 4.4 9.9 5.0 9.4 4.9 9.4 5.0 9.9 4.8 10.0 5.6
SMAD7 8.8 8.2 8.8 8.3 9.4 8.9 9.5 8.8 7.2 7.0 7.5 7.3 9.0 8.7 9.1 8.8 8.8 5.0 8.8 5.0 9.4 7.1 9.4 7.1 8.7 5.5 8.7 5.6 9.8 7.1 9.7 7.7
SMAD9 8.1 6.3 8.0 6.5 7.1 5.0 7.2 5.2 7.5 6.0 7.2 6.3 6.5 5.4 6.7 5.2 8.2 3.8 8.3 3.9 8.3 4.5 8.3 4.6 7.9 4.4 7.7 4.7 8.5 4.3 8.5 3.5
SMO 5.8 5.5 5.6 5.3 4.9 4.9 4.9 5.4 5.5 5.8 5.6 5.8 5.4 5.8 5.1 5.6 5.5 4.7 5.8 4.8 6.1 5.2 5.9 4.8 6.1 5.0 5.7 5.1 6.4 5.2 6.5 5.2
SOCS2 7.1 5.8 7.1 5.9 6.1 3.8 6.2 3.8 7.6 5.8 7.2 5.9 6.5 4.7 6.6 4.6 5.8 4.8 5.2 5.0 6.8 4.2 6.7 4.2 6.1 4.0 5.9 4.0 6.9 4.5 7.0 4.7
SOX11 4.9 5.4 5.0 5.4 5.5 6.2 5.7 6.0 4.2 4.1 4.0 3.7 4.9 5.2 5.1 5.9 4.6 4.6 4.6 4.7 4.6 6.2 4.3 6.3 5.0 4.9 4.6 4.7 4.3 6.0 5.4 6.3
SOX5 7.2 6.3 7.1 6.3 7.4 6.8 7.6 6.7 7.5 7.3 7.6 7.3 7.2 6.5 6.8 6.7 5.5 5.3 5.8 5.1 5.8 6.2 5.8 6.5 5.2 5.6 5.4 5.4 5.1 5.9 5.7 5.9
SOX6 5.9 5.3 5.7 5.2 4.9 4.4 4.9 4.0 6.6 6.4 6.4 6.6 5.7 5.4 6.1 4.8 3.6 2.8 3.3 2.7 3.8 2.8 4.2 3.5 4.7 3.2 5.1 2.6 4.1 3.6 3.9 2.5
SOX8 8.3 5.6 8.0 5.5 3.8 1.8 3.1 2.4 9.3 8.6 9.3 8.8 7.0 4.9 6.7 4.3 4.9 2.0 4.8 2.1 3.4 2.4 3.2 1.2 6.7 2.6 6.8 2.5 5.2 1.3 5.0 4.0
SOX9 10.9 9.9 10.7 9.9 9.1 8.4 9.1 8.4 12.0 11.2 11.8 11.3 9.7 9.2 9.6 9.1 9.8 7.4 9.8 7.4 9.6 8.3 9.6 8.4 10.4 7.9 10.2 8.1 10.3 7.9 10.2 7.9
SP7 8.9 8.3 8.9 8.0 8.3 6.7 8.3 6.7 8.2 8.5 8.4 8.6 9.3 8.6 9.4 8.4 8.5 1.8 8.6 2.0 8.7 2.9 8.8 2.9 8.8 3.3 9.1 3.0 9.3 3.7 9.3 4.1
SPARCL1 4.6 4.1 4.4 4.0 1.9 2.5 2.2 1.4 4.7 4.6 4.3 4.2 1.8 2.6 1.8 2.3 8.3 11.0 8.0 11.0 2.1 2.8 2.2 2.3 7.6 11.2 7.3 11.3 2.0 4.2 3.4 4.1
SPP1 14.3 12.4 14.0 12.2 15.5 13.9 15.8 14.3 9.3 11.6 9.4 11.7 15.4 14.4 15.1 14.3 12.7 5.0 12.9 5.0 14.7 12.3 14.7 12.3 11.6 5.2 11.6 5.8 12.4 8.6 12.4 9.2
STEAP3 7.1 7.3 7.1 7.3 7.0 7.4 7.0 7.2 7.0 8.1 7.1 8.2 7.9 8.3 7.7 7.9 6.5 6.8 6.4 6.9 5.6 6.7 6.2 6.6 6.3 6.2 6.5 6.2 5.4 6.9 5.3 6.7
TBP 5.6 5.5 5.4 5.4 5.3 5.2 5.2 5.1 5.1 5.5 5.3 5.3 5.8 5.4 5.5 5.3 5.8 5.0 5.6 5.2 5.4 5.1 5.8 4.6 5.6 5.5 5.7 5.9 5.8 5.3 5.6 5.0
TBX15 5.5 5.4 5.5 5.7 5.1 5.2 5.4 5.2 5.7 5.2 5.1 5.3 4.1 4.4 4.8 4.7 7.2 6.5 7.1 6.6 6.1 5.4 5.7 5.4 7.0 6.8 6.8 7.1 6.3 5.7 6.4 5.9
TBX2 7.3 6.7 7.2 6.5 6.4 5.9 6.4 6.0 5.2 5.4 5.4 5.5 6.1 5.9 6.0 5.7 8.7 5.4 8.8 5.4 9.2 6.9 9.4 6.9 8.2 5.7 8.4 5.6 8.6 6.3 8.5 6.6
TBX3 7.1 6.5 6.7 6.6 6.8 6.4 7.1 6.5 4.4 4.6 4.4 4.2 5.8 5.4 5.8 5.8 7.9 6.9 7.9 6.8 8.6 5.8 8.7 5.9 7.8 6.5 7.6 6.7 9.4 6.3 9.5 5.8
TGFB1 10.7 10.4 10.6 10.3 11.4 10.5 11.6 10.5 9.0 10.1 9.0 10.1 11.4 11.1 11.3 11.0 10.4 8.6 10.5 8.6 11.4 9.2 11.2 9.2 10.0 9.0 10.1 9.1 10.9 9.1 10.8 9.4
TGFB2 7.9 7.6 8.1 7.9 9.7 9.3 9.9 9.2 7.8 8.0 7.5 8.2 9.1 8.7 9.3 8.9 8.4 6.2 8.4 6.3 8.9 9.9 8.7 9.9 8.9 7.4 8.7 7.4 7.9 9.0 8.1 9.2
TGFB3 4.4 5.9 4.6 5.8 6.1 6.3 6.1 6.5 2.8 4.5 3.5 4.1 5.6 6.6 5.6 6.8 3.7 4.3 4.5 4.3 5.7 6.4 5.8 6.6 4.0 4.3 4.1 4.4 6.7 6.6 6.6 6.7
TGFBR1 8.1 8.2 8.0 8.3 8.0 8.1 8.3 8.1 7.6 7.8 7.6 7.8 7.6 7.9 7.8 7.7 7.0 6.1 7.1 6.0 7.0 7.0 7.2 7.2 6.7 6.3 6.5 6.1 7.4 7.5 7.4 7.1
TGFBR2 6.2 6.4 6.3 6.5 5.9 5.9 6.1 5.8 5.9 6.0 5.7 6.1 5.9 6.0 5.7 5.5 6.7 8.0 6.6 8.0 6.7 7.2 7.0 7.2 6.3 7.1 6.3 7.2 6.6 7.1 6.5 6.5
TGFBR3 3.1 3.8 2.9 3.8 3.4 3.3 2.5 3.7 2.2 2.6 2.3 2.7 2.4 3.2 2.5 3.3 5.1 7.1 4.6 7.3 4.4 5.1 3.9 4.7 5.1 8.4 5.0 8.5 4.3 5.3 4.5 5.5
TIMP2 8.7 9.4 8.7 9.3 9.6 10.2 9.8 10.2 7.1 7.9 7.1 8.0 9.1 9.8 9.3 10.0 9.1 10.0 9.0 9.9 9.3 10.3 9.2 10.3 9.0 10.5 9.0 10.5 9.3 10.4 9.3 10.6
TIMP4 8.4 7.1 8.1 7.1 4.5 4.3 4.5 4.6 9.6 8.3 9.4 8.5 5.2 5.0 4.7 4.6 10.3 10.0 10.2 10.0 5.4 4.9 5.2 4.7 10.7 10.4 10.6 10.5 6.1 5.4 5.4 5.0
TMEM100 5.6 4.9 5.3 5.1 5.2 4.6 5.5 4.3 5.5 5.4 5.4 5.4 4.2 3.4 3.4 3.7 7.3 7.1 7.2 7.4 8.3 4.3 8.6 4.4 6.9 7.8 6.7 8.0 6.5 4.8 6.3 4.1
TNFAIP8L3 5.1 4.4 5.0 4.2 3.0 1.7 3.4 2.2 5.5 4.7 5.4 4.8 3.3 3.3 3.8 2.5 4.1 4.8 4.4 4.7 3.2 2.7 2.8 2.3 4.6 4.1 4.7 4.7 2.9 1.7 3.7 1.3
TNFRS11B 2.8 3.2 2.5 2.8 3.2 3.5 2.8 2.7 3.7 4.4 3.8 4.1 4.2 3.5 4.1 4.1 2.3 3.7 2.3 3.9 3.2 4.6 2.5 5.0 2.9 4.2 2.5 4.7 3.7 4.3 1.8 5.1
TNFRSF11A 2.0 2.2 2.2 1.9 1.4 1.9 2.3 1.2 2.4 2.1 2.4 2.1 2.1 1.8 2.9 2.0 1.6 1.5 1.8 1.4 1.9 1.2 1.7 1.6 2.0 2.4 1.7 1.1 2.7 2.0 3.1 2.0
TNFSF11 7.6 7.0 7.4 7.1 9.2 8.8 9.3 8.4 6.7 7.2 6.9 7.1 8.2 7.9 8.7 8.1 3.2 3.2 3.5 3.4 5.7 6.2 6.0 6.4 2.8 3.7 3.2 3.6 6.7 5.0 6.4 6.1
TRPV4 8.2 6.2 7.9 6.1 5.6 4.6 5.0 4.3 9.3 8.7 9.4 8.8 7.3 5.9 6.9 5.4 5.6 2.8 5.5 2.8 4.9 3.7 5.2 3.2 6.7 2.7 6.0 3.2 6.3 4.2 6.1 2.1
TSC22D1 6.4 6.6 6.2 6.5 6.8 7.3 6.8 7.1 6.0 6.3 5.6 6.3 6.6 6.9 6.6 7.1 7.3 7.4 7.4 7.2 7.2 6.8 7.3 6.8 7.3 7.5 7.1 7.4 7.4 7.0 7.6 7.0
TSC22D3 10.5 10.6 10.4 10.4 7.3 7.0 7.2 7.2 10.3 9.7 9.9 9.8 7.5 7.9 7.3 7.8 10.8 10.3 10.8 10.4 7.3 5.6 7.4 6.0 10.9 11.4 10.8 11.5 8.1 6.6 8.0 6.2
TSC22D4 8.5 7.6 8.5 7.4 7.4 6.9 7.5 7.1 9.4 8.5 9.2 8.7 7.7 7.3 7.8 7.4 8.6 8.0 8.5 8.0 8.0 7.2 8.1 7.2 8.8 8.1 8.8 8.4 8.2 7.3 8.1 7.7
TUBB2A 9.5 7.7 9.3 7.7 6.6 6.7 6.4 6.8 10.7 10.1 10.9 10.0 8.5 7.6 8.4 7.4 8.0 7.0 8.0 6.9 8.1 6.0 7.9 6.0 8.3 6.9 8.3 6.8 8.8 6.8 8.8 7.0
TUBB2B 9.3 6.5 8.8 6.5 5.3 4.1 4.7 4.5 10.9 9.8 10.8 9.8 7.4 5.5 6.6 5.3 6.7 4.8 6.6 5.0 7.9 3.9 7.9 4.1 7.4 6.2 7.3 6.2 8.7 5.2 8.7 5.4
TXNIP 10.0 9.6 10.2 9.4 8.0 7.8 7.7 7.7 9.3 9.2 9.0 9.6 8.0 8.5 8.1 8.4 10.7 9.6 10.7 9.5 7.2 6.5 7.2 6.2 10.9 10.7 10.8 10.7 8.2 7.6 7.8 7.4
TYRO3 8.8 7.8 8.9 7.7 7.3 6.2 7.3 5.8 8.4 8.6 8.4 8.6 8.6 7.9 8.4 7.6 6.6 6.0 6.5 5.9 6.4 4.7 6.3 5.1 7.3 6.0 7.3 6.1 7.0 5.7 6.7 5.5
UNQ1940 9.2 7.0 8.9 6.9 6.0 4.8 5.2 4.6 10.1 9.8 10.2 9.9 7.1 5.7 6.8 5.3 5.2 5.8 5.3 5.7 4.4 5.6 4.7 5.4 6.4 6.3 6.4 6.3 4.5 6.0 5.3 5.8
UNQ830 6.0 3.4 5.6 3.3 2.9 2.2 2.5 1.4 7.5 6.2 7.5 6.1 4.9 2.8 4.8 3.1 2.9 2.8 3.0 2.4 2.8 2.8 3.2 2.9 4.0 2.4 4.4 2.4 3.6 2.2 2.9 1.8
VBP1 6.8 6.9 6.8 7.0 6.5 6.5 6.8 6.7 6.7 6.9 6.8 6.8 7.0 6.9 6.9 7.1 7.0 6.5 7.1 6.7 7.1 6.5 7.2 6.4 7.1 6.4 7.0 6.5 7.4 6.6 7.2 5.7
VCAM1 3.4 5.8 3.0 5.8 6.5 8.8 6.8 8.9 2.2 3.0 2.0 2.3 4.9 7.5 5.5 7.8 4.8 6.0 4.1 5.9 5.9 9.2 5.9 9.1 4.4 6.5 4.5 6.3 5.0 9.5 5.3 9.1
VCAN 8.3 8.5 8.0 8.6 8.4 8.3 8.4 8.3 8.0 8.3 7.9 8.1 8.7 9.0 8.7 8.7 9.6 9.2 9.3 9.3 10.0 7.3 9.7 7.3 9.7 10.1 9.7 10.0 10.5 8.3 10.7 8.5
WNT10B 4.8 3.8 4.3 3.4 3.9 2.6 3.8 2.9 4.4 5.1 4.1 5.1 6.2 5.0 6.1 4.7 2.1 1.2 2.0 1.2 2.4 1.0 2.6 0.8 2.7 2.1 4.3 0.8 2.7 2.9 1.7 2.3
WNT11 8.5 6.8 8.2 6.5 5.9 4.8 5.3 4.6 9.4 9.2 9.4 9.2 8.7 7.4 8.4 7.4 3.6 2.9 3.3 3.0 4.1 2.7 3.8 2.9 5.6 3.5 5.8 3.5 5.1 3.6 5.3 4.0
WNT3A 3.2 2.8 3.0 2.9 2.8 2.5 2.9 2.8 4.4 3.7 3.9 3.8 2.8 2.5 2.1 3.0 1.1 1.6 1.4 1.6 2.0 1.9 2.6 0.8 0.9 1.1 1.2 1.7 3.3 2.6 2.9 1.8
WNT4 3.8 2.5 3.8 2.2 2.3 2.1 3.0 2.7 4.4 4.0 4.5 4.2 3.8 3.1 2.5 2.8 2.1 2.2 2.4 1.6 2.6 1.8 3.5 1.2 2.4 2.2 2.8 2.1 3.0 2.1 3.5 2.4
WNT5A 10.5 10.2 10.4 10.3 11.7 11.3 11.9 11.3 7.9 7.6 7.8 7.6 9.8 9.8 9.9 10.1 11.8 9.5 11.8 9.6 12.4 11.3 12.4 11.4 10.1 8.5 10.1 8.4 12.1 10.5 12.2 10.4
WNT5B 8.0 8.5 7.9 8.6 8.5 8.4 8.7 8.4 6.4 7.1 6.4 7.1 7.8 8.1 8.1 8.1 7.5 8.1 7.5 8.0 7.0 7.0 6.8 7.1 6.5 7.5 6.2 7.8 7.6 7.1 7.6 7.5
WNT7A 3.4 2.4 3.0 2.3 2.4 1.8 2.8 1.6 4.7 3.4 4.4 3.9 2.7 2.6 2.8 1.1 2.8 2.3 2.6 1.8 1.6 2.8 2.0 1.4 2.9 2.4 2.4 2.8 3.4 2.4 3.2 3.5
ZBTB16 6.8 7.0 6.8 6.9 3.3 2.7 3.1 2.8 6.7 6.2 6.3 6.4 3.0 3.4 3.3 1.5 8.9 8.7 9.0 8.8 3.5 2.6 3.1 0.2 9.0 9.7 8.7 9.7 3.5 2.7 3.4 1.6
ZNF277 6.4 6.6 6.4 6.3 6.3 6.2 6.5 6.2 6.1 6.0 6.1 6.0 6.2 6.4 5.6 6.4 7.3 7.0 7.2 7.0 6.9 6.1 6.8 6.2 7.2 7.7 7.0 7.7 7.4 6.5 7.2 6.3
ZNF521 6.1 6.2 5.6 6.2 5.9 6.1 5.7 6.1 6.1 6.1 5.9 6.3 5.9 6.1 5.2 6.3 5.7 5.8 6.0 5.9 6.1 6.5 6.0 6.5 5.9 6.6 5.7 6.3 6.3 6.7 6.2 6.3
ZNF533 6.5 4.9 6.4 4.7 4.0 1.7 3.3 2.2 7.7 7.1 7.7 7.2 6.0 4.0 5.5 3.9 2.3 2.4 2.1 2.4 2.4 1.2 3.1 2.7 4.8 3.7 4.1 3.6 3.6 2.0 1.5 1.9
Heatmap of all genes significantly changed compared to condition 32 at day 7. Values are 
log2-transformed mean expressions (n = 3)
Supplementary Figure S6: Genes significantly regulated between key conditions (day 7)
Upper panel: All significantly regulated genes (>2-fold) when adding DEX to TGFB1. Lower panel: All 
significantly regulated genes (>2-fold) when adding DEX to TGFB1+BMP2. Values represent log2 to the fold 
change between the gene expression in the condition without and the condition with the specified factor added.
Supplementary Figure S7: Overlapping regulated genes when 
adding DEX to TGF or to TGFB1 with BMP2.
Venn diagram illustrating the overlap of genes significantly up- or 
downregulated corresponding to Supplementary Figure S6.
Supplementary Table 1: Geneset of chondrogenesis related genes in the custom made multiplexed geneset. 
ACAN CD59 DKK2 IFNB1 MYC SMAD2
ACTA1 CD74 DLX5 IFNG NFAT5 SMAD3
ACTA2 CD9 DPT IGFBP1 NFE2 SMAD4
ADAMTS1 CDH11 EFNA1 IGFBP2 NFIB SMAD5
ADAMTS5 CDH13 EFNB2 IGFBP3 NFIL3 SMAD6
ADAMTS7 CDH15 EIF2B1 IGFBP4 NFKBIA SMAD7
ADAMTSL1 CDH2 ELF1 IGFBP5 NGEF SMAD9
ADAMTSL4 CDKN1A ELN IGFBP6 NOG SMO
AGT CDKN1B EPHA2 IGFBP7 NOS2 SOCS2
AGTR1 CDKN1C EPYC IHH NOTCH1 SOX11
AGTR2 CDKN2A ERF IL11 NOTCH2 SOX5
AGTRAP/C11orf2 CDKN2B FGF11 IL13RA1 NOTCH3 SOX6
ALPL CDKN2C FGF2 IL16 NOX1 SOX8
ANG CDKN2D FGF7 IL1R1 NPAS2 SOX9
ANG2 CEBPA FGFBP2 IL20RB NR4A2 SP7
ANGPTL2 CEBPB FGFR1 IL6 NRG1 SPARCL1
ANGPTL4 CHAD FGFR2 IL7R OAF SPP1
ANGPTL5 CHST1 FGFR3 IRF6 OGN STEAP3
ANGPTL7 CHST3 FGFR4 IRF9 OMD TBP
APOD CHST6 FGFRL1 ITGA1 PANX3 TBX15
APOE CITED2 FMOD ITGA2 PBX1 TBX2
ARHGEF19 CITED4 FN1 ITGA3 PCOLCE2 TBX3
ARHGEF3 CNN1 FOXA2 ITGA5 PDPN TGFB1
ARNT2 CNN2 FOXA3 ITGB1 PGK1 TGFB2
BAPX1 COL10A1 FOXC1 JAG1 PLCD1 TGFB3
BCL6 COL11A1 FOXC2 JAG2 PLCG2 TGFBR1
BDKRB1 COL11A2 FOXD1 JUNB PMP2 TGFBR2
BEX1 COL12A1 FOXD2 KERA PPARG TGFBR3
BGLAP COL14A1 FOXM1 KLF13 PPP1R14C TIMP2
BGN COL18A1 FOXO1 KLF15 PRELP TIMP4
BID COL1A1 FOXQ1 KLF4 PRG4 TMEM100
BMP2 COL1A2 FRZB KLF6 PSMC4 TNFAIP8L3
BMP4 COL27A1 FZD2 LEF1 PTCH1 TNFRS11B
BMP6 COL2A1_common FZD4 LGALS1 PTCH2 TNFRSF11A
BMP7 COL2A1_isoform1 FZD6 LGALS3 PTHLH TNFSF11
BMPR1A COL2A1_isoform2 FZD7 LGALS3BP PTHR1 TRPV4
BMPR1B COL3A1 FZD8 LPAR4 RASL11B TSC22D1
BMPR2 COL4A1 FZD9 LRP5 RCOR2 TSC22D3
BST1 COL4A2 GLI1 LRP6 RNF144 TSC22D4
C1QTNF3 COL6A1 GLI2 LUM RPL37A TUBB2A
CA12 COL7A1 GLI3 MAF RPS27L TUBB2B
CA5B COL8A1 GLI4 MAFB RUNX1 TXNIP
CA9 COL9A1 GLIS3 MATN1 RUNX2 TYRO3
CARD10 COL9A2 HAPLN1 MATN2 RUNX3 UNQ1940
CASC3 COL9A3 HAPLN3 MATN3 RYK UNQ830
CASP3 COMP HAS1 MATN4 S100A1 VBP1
CASP4 CP HAS2 MEF2C S100B VCAM1
CBFB CRLF1 HAS3 MEF2D S100P VCAN
CCL2 CRTAC1 HCLS1 MGP SCIN WNT10B
CCNA2 CRTAP HES1 MIA SCRG1 WNT11
CCNB1IP1 CRYGS HESX1 MMP1 SDC3 WNT3A
CCNB2 CTGF HEY1 MMP13 SERPINA1 WNT4
CCND1 CTNNB1 HEY2 MMP2 SERPINA3 WNT5A
CCND2 CXCL12 HIF1A MMP28 SERPINA5 WNT5B
CCNF CXCL14 HIF2A MMP3 SFRP1 WNT7A
CCNYL1 CXCL16 HMBS MMP7 SFRP2 ZBTB16
CD109 CYB5B HP MMP8 SFRP4 ZNF277
CD24 CYC1 HPRT1 MMP9 SHC4 ZNF521
CD248 DCN HYAL1 MST1 SLAMF9 ZNF533
CD44 DDIT3 ICAM1 MST4 SLC13A5
CD55 DKK1 IFNA1 MSX1 SMAD1
COL2A1_common recoqnizes both splice variants of COL2A1, COL2A1_isoform 1 recoqnizes variant 1 (fetal type) and COL2A1_isoform 2 
recoqnizes variant 2 (mature type). Genes in BOLD were included as endogenous referencegenes.
Supplementary Table S2: Statistical response analysis of main effects and second 
and third order interactions at day 1 and 7. 
 
Factorial Fit Of Wanted Genes versus All Five Factors Including 
Two-Factor Interactions on Day 7 
Term Effect Coef T P 
Constant 9.3892 110.81 0.000 
TGFb1 3.3493 1.6746 19.76 0.000 
FGF2 -1.3188 -0.6594 -7.78 0.000 
DEX 1.9587 0.9794 11.56 0.000 
IGF1 0.0902 0.0451 0.53 0.596 
BMP2 1.5581 0.7791 9.19 0.000 
TGFb1*FGF2 -0.3273 -0.1637 -1.93 0.057 
TGFb1*DEX 1.1082 0.5541 6.54 0.000 
TGFb1*IGF1 0.0979 0.0489 0.58 0.565 
TGFb1*BMP2 -0.4874 -0.2437 -2.88 0.005 
FGF2*DEX 0.0864 0.0432 0.51 0.612 
FGF2*IGF1 0.0052 0.0026 0.03 0.976 
FGF2*BMP2 -0.1035 -0.0517 -0.61 0.543 
DEX*IGF1 -0.1022 -0.0511 -0.6 0.548 
DEX*BMP2 0.2296 0.1148 1.35 0.180 
IGF1*BMP2 0.0462 0.0231 0.27 0.786 
TGFb1*DEX*BMP2 -0.3821 -0.1911 -2.25 0.027 
R2 = 91.32%   
   
 
Factorial Fit Of Unwanted Genes versus All Five Factors 
Including Two-Factor Interactions on Day 7 
Term Effect Coef T P 
Constant 10.8056 225.62 0.000 
TGFb1 1.0835 0.5418 11.31 0.000 
FGF2 -0.2662 -0.1331 -2.78 0.007 
DEX 0.1495 0.0747 1.56 0.123 
IGF1 -0.0217 -0.0109 -0.23 0.821 
BMP2 1.0365 0.5183 10.82 0.000 
TGFb1*FGF2 0.0332 0.0166 0.35 0.730 
TGFb1*DEX -0.1856 -0.0928 -1.94 0.057 
TGFb1*IGF1 0.0361 0.018 0.38 0.707 
TGFb1*BMP2 -0.9729 -0.4865 -10.16 0.000 
FGF2*DEX 0.2545 0.1272 2.66 0.010 
FGF2*IGF1 -0.0015 -0.0007 -0.02 0.988 
FGF2*BMP2 0.148 0.074 1.54 0.127 
DEX*IGF1 0.0188 0.0094 0.2 0.845 
DEX*BMP2 -0.059 -0.0295 -0.62 0.540 
IGF1*BMP2 0.0155 0.0078 0.16 0.872 
TGFb1*FGF2*DEX 0.2719 0.1359 2.84 0.006 
R2= 84.67%   
 
 
Factorial Fit Of Wanted Genes versus All Five Factors Including 
Two-Factor Interactions on Day 1 
Term Effect Coef T P 
Constant 7.5912 218.76 0.000 
TGFb1 0.5807 0.2904 8.37 0.000 
FGF2 -0.4061 -0.2031 -5.85 0.000 
DEX 0.4144 0.2072 5.97 0.000 
IGF1 -0.0429 -0.0214 -0.62 0.540 
BMP2 0.735 0.3675 10.59 0.000 
TGFb1*FGF2 -0.0912 -0.0456 -1.31 0.196 
TGFb1*DEX 0.1099 0.0549 1.58 0.122 
TGFb1*IGF1 -0.0528 -0.0264 -0.76 0.452 
TGFb1*BMP2 -0.3338 -0.1669 -4.81 0.000 
FGF2*DEX -0.0326 -0.0163 -0.47 0.641 
FGF2*IGF1 -0.022 -0.011 -0.32 0.753 
FGF2*BMP2 -0.1376 -0.0688 -1.98 0.055 
DEX*IGF1 -0.0121 -0.0061 -0.17 0.862 
DEX*BMP2 0.0698 0.0349 1.01 0.321 
IGF1*BMP2 0.0409 0.0205 0.59 0.559 
R2= 88.38 %   
   
 
Factorial Fit Of Unwanted Genes versus All Five Factors 
Including Two-Factor Interactions on Day 1 
Term Effect Coef T P 
Constant 9.5693 337.77 0.000 
TGFb1 0.1489 0.0745 2.63 0.012 
FGF2 -0.2385 -0.1193 -4.21 0.000 
DEX -0.0565 -0.0283 -1 0.325 
IGF1 -0.0138 -0.0069 -0.24 0.808 
BMP2 0.2797 0.1398 4.94 0.000 
TGFb1*FGF2 -0.0746 -0.0373 -1.32 0.196 
TGFb1*DEX -0.0899 -0.0449 -1.59 0.121 
TGFb1*IGF1 0.0007 0.0004 0.01 0.990 
TGFb1*BMP2 -0.1963 -0.0981 -3.46 0.001 
FGF2*DEX 0.0284 0.0142 0.5 0.619 
FGF2*IGF1 0.0123 0.0061 0.22 0.830 
FGF2*BMP2 -0.0437 -0.0218 -0.77 0.445 
DEX*IGF1 -0.0155 -0.0078 -0.27 0.786 
DEX*BMP2 -0.0321 -0.0161 -0.57 0.574 
IGF1*BMP2 0.0536 0.0268 0.95 0.350 
R2= 65.67%   
 
R2 represent the proportion of variation in the response data that is explained by the fitted 
mathematical model.  
Supplementary Table S3: List of significantly regulated genes uniformly up- or 
downregulated by DEX in the presence of TGFb1 alone or in combination with BMP2 
corresponding to the overlap in the Venn-diagram in Supplementary Figure S6. 
 
Down  Up   
ARHGEF3 LGALS3BP ACAN CXCL14 NOS2 TRPV4 
CASP4 LUM ANG FMOD NPAS2 TSC22D3 
CD44 MMP13 ANGPTL7 FOXA2 PCOLCE2 TSC22D4 
CDH11 NOTCH3 APOD HAPLN1 PGK1 TUBB2A 
CDKN2B PBX1 BDKRB1 HPRT1 PMP2 TUBB2B 
COL18A1 RUNX1 C1QTNF3 IL13RA1 S100P UNQ1940 
COL3A1 RUNX2 CA9 IL20RB SCIN UNQ830 
CXCL12 SFRP4 CD109 IRF6 SCRG1 ZBTB16 
EPHA2 SMAD7 CDKN1C KLF15 SERPINA3  
FGFR1 TBX3 COL11A1 MATN3 SFRP1  
FOXO1 TGFB3 COL2A1_iso2 MMP7 SHC4  
FZD8 TIMP2 COL9A1 MST4 SOX8  
GLI3 VCAM1 COL9A3 MYC SOX9  
JAG1 WNT5A CTGF NFIL3 TIMP4  
 
Supplementary Table S4: List of primary and secondary antibodies used for 
immunohistochemistry.  
 
Antibodies for 
immunohistochemistry 
Working 
concentration 
Protein Company Catalog number 
Monoclonal Mouse IgG1 
anti-COL2 
0.83 mg/mL Type 2 collagen  MP 
Biomedicals 
Clone II-4C11 / 
#863171  
Monoclonal Mouse 
IgG1anti-ACAN 
4.55 mg/mL Aggrecan Biosource Clone 
969D4D11 / 
58.146.21 
Monoclonal Mouse IgG2a 
anti-COL1 
1 mg/mL Type I collagen MP 
Biomedicals 
Clone I-8H5 / 
#863170 
Polyclonal Rabbit anti-
SOX9 
0.2 mg/mL SRY-box 
containing gene 9 
Millipore AB5535 
Alexa488-conjugated goat 
anti-rabbit 
5 mg/mL  Invitrogen  
Cy3-conjugated donkey 
anti-mouse IgG 
2 mg/mL  Jackson 
Immuno 
Research 
 
 
